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Abstract 
Non-medical prescribing has been introduced in to several countries, with prescribing privileges 
being granted to health practitioners other than doctors, including pharmacists. The objectives 
behind the introduction of this new model of health care have been to create a more flexible system 
for the prescribing, dispensing and administration of medicines, increase access for the general 
public to safe and appropriate prescription medications, and to better utilise the skills of the current 
health workforce.  
Current research on non-medical prescribing is predominantly qualitative, with little evidence as to 
the safety, appropriateness, effectiveness or cost effectiveness of the prescribing. Pharmacist 
prescribing is yet to be introduced in Australia, and in light of some resistance it is important to 
ensure that this potential model of care meets expectation, prior to implementation. 
The overall aim of this thesis is to evaluate a model of pharmacist prescribing in an elective surgery 
pre admission clinic (PAC), using the validated National Health Performance Framework (NHPF), 
which was revised and approved by Australian Ministers in 2009. The framework uses six 
dimensions to assess how a health system performs; ‘effectiveness’, ‘safety’, ‘responsiveness’, 
‘continuity of care’, ‘accessibility’ and ‘efficiency and sustainability’. 
A randomised controlled trial was undertaken in PAC, with 400 patients randomised in to either the 
intervention or control arm. Patients in the intervention arm were seen by a nurse, Resident Medical 
Officer (RMO), anaesthetist and the pharmacist prescriber. The pharmacist was responsible for the 
taking of a medication history, and prescribing the national inpatient medication chart (NIMC) to 
reflect the patient’s regular medications and the plan for medications peri operatively. Within the 
pharmacist’s agreed scope of practice was also the initiation of venous thromboembolism (VTE) 
prophylaxis, following a risk and contraindication assessment. Patients randomised in to the control 
arm still saw the same four healthcare professionals, including a pharmacist for usual care duties. 
The prescribing of the medication chart, including VTE prophylaxis, was the responsibility of the 
Resident Medical Officer (RMO) from the treating surgical team. The primary end point of the 
study was the safety and accuracy of the NIMC. The secondary end point was the appropriateness 
of VTE prophylaxis prescribed in clinic.  
Medications charts were audited against the medication history and plan for medication peri 
operatively. Medication charts in the intervention arm contained significantly fewer omissions of 
regular medications, significantly less prescribing errors involving selection of drug, dose or 
frequency and significantly fewer orders with at least one component of the prescription missing, 
incorrect or unclear. VTE risk assessments were documented, and prophylaxis was prescribed, 
significantly more appropriately in clinic. 
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The significant differences between arms in omissions of medication prompted an investigation in 
to the appropriate of prescribing, and significance of omissions. A multidisciplinary panel was 
convened, and assessed the appropriateness of prescribing utilising a validated tool, the Medication 
Appropriateness Index (MAI). Panel members were asked to rate the appropriateness of 
medications prescribed, and the significance of medication omissions in terms of potential patient 
harm or ward inconvenience, from a random 5% sample of patients from the main study. For the 
appropriateness of prescribing, overall results were the same between arms, as judged by individual 
panel members. Medication charts in the control arm contained significantly more omissions than in 
the intervention arm, a number of which were rated by the panel members as having the potential 
for patient harm or ward inconvenience. 
Patient satisfaction was evaluated using a questionnaire containing 12 closed questions on a 5 point 
Likert scale, which was given to the patient after the pharmacist appointment. The response rate in 
PAC was 182/200 (91%). Consultation satisfaction was high, and high percentages of patients 
agreed that they had a plan for medication explained clearly to them, that their understanding of the 
plan was checked, that any information given was easy to understand, any questions were answered 
in a way they easily understood, and their concerns about medications were understood. This led to 
a high percentage of patients that agreed that the pharmacist had helped prepare them for their 
surgery. 
In conclusion, pharmacist prescribing in PAC has been shown to be as safe, effective and 
appropriate as usual care. Patient perceptions to the model of care appear not be a barrier to 
implementation. However, this was one pharmacist in one model of care. Future work should focus 
on the training and education requirements to reliably produce competent and fit for purpose 
pharmacist prescribers, who can replicate these results across different models of care, and ensure 
that pharmacists’ skills are utilised to their full potential in the Quality Use of Medicines (QUM). 
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1  Introduction 
 
In light of an increasing demand on the healthcare workforce, a focus has been placed on the 
role of alternative workforce options, including non-medical prescribers within the healthcare 
system. Pharmacists, with extensive knowledge and skills in the application of pharmacology and 
therapeutics, are well placed to contribute to the prescribing process. 
The main driver behind pharmacist, and other non-medical professions, prescribing has been 
the desire to: 
• provide consumers with improved, responsible and safe access to prescription medicines 
• optimise use of pharmacists’ and doctors’ skills and time 
• reduce inefficient use of health resources.[1] 
Following recommendations made in the Crown Reports to the government of the United 
Kingdom (UK) in 1999, changes were made in legislation resulting in the extension of prescribing 
privileges to non-medical professionals, including pharmacists,[2, 3] 
There are two models of pharmacist prescribing in the UK: 
(1) Supplementary prescribing was introduced in 2003, and involves a voluntary partnership 
between the responsible independent prescriber, the supplementary prescriber and the 
patient, to implement an agreed patient-specific clinical management plan [4] 
(2) Independent prescribing was introduced in 2006, in this model the pharmacist has sole 
authority to make treatment decisions and is wholly responsible for the resultant 
outcomes[5] 
An independent prescriber is defined as a ‘practitioner responsible for the assessment of patients 
with undiagnosed or diagnosed conditions and for decisions about the clinical management 
required, including prescribing’.[6] 
Prescribing rights were also granted to several other health professionals in the UK following the 
Crown Report, including nurses, physiotherapists, radiographers, podiatrists and optometrists. 
Pharmacist prescribing has been introduced in to several other countries, including the United States 
of America (USA), Canada and New Zealand (NZ), where pharmacists can prescribe medicines 
previously only prescribed by medical practitioners.  
In Australia, pharmacist prescribing is yet to be introduced as a model of care. Several other health 
professionals have been granted prescribing rights, including podiatrists, optometrists, midwives 
and nurse practitioners. In 2010, nurse practitioners were granted full access to prescribe medicines 
on the Pharmaceutical Benefits Scheme (PBS). 
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The introduction of non-medical prescribing in Australia and other countries has also been 
accompanied by the development of curricula for undergraduate and postgraduate prescribing 
training courses, to ensure the reliable and sustainable production of competent prescribers. 
Despite the granting of prescribing rights to several other professions, including pharmacy, reviews 
have shown that there is a lack of evidence from studies as to the benefits in safety, efficacy, access 
to medicines, appropriateness and cost effectiveness of non-medical prescribing.[7, 8] 
The views of the medical profession on non-medical prescribing have been mixed, with concerns 
expressed in Australia over the ‘task substitution’ that has been suggested in order to relieve the 
work pressure on doctors, and a reasonable call for evidence to prove that any new model of care is 
safe and of an acceptable quality.[9, 10] 
The lack of evidence, and call from the medical profession to prove the safety of any new scope of 
practice, are the reasons why evaluation of the model of care through pilot studies is essential prior 
to implementation. 
 The broad practice of hospital pharmacy lends itself well to developing models of 
pharmacist prescribing for the Australian setting, as pharmacists have medicines knowledge and the 
skills inherent to prescribing, along with access to patient clinical records and experience in 
practising as part of a multidisciplinary team. 
This research explores a trial of collaborative doctor pharmacist prescribing in a multidisciplinary 
surgical Pre-Admission Clinic (PAC), evaluated using a National Health Performance Framework 
(NHPF) to provide evidence across the indicators previously mentioned.[11] 
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1.1 The Current Healthcare Workforce, Access to Medicines and Healthcare 
Healthcare is defined as the prevention, treatment, and management of illness and the 
preservation of mental and physical well-being through the services offered by medical and allied 
health professions. Healthcare embraces all the goods and services designed to promote health, 
including preventive, curative and palliative interventions, whether directed to individuals or to 
populations.[12] Healthcare workers are those people whose main activities are aimed at enhancing 
health.[13] 
Healthcare workforce shortage is a well-documented global phenomenon. A 2006 report by 
the World Health Organisation (WHO) estimated that a 70% increase in the health workforce is 
required worldwide, including doctors, nurses and midwives in order to meet current demand. This 
figure increases to as high as a 139% increase required in the Africa region. The lowest scale of 
increase identified was a 40% workforce growth requirement in the Americas region.[14] In 
numbers, this equates to a predicted worldwide shortage of 4 million doctors, pharmacists, nurses, 
midwives and other healthcare workers, over the next decade. 
Australia is no exception to this phenomenon of health workforce shortage, with several 
reports over recent years highlighting the shortages, reasons behind them and possible 
solutions.[15-17]  
In 2003, Brooks et al expressed concerns regarding doctor shortages, especially in rural areas, 
and suggested various methods that they felt merited further investigation, including: greater 
flexibility for entry of highly trained overseas doctors; increasing medical school student intake; 
and workplace practice alternatives, for example ‘task substitution’.[18] 
In 2004 the Australian Health Minister’s Conference (AHMC) developed the National Health 
Workforce Strategic Framework (NHWSF). The NHWSF resulted from ministers’ recognition that 
addressing the health workforce shortage was a high priority for Australian Health Ministers.[19] 
The framework defined the following vision for the direction in which national health 
workforce effort should be focused, and the guiding principles for strategic action in achieving the 
vision, and strategies to deliver that vision: 
“Australia will have a sustainable health workforce that is knowledgeable, skilled and 
adaptable. The workforce will be distributed to achieve equitable health outcomes, suitably 
trained and competent. The workforce will be valued and able to work within a supportive 
environment and culture. It will provide safe, quality, preventative, curative and supportive 
care that is population and health consumer focused and capable of meeting the health needs 
of the Australian community.” 
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The report summarized that Australia is experiencing workforce shortages across a number of 
health professions; including doctors, nurses and pharmacists, and that those shortages were even 
more acute in rural and remote areas. 
The framework was designed to guide national health workforce policy and planning 
throughout the decade, ensuring that actions were sustainable and linked to an overall direction. It 
was recognised that a collaborative, multidisciplinary approach was needed to effectively tackle 
workforce issues. 
The key challenges driving the framework at the time of its release were health workforce 
shortages and misdistribution, and the future challenges that were recognised, including: 
• demographic changes – focusing not just on the well known fact that Australia has a slowly 
growing, but ageing population but also on the key workforce impact of demographic 
change. In Australia in 2004 the workforce was growing at a rate of 17,000 per year, by 
2020 it is predicted to be just 12,500 per year 
• new technologies – the expectation for the next 20-30 years is that health care advances and 
innovations will be upon the healthcare system at an astounding rate, with demand for their 
prompt uptake by increasingly well informed consumers. The implications for that include a 
greater demand for services, the ability to provide more services and safer care, a change in 
the way services and care are provided, and an ever expanding need for training and regular 
skills updates throughout practitioner careers. 
• empowered consumers – who will demand to know more about treatments, their 
effectiveness, and the track record of the practitioners involved in treating them. Consumers 
are likely to seek out the most advanced, safest, lowest cost care options. 
The Australian Health Workforce Official’s Committee (AHWOC) produced its annual 
report in 2004/2005, a year in which the work of AHWOC had been dominated by consideration of 
reforms of the system and structures in which the health workforce operates.[20] The annual report 
considered the issues of workforce at the highest levels of government. 
A number of reports made predictions of future workforce shortages. The Productivity 
Commission, in its 2005 report on Australia's health workforce, detailed shortages in the health 
workforce "in general practice, various medical specialty areas, dentistry, nursing and some key 
allied health areas." It suggested shortfalls of 800 to 1,300 GPs in 2002 (~5% of the GP workforce), 
and an anticipated shortfall of 10–12,000 nurses (~5% of the nursing workforce) in 2006 and 12–
13,000 in 2010. 
Also in 2005 the Australian Health Workforce Advisory Committee (AHWAC), the 
Australian Medical Workforce Advisory Committee (AMWAC) and AHWOC released a joint 
information paper entitled “A Models of Care Approach to Health Workforce Planning”, which 
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encouraged thinking and discussions about models of care health workforce planning.[21] The 
paper noted that the exploration of new approaches to health workforce planning was being driven 
by demographic shifts and broad health system changes. Workforce shortages and shrinkage in the 
available pool of potential new workers were added pressures, responsible for challenging 
Australian workforce planners to look for new, more consumer-focused and cost effective ways of 
using the health workforce, including the consideration of multi-health-professional and multi-
functional approaches to health workforce planning. The report also stated that before a ‘models of 
care’ approach to health workforce planning can be undertaken, it may be necessary to define a 
‘best practice model’, and in the absence of a defined optimal model of care the model of care 
approach to workforce planning involves: 
• selecting a particular care group 
• identifying and describing the most common prevailing models of care 
• defining the multidisciplinary workforce currently associated with these models of care, 
including the occupations represented, what they do and the skills required 
• estimating the growth in demand for a defined period using appropriate indicators 
• calculating future workforce requirements based on models and growth in demand 
• projecting future workforce supply 
• analysing any mismatch in projected workforce requirements and supply estimates 
• strategies to achieve a balance in workforce requirements and supply 
The Australian Government Productivity Commission released a research report on 19th 
January 2006 which examined issues impacting on the health workforce, including the supply of, 
and demand for, health workforce professionals.[22] They proposed solutions to ensure the 
continued delivery of quality healthcare over the next 10 years, which included initiatives to boost 
supply through more education and training and strategies to improve retention and re-entry; 
strategies to moderate demand such as through a shift toward preventive medicine; and initiatives 
which maximise the effectiveness and productivity of the available pool of health workers. 
Also in 2006, the Council of Australian Governments (COAG) agreed to a significant 
national health workforce reform package to enable the health workforce to better respond to the 
evolving needs of the Australian community, while maintaining the quality and safety of health 
services.[23]  
The National Health Workforce Taskforce (NHWT) was established as part of these 
reforms, to undertake projects which inform development of practical solutions on workforce 
innovation and reform. It is a national body created under the Australian Health Ministers’ 
Advisory Council (AHMAC) committee structure and reports directly to the Chair of AHMAC’s 
Health Workforce Principal Committee (HWPC). 
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At the same time, the Australian Institute of Health and Welfare (AIHW) have published 
multiple studies across the issue of health workforce shortage with some reports ranging from as far 
back as 1992. The reports detailed demographics and labour force statistics in medicine, eye health, 
dental, nursing and midwifery, physiotherapy, occupational therapy, psychology and pharmacy.[24-
31]  
The 2006 Census of Population and Housing provided an overview of Australia’s current 
health workforce, covering four key occupational groups: Generalist medical practitioners, 
specialists, dental practitioners and nurses, including midwives, showing that there were 450,000 
Australians employed in the health occupations, accounting for around 5% of the total 
workforce.[32]  
More than half (54%) of the workforce were employed in nursing occupations, with medical 
professions (12%) and allied health professionals (eg pharmacists, physiotherapists, occupational 
therapists) (9%) of the workforce.  
The report also stated that new models of care will be required, but did not specify what 
these models of care might be. It also suggested that with research and technology increasing 
diagnosis and treatment, growing community expectations and an ageing population, the demand 
for health workforces will increase while the available labour market will tighten. 
Specifically in terms of allied health workforce, a report was published in March 2006 by 
AHWAC entitled “The Australian Allied Health Workforce – An Overview of Workforce Planning 
Issues”.[33] It provided an overview of the status of the allied health workforce, with a view to the 
possible need to commission specific national level workforce planning projects for the allied health 
workforce. It also provided details of a range of current workforce issues for possible further 
investigation, but acknowledged it was limited by not having future predictions on workforce 
requirements. 
A ministerial report published by Allied Health Professionals Australia (AHPA) in February 
2008 acknowledged significant national shortages in key allied health disciplines, affecting health 
services in the public, private and community sectors, in cities as well as in rural areas. They also 
offered theories for the high attrition rates being related to poor career paths and inadequate pay, 
called for a comprehensive and regular workforce study to be undertaken to enable the current 
workforce problems to be addressed, noted that rural and remote areas have less allied health 
professionals per head of population than urban areas, and indigenous communities in remote areas 
often have very little or no access to allied health services. Recommendations included 
strengthening of indigenous health services by increasing the number of allied health professionals, 
in order to tackle chronic conditions such as diabetes and obesity.[34] 
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In 2008, Keane et al published the ‘Rural Allied Health Workforce Study (RAHWS)’ which 
concluded that the absence of accurate data profiling the existing allied health workforce presents a 
major challenge for future workforce planning. [35] 
The NHWT most recently released a report in April 2009, detailing the “Health Workforce 
in Australia and Factors for Current Shortages”.[15] Health workforce shortages cited were often 
linked to the ageing population in Australia driving: 
• an increased demand for health care services and the health care workforce  
• a reduced supply of health care professionals as the health workforce ages. 
The NHWT report also identified many more factors that influenced workforce shortages, and 
found that the factors broadly relate to one of the following 3 themes: 
• escalating demand for health care workers 
• labour market competition  
• a constrained training system with limited capacity to accommodate the increasing number 
of students entering the system. 
NHWT also concluded that rural and remote services suffer from well documented shortages in 
health workforce. People in rural and remote areas often have more difficulty in accessing health 
workforce services, and the number of health professionals relative to population diminishes for 
communities located further away from the major cities. 
Segal and Bolton, in 2009, also reported that on top of workforce shortages, the health 
workforce market is influenced by a much wider range of factors.[36] A number of factors were 
also identified that were increasing the demand for health workforce: 
• burden of disease in the ageing Australian population 
• changes in service delivery 
• community expectation 
• workforce expectations 
• workforce specialisation 
• unintended effects of workforce strategies (for example, hospital demand management 
strategies resulting in shifting demand from the acute to the community sector). 
NHWT released a report in 2010 from the National Health Workforce Planning and Research 
Collaboration, Which was established in 2009 between The University of Queensland, The 
University of Melbourne and PricewaterhouseCoopers. The NHWT requested the Collaboration to 
undertake a project to explore the likely nature and contingencies for a nationally consistent 
approach to prescribing medications by non-medical health professionals.[37] The report concluded 
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that non-medical prescribing in Australia will improve equitable access to medicines for patients 
within a governance framework focused on safety and quality use of medicines. 
In 2010, Health Workforce Australia (HWA) also commenced operations, established by COAG, 
who recognised that a national coordinated approach was needed to create a health workforce able 
to meet the current and future healthcare needs of all communities. HWA’s goal is to build a 
sustainable workforce in Australia, via the following objectives: 
• Building capacity by delivering more health professionals more quickly and efficiently. 
• Boosting productivity of the workforce with new workforce models that maximise the skills 
and flexibility of all health professionals across the entire workforce. 
• Improving distribution to get the workforce to the places and specialties where it is needed. 
• Building the evidence for national health workforce reform and innovation through 
planning, research and evaluation. 
• Providing leadership to inform and influence national health workforce policy and program 
decisions. 
• Working in collaboration with key stakeholders to deliver targeted programs to drive reform 
In 2011, in a national call for action for workforce reform across the health and education sectors, 
HWA released The National Health Workforce Innovation and Reform Strategic Framework for 
Action 2011–2015.[38] Proposed future outcomes were a sustainable and affordable health system, 
increased equality in access to services and sustainable partnerships between health service 
providers and educators in preparing and developing the health workforce. It was stipulated that the 
framework may ‘seek to seed innovations and reforms not previously undertaken’. 
In 2012, HWA released the first, long term national projections for doctors, nurses and midwives 
from now through to 2025; Health Workforce 2025.[39] The report’s overall goal is to ensure 
Australia’s health workforce meets the demands of the population. 
One of the key objectives of HWA’s 2012-2013 work plan was to build workforce flexibility 
through expanding workforce scope initiatives.[40]  
In line with this, another project currently being undertaken by HWA, and due for completion in 
late 2013, is the Health Professionals Prescribing Pathway Project (HPPP).[41] The HPPP aims to 
describe the key steps a health professional must complete to become a safe and competent 
prescriber within the scope of their professional practice, and deliver a standard approach to 
prescribing by health professionals, other than doctors. The report summarises that this will ensure 
Australians receive safe, high-quality healthcare when and where they need it. 
One example of the problem with access to services and medication was highlighted in a 
study by Kowanko et al in 2004.[42] The authors sent out 225 surveys, of which 114 were 
completed (51% return rate), to workers and managers from approximately 30 health and human 
 
 
9
service organisations across metropolitan, rural and remote areas of South Australia. The 
purposively selected sample had to have some involvement with Aboriginal people suffering from 
mental health disorders, and management of their medications. A number of issues influenced 
quality use of medicines in the patient population, including limited access to specialist services. 
The authors also concluded that the range of workers providing medication services was very wide, 
many of whom lacked adequate training or resources.  
Another study by Gordon et al from Townsville Hospital in Queensland, Australia also 
highlighted the issue of access to services. In the study, involving a computer assisted telephone 
interview of 410 cancer patients, the authors found that over 46% of patients lived more than 
100Km away from the hospital and 3% lived more than 600Km away. Average out-of-pocket 
expenses involved in attending hospital for treatment ranged between $563 and $6231, with a mean 
value of $4311.[43]  
1.2 Training Requirements of Existing Australian Prescribers and Review of 
Literature Surrounding Suitability 
1.2.1 Medical Practitioners 
Between June 2007 and June 2008 the total number of prescriptions written, as reported by 
the Pharmaceutical Benefits Scheme (PBS), was 171,296,023. The numbers of PBS prescriptions 
dispensed has increased each year. In 2008 there was a 1.6 per cent increase in prescription items 
dispensed compared to 168.5million  in 2007.[44] 
The cost of these medicines was significant. Total Government expenditure on the PBS 
reached $7,034 million, which amounted to 83.3% of the total cost of medicines, and another 
$1,189.5 million in patient contributions.[44] 
Due to legislated restrictions on both prescribing and dispensing authorisations in Australia, 
the ability for health professionals to prescribe or dispense under the PBS is limited. As a result, the 
majority of prescribing in Australia is done by medical professionals, with limited prescribing by 
other professions including dentists, optometrists, podiatrists and nurse practitioners. 
In order to gain access to the rights to prescribe medicines and to prescribe within the PBS, 
the training and education required to become a registered medical practitioner is rigorous and 
lengthy. There are 2 types of initial degree in Australia undertaken; an undergraduate 6 year 
Bachelor of Medicine and Bachelor of Surgery (MBBS), and a 4 year graduate entry medical 
degree. Upon completion of the medical degree, graduates enter the medical workforce, primarily in 
major teaching hospitals, as interns, for a period of 12 months. Only on completion of this year do 
junior doctors receive full medical registration.  
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The intern year involves a series of rotations to specific clinical departments, and is 
governed by the State Postgraduate Medical Education Council (PMEC) in Queensland and other 
equivalent bodies in other states. The PMEC has attempted to provide training in order to expose 
the medical practitioner to a range of clinical situations and environments whilst under supervision. 
It is often referred to as Post Graduate Year 1, or PGY1. 
After successful completion of the internship, junior medical practitioners usually spend a 
number of years rotating between clinical departments; and often rotate to regional and rural 
hospitals. Rural rotations serve two purposes; to meet the service and workforce needs and to 
expose the doctor to a greater variety of clinical settings. Doctors in this period are often referred to 
as Resident Medical Officers (RMOs). This term is known as Post Graduate Year 2 and 3 (PGY2 
and PGY3).  
In order to undertake specialisation, at the end of PGY2 or PGY3 medical practitioners may 
seek admission to a vocational “advanced” training program run by one of the medical colleges. 
These programs, some of which offer a ‘basic training program’, may be undertaken by a RMO in 
the lead up to applying for advanced training. 
Once accepted into the college advanced training program, often after a “primary 
examination”, the junior doctor must apply for and secure employment in a registrar position. This 
position must be an accredited training position by the relevant college. This stage of training 
usually takes between 3-5 years. 
Medical practitioners training in General Practice will undertake their advanced training in 
private GP training practices, as opposed to training for the majority of specialty medical fields, 
which is undertaken in the tertiary system. 
Upon successful completion of the advanced training, doctors are awarded a Fellowship of 
the respective College and will be recognised as a specialist in that particular discipline, and their 
registration with the Medical Board is “endorsed” to reflect these qualifications.  
Upon completion of specialist or GP training, the vocational options for medical 
practitioners broaden to include private practice, a combination of private and Visiting Medical 
Officer (VMO) engagement at public hospitals, or employment as a specialist in a public hospital. 
Standards for education and training of medical practitioners are monitored by the Australian 
Medical Council (AMC). The AMC is an independent national body, set up under Commonwealth 
legislation, that sets standards for medical education and training. It has four core functions: 
1. Assessment of medical courses and training programs (both medical school courses and the 
programs for training medical specialists) and accreditation of programs which meet AMC 
standards 
2. Assessment of international medical graduates who wish to practise medicine in Australia 
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3. Advice to medical boards on uniform approaches to the registration of medical practitioners 
and the maintenance of professional standards 
4. Advice to the Australian government on the recognition of medical specialties. 
In summary, the process for obtaining rights to prescription only medicines in Australia is 
rigorous and contains many steps required by accrediting bodies. These checks and balances were 
designed to achieve a robust model of training and accreditation, aimed at ensuring competent and 
fit for purpose practitioners.  
Under state and federal legislation in Australia, medical practitioners are authorised to 
prescribe as soon as graduating from university and registering with the relevant medical board. 
There are few legislative restrictions placed on intern prescribing. Those existing restrictions often 
arise from PBS requirements, for example, that restricted or authorised medications to be prescribed 
by a ‘specialist’ in that area. 
1.2.2 Views on Suitability of Training as Preparation to Prescribe 
In 2002, Pearson investigated the factors influencing intern prescribing, by interviewing 20 
randomly selected interns from two hospitals in New South Wales, and found agreement that 
Medical school pharmacology and therapeutics training was highlighted as an example of ‘how not 
to teach prescribing’.[45] The recurrent theme through responses was that medical school training 
provides ‘no practical experience’ and fails to ‘tell you what doses you should be using, how often 
you should be using the drug, the route you should be using’ and does not prepare students for the 
competing pressures interns encounter. A number of positive influences were identified, amongst 
which were nurses and pharmacists. 
A 2007 study by Tobaiqy, in Scotland, aimed to determine whether first year foundation 
doctors believed that their undergraduate education in clinical pharmacology and therapeutics had 
prepared them to prescribe safely and rationally.[46] A questionnaire was issued to all 90 first year 
doctors at Aberdeen Royal Infirmary Teaching Hospital, covering undergraduate and postgraduate 
training in pharmacology, experience of ADRs (Adverse Drug Reactions) and drug interactions, 
confidence in drug usage and any perceived deficiencies in training in clinical pharmacology. With 
a 71% return rate, the results showed only 8% of respondents rated their knowledge of clinical 
pharmacology as ‘good’, whereas 30% rated it as ‘poor’ or ‘very poor’. With regards to whether 
undergraduate training had equipped them to prescribe safely and rationally, 41% replied ‘no’. 
When asked about which topics in clinical pharmacology required more extensive coverage, the 
topics cited by more than 50% of respondents were: ‘prescribing for special patient groups, drug-
drug interactions, ADRs and therapeutic drug monitoring’. 
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Similarly in 2007 in Australia, Coombes et al assessed the attitudes of 4th year medical 
students with regards to their readiness to prescribe, associated risks and perceptions of available 
support.[47] By surveying 101 students, the authors discovered that medical students felt 
unprepared to start prescribing. Most students, or 94%, felt that they would be able to prescribe for 
most ‘simple’ complaints and 82% felt they would be able to complete discharge prescriptions. 
High risk situations instilled less confidence in the students, with only 54% and 55%, respectively, 
confident with managing warfarin prescribing and a patient with diabetes. The authors concluded 
that more work is needed to prepare doctors to prescribe safely. 
In 2008 in Australia, Coombes et al investigated factors behind intern prescribing errors by 
interviewing 14 interns involved in 21 prescribing errors.[48] The main finding was that lack of 
drug knowledge was not the single causative factor in any one error, and all errors were 
underpinned by a culture that saw prescribing as a low risk, repetitive chore.  
Pillans, in Australia in 2009, recognised that prescribing is a core skill for every graduating 
medical student and their competence should be assessed before they are allowed to prescribe.[49] 
A study by Hilmer, in 2009 at Royal North Shore Hospital in Sydney aimed to assess the 
ability of new interns to prescribe medications safely and appropriately by giving 191 of  them a 
clinical case scenario that tested prescribing ability.[50] The results showed that no intern 
completed all prescribing tasks correctly and no intern charted the patient’s regular medications on 
admission completely correctly. Only six wrote an accurate discharge list, and none wrote an 
accurate discharge list and a legal Schedule 8 discharge script.  
This is in stark contrast to the findings by Coombes et al, discussed earlier, about the 
perceptions of students of their ability to complete these tasks.[47] 
In a separate part of the study, the interns’ views of pharmacology training as an 
undergraduate were elicited via a questionnaire. None of the respondents strongly agreed that they 
felt adequately trained to prescribe medications in their intern year. 
1.2.3 Dentists 
Dentists are also established authorised prescribers of a limited number of prescription 
medicines in the Australian healthcare system. The number of approved items is a very small 
proportion of prescriptions compared to medical practitioners, attributable to their much narrower 
scope of practice. 
Dentists trained in Australia are required to have met the entry requirements of one of the 
Australian institutions offering dental courses, and then complete the required full-time academic 
training (approximately five years) leading to a dental degree. If dentists wish to specialise, they 
must complete extra study after having had clinical experience.  
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Similar to doctors, dentists have prescribing rights straight from graduation. The authority to 
prescribe is governed by individual state legislation, which may vary from state to state. Dentists 
have a narrowed scope of practice, and as such, both state and federal PBS legislation permit a 
dentist to prescribe from a restricted drug list, and only specifically for a person’s dental treatment.  
1.2.3.1 Views on Suitability of Training as Preparation to Prescribe 
There is nothing to be found in the literature assessing the suitability of dentist training with 
regards to prescribing of prescription medications. 
1.2.4 Optometrists 
Optometrist training is accredited by the Optometry Council of Australia and New Zealand 
(OCANZ) and includes: 
• undergraduate courses suitable for general registration 
• undergraduate courses which include therapeutic training suitable for general registration 
and endorsement for scheduled medicines 
• postgraduate courses in ocular therapeutics suitable for endorsement for scheduled 
medicines  
Applicants seeking registration board approval for therapeutic practice, or prescribing rights, 
must hold one of the accredited qualifications, so either one of the two undergraduate courses with 
accredited therapeutics training, or the Postgraduate Certificate in Ocular Therapeutics. 
Courses are accredited against the Accreditation Manual for Optometry Courses in Australia 
and New Zealand which defines the organisation, governance, educational goals and objectives and 
course curriculum.[51] 
Optometrists have sought prescribing rights for therapeutic drugs independently in each 
state over the last 15 years; starting with Victoria in 1996. In 2005, the Optometrists Association of 
Australia issued a response to the productivity commission’s paper on the health workforce. The 
response surmised that  
‘while the current Australian optometric workforce was sufficient to meet the eye care needs 
of the Australian community, there were several opportunities for improving the delivery of 
eye care, two of which were extending prescribing rights to optometrists in all states and 
territories, and extending the PBS to cover prescribing of certain medications by 
optometrists.’ 
Since 2005 optometrists in Victoria and Tasmania had been prescribing eye medications to 
treat eye infections, allergic reactions of the eye and, in some cases, glaucoma. Legislation to 
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similar effect had been passed in the Australian Capital Territory (ACT), New South Wales (NSW), 
the Northern Territory (NT) and Queensland, and is planned in South Australia (SA). 
Prescribing rights vary between states, with no prescribing rights at all in Western Australia 
(WA); and with each state having individual legislation and slightly different formularies available. 
One of the major concerns has been that with this approach comes a lack of nationally consistent 
standards and principles to protect the public. 
1.2.4.1 Views on Suitability of Training as Preparation to Prescribe 
In recognition of this problem, the Royal Australian and New Zealand College of 
Ophthalmologists (RANZCO) released a position paper on optometrist prescribing to answer some 
of the concerns surrounding the lack of nationally consistent standards, with a view to setting a 
nationally consistent scope of practice, along with rigorous training and assessment methods to 
assess the competencies of prescribing optometrists.[52] 
In 2008, the Council of Optometry Registration Authorities (CORA) also called for the 
states and territories to adopt a unified approach to avoid the problems of a discordant approach to 
prescribing, highlighting a main issue as the inconsistency between the states of patient access to 
medication.[53] 
Optometrists were granted PBS access from 1st January 2008, and as with dentists, limited 
to prescribing only the items relevant to their scope of practice, as listed in the PBS optometrist 
section. 
1.2.5 Podiatrists 
Surgical podiatrists are also authorised to prescribe prescription only medicines; with 
regulations being slightly different in each state. They have access to a limited list of drugs to 
prescribe, mainly comprising of antibiotics, local anaesthetics and analgesics. 
In order to gain prescribing rights, all podiatrists must complete a Bachelor of Podiatry and 
be registered to practise in the appropriate State. In some states, additional qualifications are 
legislatively required in order for podiatrists to be able to prescribe and supply of a range of 
prescription only medicines. 
In Victoria in 2002, the Podiatrist’s Registration Board of Victoria and the Australian 
Podiatry Association proposed that regulation of podiatry prescribing be undertaken by the 
Podiatrist’s Registration Board and that the Board regulate prescribing by podiatrists in the 
following manner: 
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i. Approve courses of study offered by educational and professional bodies, that in the 
opinion of the Board, provide training which qualifies podiatrists for endorsement of their 
registration to prescribe 
ii. Ensure that therapeutic competencies are monitored and maintained. This will be 
achieved through clinical audits and ongoing development of clinical pathways. Training 
programs will be modified appropriately in response to these activities. 
iii. Maintain a register of individuals who have acquired and are maintaining competency as 
prescribers 
iv. Keep the content of prescribing formulary under review and submit any proposals for 
change to the appropriate bodies. 
A permanent sub–committee of the board is to be formed, for the purpose of: 
1. Making recommendations to the board regarding: 
• Alteration to register, removing or adding prescribers 
• Adding or removing approved drugs 
• Academic requirements for prescription rights 
2. Investigating complaints with regards to prescribing, as directed by the Board 
3. Liaising directly as required with external bodies such as: 
• Adverse Drug Reaction Advisory Committee (ADRAC) 
• Poisons Advisory Committee, Department of Human Services”[54]. 
In Queensland in 2006, amendments were made to the Health (Drugs and Poisons) 
Regulation 1996 to allow recognised ‘surgical podiatrists (who hold fellowship with Australasian 
College of Podiatric Surgeons) to prescribe, supply or administer a limited formulary of Schedule 4 
and one Schedule 8 drug.’ 
In Victoria, under the terms of the Health Professions Registration Act (2005) and the 2007 
Regulation amendments to the Drugs, Poisons and Controlled Substances Act 1981, the Podiatrists’ 
Registration Board had been given authority to determine which Schedule 2, 3 and 4 medicines may 
be possessed, used, sold or supplied by its registrants following approval by the Health Minister. As 
a result, the Podiatrists’ Board was empowered to create a subset of registrants known as 
‘authorised prescribers’. Final approval of the initial formulary was given by the Health Minister in 
June 2009. 
Under the process of National Registration & Accreditation, local state and territory health 
professional registration boards were disbanded and replaced by national authorities. As such, the 
Podiatry Board of Australia was constituted in 2009, with the task of taking over the administration 
of registration and regulation of standards of practice for all Australian podiatrists in July 2010. 
Under the requirements of the Health Practitioner Regulation (Administrative Arrangements) 
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National Law Act 2008, the Board began consultation on the mechanisms for implementation of 
national standards for podiatric prescribing within Australia, submitted for approval by the 
Australian Health Workforce Ministerial Council. 
The standard was approved on 31 March 2011, with approval taking effect from 1 July 
2011. To be eligible to be granted an endorsement for scheduled medicines ie to administer, obtain, 
possess, prescribe, sell, supply or use Schedule 2, 3, 4 or 8 medicines for the treatment of podiatric 
conditions an applicant must have completed: 
• an approved program of study in podiatric therapeutics, or 
• a program of study determined by the Board to be substantially equivalent to an 
approved program of study, and 
1. a period of postqualification experience (seven years clinical experience in an 
appropriate setting where active prescribing is occurring and two confirmatory 
references of applicant exposure to patient care involving restricted drugs), or 
2. completion of web-based case studies approved by the Board (20 hours) and a 
specified period of supervised practice (40 sessions of supervision by an endorsed 
prescriber approved by the Board in an appropriate setting where active prescribing is 
occurring in a 12 month period). 
1.2.5.1 Views on Suitability of Training as Preparation to Prescribe 
The issue of podiatrist suitability to prescribe and scope of practice was highlighted in 
Victoria after legislation was passed allowing podiatrists to prescribe ‘drugs of addiction’, such as 
temazepam and codeine. Response from the Australian Medical Association was less than 
supportive, suggesting “podiatrists would be out of their depth”.[55] 
Such media response has highlighted the importance of a formalised agreement of scope of 
practice for non-medical prescribers with all of the members of the healthcare team, especially the 
medical staff. Once the scope starts to stray from a perceived competency framework, 
implementation has become difficult and was met with objections, usually from the traditional 
prescribing workforce. 
A 2010 paper from Australia, by Borthwick et al, used a range of published material and 
unpublished material in private possession to trace a chronological account of the development of 
podiatrist prescribing in both the UK and Australasia.[56] The paper concluded that the changes 
were met with resistance on the right to access, administer, supply and prescribe medicines from the 
traditional prescribing workforce. However, the broader policy agenda allowed workforce redesign 
to continue, and podiatry has assumed wider roles and responsibilities in prescribing. 
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1.2.6 Nurse Practitioners 
Since 1998, a selected subset of nurses, midwives, have been able to order and interpret a 
limited range of tests and to subsequently prescribe specified drugs, under a very limited scope of  
care, to healthy women and their babies during uncomplicated pregnancy, childbirth and the early 
postnatal period. However, similar to optometrists and podiatrists, again a lack of consistency 
across states in legislation acts as a barrier to enabling these guidelines. Access to the PBS was not 
granted at this point in time, and medication was for administration in specified settings.  
In some States and Territories amendments have been made to broaden the scope of such 
legislation to allow midwives to initiate (but not ‘prescribe’ in the full sense given above) the use of 
medications in some circumstances.  
NSW was the first state to authorise the role of the nurse practitioner in 2000, Tasmania and 
the NT in July 2008 and March 2008 respectively. 
 A Nurse Practitioner is defined as  
‘a registered nurse educated and authorised to function autonomously and collaboratively in 
an advanced and extended clinical role. Nurse practitioners are registered nurses with at 
least five years in their chosen area of practice post-registration and at least seven to nine 
years study, including masters-level university qualification. The nurse practitioner role 
includes assessment and management of clients using nursing knowledge and skills and may 
include but is not limited to, the direct referral of patients to other health care professionals, 
prescribing medications and ordering diagnostic investigations”.[57] 
Latest figures suggest there are about 400 nurse practitioners in Australia, working primarily 
in illness prevention, chronic disease management, aged care, emergency care, wound care, diabetes 
education, sexual health and rural health. According to the 2006 AIHW report on Health and 
Community Services Labour Force 29% of nurse practitioners work outside of major cities.[58] 
The nurse practitioner course is accredited by the Australian Nursing and Midwifery 
Council (ANMC), with the standards for course management and curriculum set out in the 
document “Nurse Practitioners – Standards and Criteria for the Accreditation of Nursing and 
Midwifery Courses leading to Registration, Enrolment, Endorsement and Authorisation in Australia 
– with Evidence Guide”.[59] Entrance criteria stipulates that a nurse must have 5 years experience 
as a registered nurse, with 3 years in a speciality and 1 year working at an advanced practice level 
within the speciality. Candidates must have a Bachelor of Nursing, or equivalent, and a 
postgraduate qualification in a speciality field that has prepared the student for advanced practice, 
either as a pre-requisite or integrated into the Masters degree. With regards to prescribing of 
medications the document states “that the curriculum addresses knowledge in advanced 
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pharmacology and therapeutic medication management for prescribers (or for nurse practitioners to 
prescribe competently, legally and ethically)”  
The Nursing and Midwifery Board of Australia (NMBA) released guidelines  in 2011 which 
outlined the educational requirements for courses suitable for attaining the qualifications required 
for a registered midwife to be recognised as an ‘eligible midwife’ and endorsed for scheduled 
medications.[60] There are six recommendations that a midwife has to be able to meet: 
• current general registration as a midwife in Australia with no restrictions on practice 
• midwifery experience that constitutes the equivalent of three years’ full-time post initial 
registration as a midwife 
• current competence to provide pregnancy, labour, birth and postnatal care to women and 
their infants (the continuum of midwifery care) 
• participation in an additional 20 hours per year of continuing professional development (i.e. 
a total of 40 hours) relevant to the continuum of midwifery care 
• successful completion of an NMBA-approved professional midwifery practice review 
program for midwives working across the continuum of midwifery care (to be conducted 
every three years) 
• formal undertaking to complete, within 18 months of recognition, an accredited and 
approved program of study determined by the Board to develop midwives’ knowledge and 
skills in prescribing, or a program that is substantially equivalent to such an approved 
program of study, also to be determined by the Board 
1.2.6.1 Views on Suitability of Training as Preparation to Prescribe 
In 1998 concerns were expressed in the Australian Nursing Journal over nurses’ lack of 
pharmacology training to enable them to prescribe safely and effectively, and that any training 
nurses undergo before prescribing must be tailored to this.[61]  
In 2000 Offredy et al also raised concerns about the pharmacological knowledge and 
decision making skills of nurses in a study where 25 nurse prescribers were presented with a 
number of scenarios.[62] Only a minority were able to identify more than half of the 
pharmacological problems relevant to each case and to suggest an appropriate course of action. This 
resulted in Pulse, a weekly newspaper for GPs, to state that nurses are ‘floundering’ in their 
prescribing role.[63] This was echoed in many other articles in this particular publication.[64-75] 
In 2003 Aronson, a clinical pharmacologist, wrote of the concerns of the nursing profession 
being adequately prepared, especially in the sciences of pharmacology and clinical pharmacology, 
as previously discussed by others.[76]  
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By 2003, the Australian Nursing Journal reported that the UK Nursing and Midwifery 
Council (NMC) had included training in prescribing medicines in the pre-registration curriculum for 
nursing students, to enable all nurses to become supplementary prescribers.[77] 
In 2004 Banning prepared a review of the literature using MEDLINE, CINAHL, OVID, 
PUBMED, EBESCO and also the National Prescribing Service (NPS).[78] The search was limited 
to evidence published in England and relevant to nurse prescribing developments in the UK and 
papers between 1994–2003, the timeframe reflecting the year nurse prescribing was first 
implemented. Banning concluded that the review had drawn attention to the deficits in the scientific 
preparation of nurses in applied pharmacology and therapeutics and called for a more clinically-
focused pre-registration and training programme to provide nursing students with the appropriate 
scientific and professional knowledge to act as a foundation for post graduate education. 
In 2005 Avery, a professor of primary health care and Pringle, professor of general practice 
wrote in the BMJ along similar lines, and referred to both nurse and pharmacist prescribing when 
they said that to ensure safe and effective prescribing the practitioners must be trained 
appropriately, have access to all the tools they need to help them prescribe safely, and strong 
clinical governance is essential to identify any prescriber exceeding his or her competency.[79]  
In 2005, Banning investigated these claims in an article exploring independent nurse 
prescribers’ views on the use of evidence based medicine and practice in nursing.[80] A cross 
section of 16 nurses from practice and district nursing, nurse practitioner, accident and emergency 
nurse practitioner, palliative care nurse, family planning nurse and health visitor participated. Two 
data collection methods were used, a short answer questionnaire and semi structured interviews 
using a focus group technique. All nurses completed the questionnaire. The findings of the study 
were that many nurses were not familiar with evidence based practice, and one recommendation 
was more focus on the exploration of evidence from randomized controlled trials in the training of 
independent nurse prescribers to enable maximum contribution to the medication management of 
patients.  
In 2006 Banning followed this up by suggesting a variety of teaching and learning 
approaches which can be used by nurse prescribers to develop critical thinking skills, on the 
premise that critical thinking is an essential skill in making judgements and informed clinical 
decisions.[81]  
In 2006 Aronson again wrote of an overall concern about the adequate teaching of all non-
medical prescribers to prescribe, with the conclusion that if the correct amount of time and teaching 
was not put into training prescribers it would invariably lead to more patient harm.[82]  
In 2007, Avery wrote again in the BMJ about nurse prescribers specifically, and suggested a 
new model of training, and moving away from the stand alone training package then on offer, to 
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train nurses to prescribe to incorporating the ‘task’ of prescribing within the broader framework of 
the recognised clinical role of nurse practitioners.[83]  
In 2007, the National Prescribing Service (NPS) in Australia announced a two- year project 
aimed to provide nurse practitioners with resources to assist in the quality use of medicines, 
including four new educational packages.[84] 
In 2010 Tuaoi reviewed the evidence and debate that saw the role of nurse practitioner move 
to the doctoral level in America, in order to open the debate about whether it is timely for 
Australian universities to consider the need for a Doctor of Nursing Practice.[85] 
In 2010, Latter et al  evaluated several aspects of pharmacist and nurse independent 
prescribing, including educational courses and suitability, through a postal questionnaire to Nurse 
Independent Prescribers (NIPs) and Pharmacist Independent Prescribers (PIPs) asking specifically 
about any changes that may need to be made to existing courses.[86] Focus group discussions were 
also held with Higher Education Institution (HEI) leads and Designated Medical Practitioners 
(DMPs)  
The study findings indicate that current educational programmes of preparation for nurse 
and pharmacist prescribing are operating largely satisfactorily, and provide fit-for-purpose 
preparation for current pharmacist and nurse prescribing roles. The report recommended that 
attention needs to continue to be given to nurses and pharmacists’ assessment and diagnostic skills 
which underpin their independent prescribing role. 
1.3 Training Requirements of United Kingdom Pharmacist Prescribers 
In 2010 the Royal Pharmaceutical Society of Great Britain (RPSGB) was replaced by the 
General Pharmaceutical Council (GPhC) as the regulator for pharmacy. As such, it is the 
responsibility of the GPhC to set the standards for education and training that regulate both 
provision of pharmacy degrees and pre-registration training to ensure competent and fit for purpose 
clinicians. 
Since 1997, and in line with European Directive requirements the pharmacy degree was 
extended from three to four years, leading in to a one year pre-registration year. All undergraduate 
pharmacy schools were obliged to restructure their programmes and the degree award changed from 
a Bachelors to a Masters of Pharmacy (MPharm). After the one year pre-registration training 
graduates can then register with the GPhC. 
In April 2008, the Government published a White Paper, ‘Pharmacy in England: building 
on strengths, delivering the future’, which recognised that in order to develop consistent and 
coherent high quality practice a number of aspects of education, training, career development and 
workforce planning needed to be addressed, and made specific recommendations as to how the 
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profession’s infrastructure ought to be modernised.[87] More particularly, areas for consideration 
included: post-registration education that supported continuous professional development within a 
coherent nationally recognised framework and called on the profession to rise to the challenge of 
modernising the profession. 
Relevant courses to our research context that the GPhC recognise and accredit are: 
• Master of Pharmacy degrees leading to pre-registration then pharmacist registration 
• prescribing courses leading to pharmacist annotation 
Accreditation relates to specific course providers where all processes are directly quality 
assured. Courses are mapped to the quality credit framework and are agreed national occupational 
standards. The standards define the prerequisites, outcomes, processes and structures expected of a 
Master of Pharmacy Course. The standards also contain an indicative syllabus under the subtitles; 
‘the patient’, ‘medicines: drug action’, ‘medicines: the drug substance’, ‘medicines: the medicinal 
product’, ‘healthcare systems and the roles of professionals’ and ‘the wider context’ 
GPhC also accredits the pharmacist independent prescribing programmes, and the 
Pharmacist Independent prescribing – conversion programme, which is a condensed course aimed 
at pharmacists previously qualified as supplementary prescribers, wishing to become independent 
prescribers. 
Governance, structure and content of courses is dictated by the Accreditation of Independent 
Prescribing Programmes manual.[88] The manual indicates what the learning outcomes and 
indicative content of the course should be to achieve accreditation. 
The indicative content headings; ‘consultation, decision-making, assessment and review’, 
‘influences on and psychology of prescribing’, ‘prescribing in a team context’, ‘applied 
therapeutics’, ‘evidence based practice and clinical governance’, ‘legal, policy, professional and 
ethical aspects; and ‘prescribing in the public health context’ are derived from the prescribing 
competencies first produced by the National Prescribing Centre (NPC) in 2003 and updated in 
2006.[89] 
For entry on to a prescribing course GPhC stipulates that pharmacists must: 
• be a registered pharmacist with the GPhC or the Pharmaceutical Society of Northern Ireland 
(PSNI) 
• have at least 2 years appropriate patient orientated experience in a UK hospital, community 
or primary care setting following their pre-registration year 
Applicants must: 
• have identified an area of clinical practice in which to develop their prescribing skills and 
have up to date clinical, pharmacological and pharmaceutical knowledge relevant to their 
intended area of prescribing practice 
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• demonstrate how they reflect on their own performance and take responsibility for own 
continuing professional development (CPD) 
Additionally: 
• the pharmacist must identify a designated medical practitioner (DMP) who has training and 
experience appropriate to their role. The DMP must have agreed to show supervision, 
support and shadowing opportunities for the student. 
1.3.1 Views on Suitability of Training as Preparation to Prescribe 
The feelings of some of the medical profession as to the suitability of the training for nurse 
and pharmacist prescribing was summed up, in 2005, by a quote in the BMJ from James Johnson, 
the British Medical Association (BMA) chairman.[90] Johnson said “It is difficult to see how 
healthcare professionals who are not trained to diagnose disease can safely prescribe appropriate 
treatment.” 
In the same news article, Hamish Meldrum, the Chair of the BMA’s General Practitioners 
Committee said “This announcement (of extended prescribing rights) raises patient safety issues, 
and we are extremely concerned that the training provided is not remotely equivalent to the five or 
six years’ training every doctor has undertaken. While we support the ability of suitably trained 
nurses and pharmacists to prescribe from a limited range of medicines for specific conditions, we 
believe only doctors have the necessary diagnostic training and prescribing training that justifies 
access to the full range of medicines for all conditions” 
In an editorial in 2005, McGavock cautioned the UK about independent prescribing for 
pharmacists, saying pharmacists were not trained to diagnose and that the specialty should be left to 
the more qualified medical practitioners.[91] He also said that pharmacists were appropriately 
qualified in pharmacology and should be used more in partnership with GPs in prescribing once the 
doctor had provided the correct diagnosis. He also added that nurses are not trained adequately in 
either diagnostics or pharmacology, leading to nurse prescribing being ‘fraught with risk’. 
Weiss et al published a report through the RPSGB, in 2006 which interviewed pharmacist 
supplementary prescribers to explore their views on the education and training they had received to 
prepare them for the new role.[92] On the whole pharmacists found the training course useful, with 
the aspects they found most useful varying according to their background and place of work. Most 
felt that it was the practice based element of the course, with the DMP, that was most useful. 
In 2008, Cooper et al sent a postal questionnaire to all 808 supplementary prescribers 
registered in England exploring training prescribing, safety culture and perceptions of 
supplementary prescribing (SP).[93] With a return rate of 51%, the results showed that 82% thought 
SP training was useful, 58% thought courses provided appropriate knowledge and 62% agreed that 
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the necessary prescribing skills were gained. More diagnostic training was thought to be important 
by 67% of respondents. 
The findings of a review of Pharmacist Independent Prescribing (PIP) training from UK in 
2010 by Latter et al are discussed previously.[86] 
In 2010, in Australia, an article in The Medical Observer reported similar concerns to the 
initial concerns in UK.[94] Australia Medical Association (AMA) vice-president Dr Steve 
Hambleton was quoted as saying “Pharmacists have two choices if they want to prescribe. They can 
either complete medical degrees to become doctors, or they’re welcome to submit a training 
program to the Australian Medical Council (AMC) that would bring them up to the equivalence of 
doctors. Where is the evidence to suggest pharmacist-driven prescribing is safe? Why is it up to 
doctors to prove it is not?” 
In 2011, McIntosh et al surveyed newly registered pharmacists in Great Britain (GB), for 
their views on potential future roles as prescribers.[95] A 5-point Likert scale questionnaire was 
sent out to all 1658 pharmacist entering on to the register in 2009, with a response rate of 25.2%. 
Most pharmacists (86.4%) registered an interest in in prescribing, with most agreeing that they 
should have 2 years of experience as a pharmacist prior to engaging in training. Training needs in 
clinical examination, patient monitoring and medico-legal aspects were acknowledged, with led the 
authors to conclude that a review of the undergraduate course may be necessary to incorporate these 
aspects of training. 
1.4 Scopes of Practice 
Dentists, optometrists, podiatrists and midwives have a limited and clearly defined scope of 
practice, or a limited formulary of drugs from which they can prescribe.  Under the current disparate 
system, the different professions have developed multiple different training and education packages 
tailored to their narrow scope of practice. Assessment of competence for prescribing remains 
inconsistent and without transparency across professions, as highlighted by Morris in an editorial 
from Australia in 2011.[96] 
Defining formularies limited to scope of practice has been achievable for these professions, as 
the drugs required to practice in their scopes are limited and often obvious. Medical practitioners 
have historically either specialised in one field, so effectively limiting their scope of practice in the 
same way, or become GPs.  
The training, education, experience required and competency assessments for becoming a 
specialist or GP are well defined and accepted as producing fit for purpose clinicians who have a 
right to prescribe medications at the end of their training. 
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Nurse practitioners and pharmacists face a different challenge, which is predominantly due to 
the fact that they can practice in a wide range of clinical settings and may not have a defined 
specialist role, making defining a scope of practice for prescribing much more difficult, and a 
formulary basis for restriction untenable.  
1.5 The Current Healthcare System  
1.5.1 The Medication Management Pathway 
The Australian Council for Safety and Quality in Healthcare recommended that “in order to 
recognise what can go wrong with the use of medicines we need to understand the processes that 
are involved”.[97] 
There are multiple stages in this pathway originating from the decision to prescribe through to 
monitoring the outcome of that medication on the patient (See Figure 1).  Medication errors have 
been shown to occur in every stage of this pathway; prescribing, medication order generation, 
reviewing, dispensing and administration processes. 
Figure 1 ‐ The Medication Management Cycle 
	
1.5.2 Prescribing Process 
The prescribing of a medication is the most frequent medical intervention a patient receives in 
hospital.[98] Whilst the literature suggests the standard of prescribing was reportedly generally 
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high, patients were most frequently harmed as a result of prescribing errors; the majority of which 
were preventable. 
In 1994 the WHO published “A Guide to Good Prescribing : A Practical Manual”, which 
acknowledged that “at the start of clinical training most medical students find that they don't have a 
very clear idea of how to prescribe a drug for their patients or what information they need to 
provide.”[99] The main reason behind this was stated to be that undergraduate training did not 
prepare the medical student to prescribe, mainly as training was often diagnostic rather than 
therapeutic, and more specifically pharmacology training focused more on theory than practice. The 
guide states that the result of this is although pharmacological knowledge is acquired, practical 
prescribing skills remain weak. The consequence of bad prescribing habits is stated to be; 
ineffective and unsafe treatment, exacerbation or prolongation of illness, distress and harm to the 
patient and higher costs. The manual focuses of the process of prescribing. 
The opinion of the guide with regards to lack of preparation of medical students to prescribe 
would appear to be backed up by the literature reviewed so far within this document. [47] 
In 2007, Page undertook a qualitative study of the social and cultural influences on 
prescribing practices in two Australian teaching hospitals.[100]  The research identified that 
prescribing was a complex process, which involved six stages: 
• diagnose 
• make primary decisions ie select treatment plan, drug if necessary 
• select dose of drug, duration, communicate order 
• check and review, revise decision if necessary 
• educate patient 
• monitor and review 
 It also outlines the actions undertaken by several different health professionals, including 
pharmacists, in the prescribing process and their key responsibilities. 
In 2010, Coombes et al suggested a similar model of prescribing, involving a four stage 
process with each stage impacting on the next (See Figure 2): 
• gathering patient and drug information including medication history, previous ADRs and an 
accurate diagnosis, 
• making a clinical decision to select the correct drug, form, route, dose and duration of 
treatment depending on the patient’s characteristics and other concomitant diseases and drug 
therapy, 
• communicating these decisions by generating instructions for the supply and administration 
of these drugs 
• reviewing the outcome and revising the prescribing decisions.[101] 
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Figure 2 ‐ Suggested Model of Prescribing (Coombes et al) for Development of Prescribing 
Competencies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The suggested model has also been put forward as a suitable building block around which 
prescribing competencies can be developed in the Australian healthcare setting, which would in turn 
inform the training, development and credentialing of all clinicians.[96] 
The guideline discussed earlier, produced by the Nursing and Midwifery Board of Australia, 
is the first official document in Australia to suggest use of the above prescribing competencies as a 
foundation for a suitable prescribing course.[60]  
This thesis will attempt to evaluate the safety, efficacy and appropriateness of pharmacist 
involvement in various stages of the prescribing process in the pre-admission clinic (PAC) setting, 
when compared against usual care. This is novel research within the Australian healthcare system.  
1.5.3 Prescribing Errors 
Dean et al defined a prescribing error, through a two stage Delphi technique involving 34 UK 
judges, including physicians, surgeons, pharmacists, nurses and risk managers.[102] The definition 
developed from the process was: 
 “A clinically meaningful prescribing error occurs when, as a result of a prescribing decision or 
prescription writing process, there is an unintentional significant reduction in the probability of 
treatment being timely and effective or an increase in the risk of harm when compared with 
generally accepted practice.” 
Consensus was also achieved that errors occur when there is: “a failure to communicate 
essential information; the use of drugs or doses is inappropriate for the individual patient; and 
transcription errors.”  
1. Information gathering: 
• Medication History, ADRs, medication taking 
behaviour, adherence 
• Presenting complaints 
• Current problems 
• Relevant signs and symptoms 
• Pathology results 
• Guidelines, protocols, pathways 
2. Clinical decision making 
• Diagnosis 
• Consider ideal therapy 
• Balance risks and benefits of drug-drug, drug-
patients, drug-disease, actual / potential problems 
• Consider economic / availability of therapeutic 
options 
• Select drug, route, form, dose, frequency, 
duration
4. Monitor and review: 
• Review control of signs and symptoms 
• Review adherence 
• Review patient outcomes 
• Consider need for therapy to be tailored, 
continued or ceased 
• Reflection by prescriber and peer feedback 
3. Communicate decision as an instruction to: 
• Other prescribers to continue and monitor 
• Nursing staff to administer or supply 
• Pharmacy staff to review and dispense or arrange 
supply 
• Patients and carers to administer 
 
Four components of prescribing 
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According to what definition of ‘error’ is used, the literature reports very different error rates 
from studies.  
A study from the UK in 2002 by Dean et al  identified a 1.5% error rate from 36,200 
medication orders written during the study period, which in numbers equated to 135 prescribing 
errors per week during a 4 week period.[103] 
A study from United States of America (USA) by Potts et al showed, from a prospective trial 
of 514 paediatric patients, and 13,828 medication orders a medication prescribing error rate of 
30.1%.[104] The main errors detected in the study were either omissions of core components (such 
as name, form, route, dose or frequency) or unsafe abbreviations. 
1.6 Evidence of Healthcare Benefits of Non-Medical Prescribing Models 
 
A review of the literature has identified a dearth of evidence for the benefits of non-medical 
prescribing. Most of the research so far has originated from the UK or USA, with pharmacist 
prescribing accounting for the largest number of articles. 
1.6.1 Optometrists 
Little research has been published on the safety and effectiveness of optometrist prescribing. A 
greater focus of publishing has been on professional surveys aimed at establishing the scope of 
practice of optometrists and the perceived barriers to implementation of prescribing; particularly 
from an education and training point of view. 
Soroka has been responsible for a number of published journal articles evaluating the 
profession in USA, across both hospital and primary care, predominantly in terms of workforce 
shortages and scope of practice. In 1977, in a study of 4,156 patients, the referral patterns from an 
optometric clinic were analysed with a view to planning the staffing requirements of present and 
future optometric clinics.[105] Thirty percent of the patients examined required further testing and 
specialised services, suggesting that a group practice environment that provides comprehensive eye 
care of ophthalmologists and optometrists would ensure such services are readily available. This 
study did not recommend the prescribing of therapeutic agents, but provides insight into patient 
requirements and referral patterns.  
In 1978, Soroka sent a questionnaire to all hospitals within the 5 counties of New York City, 
a total of 132 institutions.[106] A 77% return rate was achieved and found that 27% of the 
institutions had an optometrist associated with their institution and concluded that optometrists were 
used inadequately as a healthcare resource. The article highlighted a scope of practice that the 
optometry profession would be competent within, which when supported by appropriate education 
and training, optometry could work with ophthalmology to prevent duplication of services and to 
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improve the vision care of the patient population. It was suggested several system changes, 
including clear and distinct reporting relations of optometrists, optometrists triaging patients with 
ocular and visual complaints and development of service protocols for staff optometrists would all 
assist in preventing duplication of services, and contribute to an efficient and effective delivery of 
vision care. This article did not suggest prescribing rights for optometrists, but laid foundations for 
a clear scope of practice and referral system to ophthalmologists to facilitate the acceptance of 
optometry within the healthcare team. 
In USA in 1990, McAlister surveyed Missouri optometrists who had not been certified to 
use therapeutic pharmaceutical agents, and found a lack of time to undertake extra educational 
requirements was the major barrier to taking on the extra scope.[107] 
In the same year, the same author assessed the effects of the expansion on scope of practice, 
and noted a majority of respondent optometrists reported they were comfortable in providing a 
prescribing service and reported an increase in income and patient retention. Over half of the 
respondents had received referrals from primary care physicians for therapeutic services. 
By 1991, optometrists were licensed to use diagnostic drugs, those used to diagnose ocular 
disease, in all 50 states of the USA, and to prescribe therapeutic drugs for the treatment of ocular 
diseases in 25 of the states. Soroka assessed, via a national telephone survey of 1000 optometrists 
and 1003 ophthalmologists, the examination fees and availability of routine vision care by the 2 
groups.[108] The survey showed that average fees were significantly less amongst optometrists than 
ophthalmologists; for a routine eye test, $42 compared to $61, and that the average wait for the 
earliest appointment was 5 days for optometrists and 20 days for ophthalmologists. Notably, whilst 
3 out of 4 optometrists had evening or weekend hours for routine eye care, only 1 out of 4 
ophthalmologists were available for this service during these times. Soroka concluded that changes 
to legislation to extend prescribing rights of therapeutic drugs in the remaining states would 
increase patient access to eye care. Similarly, a study in 1991, by Saroka again, compared average 
charges made by optometrists and ophthalmologists and found optometrist charges to be 
considerably lower.[109] 
The advances made by the optometry profession in improving standards of patient care were 
demonstrated in an article written by Soroka et al in 1994 which aimed to develop an evidence 
based standard of optometric care for patients with diabetes mellitus to aid in the prevention, 
diagnosis, treatment, management, and rehabilitation of their patients.[110]  
In 1999, a study was conducted to determine how managed care plans were used by 
optometrists to provide vision and eye care across several different states.[111] The study found 
that optometry scope of practice was influenced by legal, financial and organisational factors. In 
some cases, care plans skills were underutilized relative to their legal authority, whilst in other care 
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plans the benefits of optometry were extended beyond the existent practice laws by creative, co-
operative arrangements. In 2000, this was followed up by study that investigated the role of 
optometry in managed care plan.[112] 
Both of the above studies looked at the appropriateness of optometric care, with the second 
study also assessing the extent to which optometrists provided various kinds of eye care 
independently, and whether referrals to ophthalmologists were appropriate. The latter study showed 
that optometrists provide a substantial range of eye care, which was reflective of the advances made 
by the optometric profession over the previous number of years during which prescribing was 
incorporated into their scope of practice in USA. 
In Australia in 2000, Schmid et al surveyed Queensland optometrists to assess their level of 
education, scope of practice and the workforce preparedness to prescribe therapeutic agents.[113] A 
45% response rate to the survey, 231 out of 517, was obtained. A majority (88%) wanted to be able 
to prescribe therapeutic agents and in line with like work, the profession felt comfortable within a 
narrow scope of practice; namely dry eye, blepharitis, allergic conjunctivitis, corneal abrasions and 
contact lens induced conjunctivitis. More than 90% felt competent to recommend topical lubricants 
and antihistamines, while 65% felt they were prepared to prescribe topical antibiotics. Education 
level, and in particular the completion of a therapeutic drug course, was the main factor that 
determined whether the respondents practised or were willing to practise at an advanced level. 
In USA in 2001, Krumholz et al assessed the competence and prescribing patterns of 
optometrists newly qualified to prescribe.[114] Out of 8,936 initial visits in the study only 89 
patients required ophthalmological referral and the most frequent diagnoses were related to 
allergies, conjunctivitis and blepharitis. On analysis, it was found the patterns of prescribing 
adhered to currently accepted clinical guidelines, and concluded that use of topical medicines by 
optometrists in New York State appeared to be safe. 
In 2002, Mason and Mason investigated the potential for optometrist prescribing in UK via a 
national postal survey of optometrists.[115] The Anonymous Enquiry of the Scope for Optometrist 
Prescribing (AESOP) consisted of 22 questions in 5 sections, covering demographic details, nature 
of work and views on prescribing, reimbursement and audit. Surveys were sent to roughly 10% of 
the optometrist population, with 758 being mailed out achieving a response rate of 57%, or 432. 
Most respondents, 87%, thought optometrists should be able to train as therapeutic prescribers, with 
67% wishing to participate personally in independent prescribing and 69% dependent. Results 
showed respondents, who were all optometrists, anticipated that referrals to GPs would be reduced 
by 39% and to ophthalmologists via a GP by 18% if they were permitted to prescribe. It was 
estimated optometrist prescribing could increase patient access to therapeutic ocular care by 
between 29% and 50%. Overall, it was suggested authorising UK optometrists to prescribe would 
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make good use of existing skills and improve access to eye care, while relieving pressure upon 
other healthcare providers. 
In 2008, Needle et al surveyed the scope of practice of UK optometrists and attitudes 
towards an extended prescribing role via an online survey.[116] Registered optometrists were 
recruited by the College of Optometrists sending an e-mail to 5284 of its members. A total of 1288 
responses were received, a return rate of 24.4%. As also found by Krumholz, the response showed 
blepharitis and dry eye were the most commonly managed conditions, managed frequently by 74% 
and 75% of responders respectively.[114] Over the counter preparations, such as lubricants and 
anti-allergy medications were supplied frequently by 87% and 32% respectively, with only 21% of 
respondents frequently supplying antibiotics. With regards to the extension of their scope of 
practice to prescribing, 75% of respondents felt they should be able to prescribe non-steroidal anti-
inflammatory drugs (NSAIDs), 69% anti-glaucoma drugs, 84% further anti-infectives and 60% 
anti-virals, assuming further training is undertaken. A few barriers in undertaking further training 
for prescribing were identified, including; cost and time required, lack of remuneration for a 
prescribing role, and a fear of litigation. Only 14% of respondents showed no interest in 
undertaking further training. 
In summary, the majority of optometrist evidence has been in the form of qualitative surveys 
to determine current scopes of practice and the willingness of the profession to undertake the 
extended role of prescribing, and within what scope. There has been little research in the form of 
pilots prior to application for prescribing rights, or evaluation once prescribing rights were granted 
to assess the safety, effectiveness, improvement in access or acceptability to either the patients or 
other members of the healthcare system. 
1.6.2 Podiatrists 
 
Minimal evidence on podiatrist prescribing has been reported in the literature with regards 
to safety and appropriateness. One study, in 2000 from London, by Kalra et al showed that where 
diagnosis, management and treatment was uncomplicated, the ability of authorised podiatrists to 
prescribe drug therapy would improve healthcare delivery and lessen inconvenience to patients 
receiving treatment for foot pathology.[117] 
Several articles have discussed the notion of safe prescribing, however they have not 
assessed the quality of prescribing by podiatrists or podiatric surgeons in terms of frequency of 
prescribing errors.  
Martin, in 2004, discussed strategies for optimal pharmacological management of foot pain, 
and touched on common errors in pain management and prescribing errors.[118]  
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In a similar manner, also in 2004, Wright and Warpula discussed prescribing in the elderly, 
more from the point of view of considerations that need to be made in order to prescribe safely and 
effectively, and again not actually assessing current practice.[119] 
In 2005, Biederman discussed the use of non-steroidal anti-inflammatories (NSAIDs) in 
podiatry, and in particular the serious side effects associated with their usage, in an attempt to 
educate podiatrists in safe and effective prescribing.[120] Again, there was no assessment of current 
prescribing practice. 
In 2005, Smith wrote an article on how to safely and effectively prescribe low molecular 
weight heparins for the prevention of venous thromboembolism, but again did not assess the safety 
of current practice.[121] 
And in 2006, Smith also discussed pain management in podiatry patients, focusing on usage 
of opioid analgesics.[122] The article was a guide to aid the selection of opioids to treat lower 
extremity pain, but did not include any assessment of podiatrist prescribing. 
1.6.3 Nurse Practitioners 
 
Although nurse practitioners are able to prescribe medications, and have been granted access 
to the PBS, prescribing is only one element of their advanced scope of practice. PBS access may be 
regulated locally within the scope of practice of the individual or particular profession group and 
would remain in accordance with the state and territory legislation under which they work. 
A number of articles have been written on registered nurse and nurse practitioner 
prescribing from various countries, in various clinical settings and assessing different models of 
prescribing. There has also been a mixture of qualitative and quantitative research. 
In the UK, primary legislation to allow nurses to prescribe was passed as far back as 1992. 
In 1994, nurse prescribing began at 8 pilot sites and in 1998 a national roll out of nurse prescribing 
was announced. Initially, this applied only to district nurses and health visitors.  
In 1998, Allen assessed the scope of practice of advanced practice psychiatric nurses via a 
postal survey, mailed out to a randomly selected 100 members of the Network for Psychiatric 
Nursing Research, and achieving a 78% return rate.[123] It was found that psychiatric diagnoses 
were undertaken by 55.8% of respondents, forming a good case for advanced practice roles. 
Prescribing of one off emergency doses and modifying doses prescribed by psychiatrists of various 
medications was also undertaken by significant numbers of nurses, for example short acting 
neuroleptics 50% and 56%, long acting neuroleptics 50% and 50% and anxiolytics 55% and 56%. 
There was no assessment of the appropriateness of the prescribing unearthed in the questionnaire 
and the study concluded that pilot sites should be established to test the effectiveness of an 
advanced role. 
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In 1998, a postal survey was also sent to senior nurses in all major accident and emergency 
departments in the UK in an attempt to identify scope of clinical activity, role configuration and 
training.[124] Response rate from 293 surveys posted out was 94% or 274 replies. Sixty eight 
percent of departments allowed supply of ‘over the counter’ medications under local protocol, and 
54% ‘prescription only’ drug supplying from an agreed list. The article noted a wide variety in 
service organisation, training and scope of activity.  
Similar to the optometrist articles from the USA, these articles are examples of essential 
work in a review of traditional role boundaries and ever evolving scopes of practice within a 
profession. Also, importantly, they aided in defining a niche in the healthcare system for the nursing 
staff that was acceptable to other members of the healthcare team according to training and 
perceived competence. This was a vital step in being able to expand scopes of practice further down 
the track.  
In 1999, the Department of Health recommended that prescribing rights be extended to 
include other groups of nurses and other health professionals. In 2000 The NHS Plan, which 
emphasised that health services needed to change and modernise to improve service delivery, 
endorsed these recommendations and the Health and Social Care Act (2001) contained the 
necessary clauses to allow supplementary nurse prescribing.[125, 126] This meant that patients with 
more complex conditions such as chronic diseases and mental ill-health could be managed by a 
nurse practitioner after initial assessment of the patient by a medical practitioner. 
In 1999, Nursing Management in England published a summary of the key points of the 
report on prescribing, supply and administration of medicines which recommended introducing a 
distinction between two new categories of prescribers, independent and dependent prescribers.[127] 
It also made a number of important recommendations for other groups of professionals considering 
prescribing. In particular it recommended that proposals for new professional groups to be 
considered as potential prescribers would be expected to come from nationally recognised 
organisations and that professional groups should ensure adequate arrangements are established for 
accrediting training programmes. 
In 1999 in the UK, Bond et al explored the educational requirements for nurse practitioners 
in general practice, compared their performance against GPs and assessed their acceptability to 
patients.[128] After one year of working in a GP practice, the diagnoses and management decisions 
of the nurse practitioners were compared with GPs for 586 patients. The nurse diagnosis was found 
to agree in 94% of diagnoses and 96% of the time for clinical management decisions made. Patients 
were asked to complete a satisfaction survey, of which 80% complied. While results illustrated that 
38% of patients would have preferred to see a GP, they rated the nurse consultations as good as or 
better then the GP.  
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In 2000, Venning reported on a randomised controlled study of patients in 20 general 
practices across England and Wales requesting same day appointments.[129] The study recruited 
1303 eligible patients and compared the cost effectiveness of general practitioners and nurse 
practitioners. Data was available for 652 general practitioner consults and 642 nurse practitioner 
consults. The study found the length of consultation of the nurses to be considerably longer than the 
GPs, 11.57 vs 7.28 minutes. There was no significant difference between prescribing patterns or 
health outcome status between groups. Patient satisfaction was assessed and patients were more 
satisfied with nurse consultations. There was no assessment of appropriateness of treatment, with 
the article focusing primarily on economic outcomes. 
Wilmhurst et al, also in 2000, investigated the effect of nurse initiated thrombolysis, under a 
local protocol, on the time between arriving at hospital and starting thrombolytic treatment.[130] 
Patients included in the study were all patients admitted with suspected myocardial infarction 
between 1995 and 1999. Prior to the initiation of the nurse initiated thrombolysis and a new chest 
pain protocol time from door to needle was assessed in seven periods, each of four months, during 
which time 437 patients were given thrombolytic treatment. Following introduction of nurse 
initiation, and during four periods totalling 20 months, 308 patients were given thrombolytic 
treatment. The median ‘door to needle time’ was reduced from 50-58 minutes before 
implementation to 25-30 minutes afterwards. 
In 2001, Blue et al conducted a randomised controlled trial to determine whether nurse 
interventions improved outcomes in patients suffering from chronic heart failure, a model which is 
often cited as appropriate for a supplementary prescribing role due to the functions of dose 
initiation, titration and monitoring of effectiveness of treatment, lending themselves well to being 
guideline driven.[131] Out of a cohort of 165 patients, it was found that fewer patients in the 
intervention group had fewer readmissions for any reason, for heart failure and also spent fewer 
days in hospital for heart failure.  
In 2002, the publication Emergency Nurse reported that the A&E Nursing Association 
refuted claims by The Lancet that nurse prescribing was being rolled out too quickly and was ‘a 
dangerous uncontrolled experiment’.[132] Dr Richard Horton, editor of The Lancet had questioned 
whether nurses could appraise evidence from clinical trials and whether nurse prescribing would 
make any difference. 
In 2004, Albarran investigated the literature in order to examine the content of educational 
programmes, teaching methods and assessment strategies to prepare nurses to initiate thrombolytic 
therapy.[133] The summary stressed there was a need for national consultation relating to 
guidelines, standards and accreditation of practice schemes. 
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In 2005 Seale et al compared nurse practitioner and General Practitioner (GP) consultations 
in nine general practices across England and Wales by taping 18 matched pairs of nurse and doctor 
consultations, form an original 55 recordings of consultations.[134] Similar to previous studies, 
they found that nurse practitioners spent twice as long with patients as doctors did, and wanted to 
show what the nurse practitioners did with that extra time. It was found that is was due 
predominantly to them spending more time discussing treatments. Some of the extra time was also 
due to the requirements of getting doctors to sign prescriptions which also prompted the authors to 
suggest it may be worthwhile investigating a system that afforded nurses more clinical autonomy. 
In 2005, Allsop described the experiences of nine psychiatric nurses who were part of the 
first cohort in the UK to undertake the supplementary prescribing course.[135] Some of the 
proposed benefits of the nurses being able to prescribe included increased efficacy, an increased 
concordance with medication and an increased access to medication. No data were published to 
back these claims up. 
Also in 2005, Allen evaluated a community aged care nurse practitioner service by inviting 
all new clients and carers visited by the Aged Care Nurse Practitioner Candidate (ACNPC) to 
participate in a semi-structured interview.[136] From 18 new clients invited, 15 agreed to be 
interviewed and 10 health care professionals on the aged care team were interviewed. The analysis 
of responses showed that the respondents thought the service would be of high quality and 
positively impact on client health outcomes to improve quality of life. Again, there was no 
evaluation of the service via any other means or hard data to back these claims up. 
Evidence from USA is slightly more robust, with several trials assessing the effectiveness of 
nurse practitioners. Dunagan et al, in 2005, assessed the efficacy of a nurse led telephone follow up 
service, after their initial physician contact, for patients suffering from heart failure.[137] The 
intervention involved randomisation of 151 patients hospitalised with heart failure to either usual 
care, which was an educational package describing the causes of heart failure, the basic principles 
of treatment, their role in routine care and monitoring their condition, and appropriate strategies for 
managing an exacerbation of heart failure or intervention, which involved additional regular follow 
up telephone contact by specially trained nurses to assess self-management, diet, adherence to 
medications and any exacerbations of heart failure symptoms. The results showed that at 6 months 
the number of total admissions, hospital days and hospital costs were significantly lower that the 
control group. However, at 12 months the results were no longer statistically significant. Whilst the 
study did not directly assess prescribing, it did assess an intervention of an advanced level, specially 
trained nurse in the monitoring and treatment of a chronic disease. 
Astles, in 2006, conducted a literature review of nurse practitioner services in elderly 
patients, which summarised that nurses are excellently placed to diagnose due to the long term 
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relationship many had developed with the patients.[138] This was theorised to reduce the time the 
patients waited for treatment and increased the cohesion within multidisciplinary teams. In the ‘key 
points’ summary the authors were confident in stating that nurse practitioners were ‘safe and 
effective diagnosers and prescribers’, but only pertaining to the limited scope of practice, and 
limited drug formulary for the treatment of elderly patients for a limited number of conditions.  
One of the few authors to actually assess the appropriateness of prescribing, Latter et al, 
from the School of Nursing and Midwifery in Southampton, England in 2007 developed a 
methodology for testing which involved sending an audio recording of consultations to a panel of 
prescribing experts.[139] There were ten prescribing nurses selected from a range of sites, and the 
final cohort included six nurse practitioners and two practice nurses in general practice settings, two 
senior nurses in a walk in centre, two community midwives, a nurse consultant in secondary care, 
and a community palliative care nurse. To be included in the study each nurse had to have a 
reported prescribing rate above 10 items per week, and regular reported prescribing of 
antimicrobials. The expert panel consisted of seven experts who were known nationally for research 
in to medical prescribing, clinical expertise in prescribing and/or were in leadership positions in 
national or regional prescribing related organisations. Five were GPs and two were 
physicians/clinical pharmacologists. In the study 118 prescribing episodes were evaluated using a 
modified version of the Medication Appropriateness Index (MAI), a tool which had been used by 
both pharmacists and doctors to rate appropriateness of prescribed drugs, and showed good inter-
rater and good intra-rater reliability coefficients in preliminary research, Findings from the panel 
highlighted that nurses in the study were generally making prescribing decisions that were clinically 
appropriate across a number of indicators.  
In 2007 in USA, Barth et al undertook a descriptive review of 366 patients having 28,192 
blood glucose measurements in three intensive care units, Surgical Trauma Intensive Care Unit, 
Medical and Coronary Care Unit to assess the effectiveness of a nurse initiated insulin infusion 
protocol.[140] Results showed that it was safe and effective in controlling BSLs and that deviations 
from protocol were uncommon in all three units. 
Two articles by Stenner in 2008 explored nurses’ views on the benefits for patients of nurse 
prescribing for patients in pain, and secondly, the role of inter-professional relationships and 
support for nurse prescribing in acute and chronic pain.[141] [142] Twenty six nurses were 
interviewed and a number of benefits were reported, including faster access to treatment, improved 
quality of care, improved relations and communications with patients, greater efficiency and cost 
effectiveness. There was no evidence to back any of these claims up, bar anecdotal evidence and 
scenarios. 
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The same interviews were analysed for views on the role of inter-professional relationships 
and found the nurses believed that prescribing encouraged collaborative working with doctors, 
which served a number of functions including support and continuous learning. The biggest barrier 
to nurse prescribing was believed to be a lack of understanding of the nurses prescribing role 
amongst healthcare professionals.  
In the lead up to the federal budget, in 2008, Dragon published a timely article which 
highlighted that despite the fact nurse practitioners can prescribe, order diagnostic tests and refer, 
few are working to potential capacity to the restrictions that not having access to the PBS places 
them under.[143] 
Gardner, in 2009, mailed out a five section questionnaire in July 2007 to all 234 registered 
nurse practitioners in Australia achieving an 85% response rate.[144] Over 70% stated that lack of 
Medicare provider numbers and lack of authority to prescribe through the PBS was extremely 
limiting to their practice, which is a finding consistent with the international literature describing 
establishment of reformative health care roles 
In the 2009 Federal Budget, the Health Minister outlined her intention that nurse practitioners and 
midwives would be granted access to the PBS from 1 November 2010.   
In 2012, Latter et al used a similar methodology to assess the appropriateness of both nurse and 
pharmacist prescribing decisions as previously to assess the appropriateness of nurse prescribing in 
2007.[145] As in 2007, the study showed that nurses and pharmacists were generally making 
clinically appropriate prescribing decisions. Potential room for improvement was noted from 
qualitative comments in nurses and pharmacists history taking, assessment and diagnosis skills. 
1.6.4 Pharmacists 
 
The literature review identified the largest number of research papers published on non-
medical prescribing were in the pharmacy profession. This included a number of published research 
papers focusing on clinical and economic outcomes of pharmacist supplementary prescribing in the 
UK.  
Pharmacist prescribing is an established initiative in USA, with prescribing in some form 
having been implemented in 45 states.  
In 1998 in USA, Martin et al explored pharmacist prescribing of antiemetic agents in 
patients receiving chemotherapy, with pharmacists managing antiemetic therapy for more than 1200 
patient visits.[146] The authors reported that this model was accepted by both patients and other 
professionals in the clinic. 
In 1998 in UK Bleiker and Lewis sought to ascertain views of GPs on a potential extension 
of the role of community pharmacists.[147] A questionnaire including attitude scales and open 
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ended questions was sent out to 368 GPs of the South and West Devon health commission area, 
achieving a 81.2% response rate. Overall there was a positive attitude towards pharmacists as part 
of the primary healthcare team, but there was little support for the idea of pharmacists undertaking 
screening and running therapeutic monitoring clinics, with only 14% agreeing to pharmacists 
running lithium monitoring clinics. 
Also in 1998, Child et al investigated healthcare professionals’ views on hospital pharmacist 
prescribing, with questionnaires being sent to 195 doctors, 200 nurses and all 87 pharmacists 
working at 5 hospitals in Birmingham, England.[148] The combined response rate was 57.5%. 
Overall a high proportion of doctors and nurses responding agreed (78.7 per cent and 86.1 per cent 
respectively) that it would be useful to permit pharmacists to write prescriptions and prescribe drug 
treatment, though a majority believed that this should only include pharmacists with postgraduate 
education/training and that the pharmacist was routinely attached to the clinical area in question. 
Important issues highlighted as potential barriers to pharmacist prescribing included pharmacist 
willingness to accept the new role, education and training, familiarity with the patient, 
communication between healthcare professionals, professional and legal accountability and 
resource implications. If further training and education was made available for those who felt there 
was a need for it, 98.5% of pharmacists stated they would be happy to write a prescription for 
existing therapy. 
Two studies, in 1998 and 2000 investigated the ‘repeat prescribing’ model for community 
pharmacists. Dowell recruited a convenience sample of five medical/pharmacy practice pairs across 
Tayside in Scotland.[149] A stratified, random sample of 156 adult patients receiving thyroxine, 
atenolol, oral hypoglycaemics or allopurinol were randomised to receive repeat dispensing or their 
usual service. After one year practices were allowed to expand the system as they wished. After the 
trial year a postal questionnaire (n=214) was sent out to evaluate patient opinion of the new scheme 
and professionals’ opinions were sought by interview. The results showed employing community 
pharmacists to streamline the process and provide clinical supervision was popular with patients 
and GPs, and worked well for patients in stable treatment regimes, however the evaluation does not 
provide robust data on quality of care.  
In 2000, Bond et al conducted a much larger study comparing community pharmacy 
managed repeat prescribing system versus usual care across 19 general medical practices, 3074 
patients and 62 community pharmacists in Grampian, Scotland.[150] The results showed that there 
were more adverse drug reactions, more hospital admissions and more compliance problems found 
in the arm managed by community pharmacists and significant savings made in the drug bill of 
patients by monitoring more closely the medications that were actually required by the patients. The 
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authors acknowledged anecdotal evidence of some patients being excluded from recruitment as the 
GPs may have classed them as ‘unsuitable’, which may have affected the study sample. 
Jones explored the patient satisfaction element of the study by Bond in 2000, by sending 
questionnaires to 2667 patients, 1625 intervention and 1042 control patients.[151] Return rate was 
73% and the results showed the pharmacist managed repeat system was preferred to the usual 
system by 81% of patients, although it was acknowledged that satisfaction was influenced 
positively by reduced waiting time and financial cost. 
In 2000, Holden et al compared the effectiveness of pharmacist managed warfarin in the 
community against GPs by means of a retrospective analysis of patients who had been managed by 
GPs and subsequently referred to the pharmacist led outreach service within Gateshead and South 
Tyneside Health Authority.[152] The audit looked at individual international normalised ratio (INR) 
results, the time interval between tests and whether the INR was within therapeutic range. Both the 
GP and pharmacist managed care was audited and it was found, among the 51 eligible patients, that 
the pharmacy management was at least as effective, with the proportion of test results that were in 
range greater than with GP monitoring and the interval between tests was longer. 
In Canada, the Canadian Society of Hospital Pharmacist (CSHP) released an information 
paper on pharmacist prescribing in 2001, in an attempt to help support CSHP members in their 
attempts to extend their practice into the area of prescribing.[153] 
In 2001, Boddy investigated the effects of the involvement of a pharmacist on the quality of 
medical inpatient maintenance coagulation.[154] For 4 weeks warfarin dosing by doctors was 
investigated on 4 medical wards, and found delays in initiation of warfarin, failure to maintain INR, 
inappropriate frequency of measurement, delayed administration and poor continuity of care. 
Following circulation of prescribing guidelines to all consultants and junior doctors, the 
haematology pharmacist was responsible for warfarin dosing on 2 of the wards, while on the other 2 
wards warfarin dosing was continued by the doctors. The study period was 12 weeks. The study 
found that in the pharmacist group INR control was improved, with 58% of INRs measured from 
day 4 onwards being in the therapeutic range, when compared with 17.7% of the doctor INRs. A 
higher percentage of patients reached therapeutic INR by day 8 (88% vs 72% and 77%). Fewer 
INRs were requested by the pharmacist, on average 2 INRs per 7 patient days compared to 4.5 INRs 
per 7 patient days by the doctors. Timing of warfarin dosing was more appropriate according to 
guidelines, with 90% of the doses prescribed by the pharmacist given within 1 hour of the 6pm 
administration time, compared to 15% of the doctors’ doses. 
In 2004, another warfarin study was conducted by Burns, again evaluating the effectiveness 
of pharmacist dosing of warfarin for inpatients compared against usual care of junior doctors.[155] 
The study was undertaken at Brighton General Hospital, England and two medical wards were 
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under pharmacist control of warfarin dosing and three medical wards remained under the care of 
doctors. From all wards, 33 patients were recruited in to both arms and results showed that patients 
in the intervention received more appropriate loading doses (100% vs 73%), so reached target INR 
quicker (93% at day 6 vs 73%), better INR control with only 67% of patients being out of range at 
some point during their stay in the intervention group, compared to 91% in the control group. There 
were also fewer adverse events in the intervention arm (2/33) than the control arm (4/33). The 
authors acknowledged a number of limitations, including small patient numbers. 
In a short article in the pertaining to pharmacist prescribing in Northern Ireland, Maguire 
referred to three pilots; two where costs were not increased by using pharmacist prescribers, and 
one which referred to pharmacists independently prescribing from a limited formulary for coughs 
and colds.[156] Maguire held the view that the government in Northern Ireland was only supporting 
supplementary prescribing to make existing clinics, such as warfarin clinics, legal. 
In 2004, Bellingham described three pharmacists providing supplementary prescribing 
services in an acute setting in hospital and one in an outpatient HIV clinic.[157] The three 
pharmacists in the acute setting prescribed total parenteral nutrition (TPN) and described 
supplementary prescribing of a way to legalising what pharmacists did before. The advantages of 
the supplementary prescribing role were listed as: uses pharmacists better; saves junior doctor time; 
provides junior doctors with a good role model for prescribing; and, the patient gets care from a 
skilled practitioner.  
Australian literature on pharmacist prescribing is also limited, with the first discussion in 
2004 by Hanes and Bajorek focusing on whether the Australian pharmacy profession was prepared 
to take on the role of prescriber, using a questionnaire to explore hospital pharmacists’ opinions of 
pharmacist prescribing.[158] Small numbers of hospital pharmacists (N=10) and teacher 
practitioners (N=5) rated the appropriateness of suggested models of pharmacist prescribing. The 
authors concluded that ‘discharge or specialist settings may be ideal to pilot pharmacist 
prescribing’. 
In the same year, Kay and Brien encouraged discussion about future roles for pharmacists in 
Australia suggesting that new roles, such as prescribing, should be evaluated for impact on the 
profession and on health outcomes.[159] 
In 2004 Weeks, in a letter to the editor, encouraged the pharmacy profession to start 
discussion and debate on pharmacist prescribing and lay the foundation for pharmacy practice 
reform.[160] 
In a literature review in 2004, Kay et al identified only 18 studies conducted since the 
1970’s which measured outcomes comparing pharmacist prescribing to standard care.[161] The 
summary reported positive outcomes associated with pharmacist prescribing included: improvement 
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in disease control; improvement in compliance; improved patient outcomes; reduced adverse 
effects; fewer drugs prescribed; reduced death rate; increased discharge rate; and, reduced resource 
utilisation. 
In 2004 in USA, Rapoport assessed the effectiveness of pharmacist involvement in the 
management of patients in a pain clinic.[162] It was found that waiting time for an appointment in 
the pain clinic was reduced and unscheduled visits for narcotic prescriptions were eliminated. 
Also in USA in the same year, Lynn reported their assessment of pharmacist interventions to 
optimise pain management in a study of 22 patients reportedly expressed they were satisfied with 
the service and grateful the pharmacist had improved their level of comfort.[163] 
In 2005, a much larger study funded through the Third Community Pharmacy Agreement in 
Australia by Bessell et al developed four theoretical prescribing models and assessed the 
applicability of each model in an Australian context via semi-structured interviews with 34 
participants, including policy makers, medical practitioners, pharmacists and consumers.[1] 
Rahman et al, in 2005, evaluated the quality of pharmacist written discharge prescriptions 
from a general surgical ward in a UK hospital by running a 2 phase study over 2 weeks.[164] In 
phase 1, doctors wrote the discharge prescriptions which were checked by the ward pharmacist. In 
phase 2, ward pharmacists wrote the discharge prescriptions which were then checked by the junior 
doctor. Both phases were subjected to a final check by the dispensary pharmacist, and all 
interventions were recorded on a data collection form. There were 128 doctor written discharges, 
compared to 133 pharmacist written. In total 755 interventions were recorded during the doctor 
written phase, compared to 76 during the pharmacist written phase. Pharmacist written discharge 
prescriptions contained fewer errors, omissions and unclear information in comparison to doctor 
written discharge prescriptions. The authors acknowledged the short study time, and the fact that 
both groups were aware of the assessment as major limitations. 
In 2005 Shulman conducted a randomised controlled trial in an ICU setting to determine the 
level of adherence to guidelines of anti-infective agents in haemofiltered patients by pharmacist 
prescribers and doctor prescribers.[165] Results showed 53.7% of doctor prescriptions compared to 
100% of supplementary pharmacist prescriber prescriptions were deemed appropriate. 
In 2005, Ahmed described his experience as a supplementary prescriber; prescribing in the 
areas of hypertension, hypercholesterolaemia, hypothyroidism, epilepsy, ischaemic heart disease 
and pain management.[166] He made several claims in the article resulting from pharmacists 
prescribing, including better inter-professional relationships, more effective use of pharmacy skills, 
fewer drug errors and satisfaction from independent prescribers, patients, practice nurses and other 
staff. However, none of these claims were backed up by any evaluation or data. 
 
 
41
Also in 2005 in USA, Bond assessed clinical and economic outcomes of pharmacist 
managed aminoglycoside or vancomycin therapy in a hospital setting, in a study population 
composed of 199,082 Medicare patients treated in 961 hospitals.[167] The author reported 
significant improvements in the management of both therapies; hospitals that did not have 
pharmacist managed vancomycin or aminglycoside therapy, death rates were 6.71% higher, length 
of stay was 12.28% higher, drug charges were 8.15% higher. With regards to adverse effects, 
hearing loss was 46.42% higher and renal impairment was 33.95% higher. 
Much of the qualitative research published from UK has involved pharmacists who were 
already supplementary prescribers. Most of the literature reported intra-professional perspectives, 
with little data reported exploring the perspectives of patients and other professions. One small 
study in 2006 by Smalley investigated patient perceptions of a pharmacist led supplementary 
hypertension clinic, via a postal questionnaire, sent out to 127 patients.[168] Following two 
mailouts, the response rate was 87% and the results indicated that there was a general acceptance of 
patients for non-medical prescribing, with 57% of patients feeling standard of care was better than 
they received previously, 86% of respondents said they understood more about their condition, and 
92% saying supplementary prescribing by pharmacists was a good idea. 
In 2006, Khoo et al aimed to identify opportunities for pharmacist prescribing activities in 
warfarin management in the hospital setting via an audit of pharmacist interventions in the 
management of patients’ warfarin therapy.[169] The authors concluded there was ample 
opportunity for pharmacist prescribing within this model, however the outpatient setting may be 
more appropriate for a trial of pharmacist prescribing due to significant practice change being 
required in hospital. 
Dole et al in USA in 2007 assessed pharmacist prescribing in a pain setting and found that 
patients were effectively managed, using the pain score as the clinical measureable endpoint.[170] 
The pharmacist saw an average of 18 patients a day between June 2004 and June 2005. The study 
also looks at safety and economic outcomes, finding an improvement in both, with the clinic 
generating $107550 of actual revenue and saving the health plan over $450000. 
Following on from the initial paper in 2001, in 2007 the Canadian Pharmacists Association 
(CPA) released a position statement on pharmacist prescribing which highlighted that in recent 
times that pharmacist scope of practice had widened to include a greater range of activities, 
including: modifying prescriptions written by another prescriber to either improve drug therapy or 
provide continuation of drug therapy; and, prescribing medications through delegated authority or 
under collaborative practice agreements [171]. 
In 2008, Vracar et al assessed Australian GP views on extended prescribing rights for 
pharmacists via a questionnaire and a semi-structured interview.[172] Some major issues were 
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raised by the GPs, including safety issues, lack of awareness of pharmacist capabilities, interference 
with the GP-patient relationship and remuneration. The authors concluded that the issues raised 
would need to be addressed before pharmacist prescribing could be pursued. 
In a follow up of the 2004 letter, Weeks used a postal questionnaire in 2008 to assess the 
views of Society of Hospital Pharmacists of Australia (SHPA) members on collaborative 
prescribing, and the extent of ‘de facto’ prescribing within their institutions.[173] From 1367 
invitations to participate, 551 pharmacists responded, with the results showing that there was strong 
support for development of collaborative prescribing in Australia, with hospital pharmacists already 
undertaking a range of ‘de-facto’ prescribing activities. 
One of few studies, by Charrois et al, to assess clinical outcomes is underway in 
Canada.[174] The multi-centre study aims to assess the effect of pharmacist managed prescribing, 
and titration of antihypertensives, on change in systolic blood pressure between baseline and 24 
weeks, with a view to providing high level evidence about pharmacist prescribing. 
More patient perspectives were sought in 2011 by Stewart et al in UK, this time from 
patients who had experienced pharmacist prescribing in primary care.[175] All 1162 registered 
prescribers were asked to participate, by inviting up to five consecutive patients who had 
experienced their prescribing services to complete a questionnaire. From the 49 pharmacists eligible 
to participate, 143 patients were recruited, with a response rate of 73.4%, or 105 surveys. Overall 
patients were very satisfied with their pharmacist, and most would recommend seeing a pharmacist 
prescriber. However, due to small numbers, findings may not be generalizable. 
In 2012, an Irish study by McCann et al evaluated views on pharmacist prescribing from patients, 
doctors and relevant stakeholders.[176] Interviews were conducted with 11 pharmacists, eight 
doctors who had acted as mentors during prescribing training, and 13 stakeholders who were 
viewed as having a vested interest in the development of pharmacist prescribing. Key themes to 
emerge from the semi structured interviews were effect on patient care, challenges facing 
pharmacist prescribers and the importance of the inter professional team. The main advantage in 
patient care was an enhanced medication focus during consultations, the main challenge was seen to 
be medical resistance, and the focus on the professional team was suggestive that a collaborative 
approach to prescribing was more favourable than the pharmacist acting independently, and 
possibly causing fragmentation of care. 
A UK study in 2013 by Bruhn et al investigated chronic pain control in a three way 
randomised control study; pharmacist review with pharmacist prescribing, pharmacist review with 
feedback to GP or usual care.[177] Final numbers of patients who completed questionnaires was 
152 across the three arms, with 50 in the pharmacist prescribing arm. Results showed a statistically 
significant improvement in the Chronic Pain Grade (CPG) in the pharmacist prescribing arm, 
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however the study acknowledged low numbers and the need to repeat the study on a larger scale, to 
achieve higher power. 
A Canadian before-after design study in 2013, by Hamameh et al, assessed the effect of pharmacist 
prescribing on glycaemic control, in patients with poorly controlled type-2 diabetes, and an HbA1c 
of 7.5-11.[178] Results showed, in the 100 patients recruited in to the study, an average 1.8% 
reduction in HbA1c over the 26 week study period. Over half of the patients achieved an HbA1c of 
<7 by the end of the study period. The results were comparable to any previous studies of physician 
diabetes management, and provide evidence for a potential enhanced role for pharmacists in 
diabetes management 
1.7 Evidence of Healthcare Benefits of Non-Medical Prescribing Models 
 
The Australian Health Ministers’ Conference (AHMC) established the National Health 
Performance Committee (NHPC) in August 1999. This committee was responsible for the 
development and maintenance of a national health performance framework that could be used as the 
basis for its annual report to Health Ministers. The framework developed consisted of three tiers: 
health status and outcomes; determinants of health; and health system performance, and was 
endorsed by the Australian Health Minister’s Advisory Council in 2001. It was subsequently 
reviewed by the NHPC in 2007-08, with a revised framework agreed by the National Health 
Information Standards and Statistics Committee (NHISSC) and noted by Health Ministers in 
September 2009.[11]  
Health system performance consists of six measures to assess the following criteria: 
• How well does the health system perform? 
• What is the level of quality of care across the range of patient care needs? 
• Is it the same for everybody? 
• Does the health system deliver value for money and is it sustainable? 
The framework can also be used as a guiding structure when developing sets of performance 
indicators for more discrete components of the health system, such as a particular program, or a 
specific target group. The evaluation framework is proposed to attempt to demonstrate positive 
outcomes in as many of the six measures as possible: 
1. Effectiveness 
2. Safety 
3. Responsiveness 
4. Continuity of care 
5. Accessibility 
6. Efficiency and Sustainability 
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Health Status
How healthy are Australians? Is it the same for everyone?
Where are the best opportunities for improvement? 
Determinants of Health
Are the factors determining good health changing for the better? Where and for
whom are these factors changing? Is it the same for everyone?
Health System Performance
How does the health system perform? What is the level of quality of care across the
range of patient care needs? Is it the same for everyone?
Does the system deliver value for money and is it sustainable?
Effectiveness
Care/intervention/action provided
is relevant to the client’s needs
and based on established
standards. Care, intervention or 
action achieves desired outcome
Safety
The avoidance or reduction to
acceptable limits of  actual or
potential harm f rom health care
management or the environment
in which health care is delivered
Responsiveness
Service is client orientated, 
Clients  are treated with dignity, 
conf identiality, and encouraged
to participate in choices related 
to their care
Continuity of Care
Ability to provide uninterrupted,
coordinated care or service
across programs, practitioners,
organisations and levels over
time
Accessibility
People can obtain health
care at the right place and right
time irrespective of  income,
physical location and cultural
background.
Efficiency &
Sustainability
Achieving desired results with
most cost ef fective use of
resources. Capacity of  system 
to sustain workforce and 
inf rastructure, to innovate
and respond to emerging needs
Environmental
factors
Physical, chemical
and biological
factors such as air,
water, food and
soil quality
Community and
socioeconomic
Community factors such 
as social capital, support 
services, and socio-
economic factors 
such as housing,
education, employment 
and income
Health 
behaviours
Attitudes, beliefs, know-
ledge and behaviours 
such as patterns of  
eating, physical activity,
smoking and alcohol
consumption
Bio-medical
factors
Genetic-related 
susceptibility to disease 
and other factors such 
as blood pressure, 
cholesterol levels and 
body weight
Health 
conditions
Prevalence of  disease,
disorder, injury or 
trauma or other  
health related states
Human
function
Alterations to body,
structure or function
(impairment), 
activity limitations and
restrictions in 
participation
Wellbeing
Measures of
physical, mental, and
social wellbeing of
individuals
Deaths
Mortality rates and 
life expectancy 
measures
Community and Health System Characteristics  
Figure 3 ‐ The National Health Performance Framework 2009 
With this determination in mind, matching the literature on non-medical prescribing against 
this framework for health system performance has indicated that the quality of published research is 
generally poor when assessed against all measures. 
A review of the literature has identified that all three of the main professions in the literature; 
pharmacy, nurses and nurse practitioners have attempted to demonstrate their ability to prescribe 
through studies and reports, looking at capability and effectiveness. Pharmacists also assessed the 
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safety and efficiency of their prescribing. Nurses and nurse practitioners mainly evaluated 
responsiveness, as well as sustainability and accessibility to services. 
In the light of a gap in the literature of research into pharmacist prescribing within the 
Australian healthcare system assessing the impact of service quality against a defined and endorsed 
evaluation criteria, this thesis intends to investigate a pilot of pharmacist prescribing, using 
methodology designed to assess quality of the collaborative prescribing model in line with the 
national health performance framework.[11] 
1.8 Independent Reviews of Non-Medical Prescribing Services 
 
Pharmacists and nurses were found to be best represented in published trials of non-medical 
prescribing, from a literature review published by Cooper et al  in 2008.[7] The authors searched 
the literature between 1997 and 2007, using MEDLINE, EMBASE, CIMAHL IS web of 
Knowledge and Zetoc and found 35 published trials of nurse and pharmacist prescribing, 20 
alluding to pharmacy and 15 to nursing. Studies were mainly qualitative in nature, and assessed the 
views of different members of the healthcare team with regards to the possible advantages of non-
medical prescribing, without backing these theories up with prescribing audits and data. Few studies 
assessed clinical indicators as an evaluation of the quality of prescribing by non-medical 
prescribers. 
The same authors, also in 2008 published a review of stakeholders’ views on nurse and 
pharmacist supplementary prescribing (SP), by undertaking semi structured interviews with 43 UK 
stakeholders, including pharmacist and nurse supplementary prescribers, doctors, patient group 
representatives, academics and policy developers.[179] Overall views were positive and the 
suggestion was that SP has the potential to fulfil the UK Governments objectives with regards to 
improved access to medicines and reducing delays in seeing healthcare professionals. In summary 
the authors suggested that several years after implementation in the UK that challenges, and a 
number of tensions still remained, which could potentially threaten the success of supplementary 
and other forms of non-medical prescribing. 
The biggest implementation threat was perceived to be that patients remained largely unaware of 
SP, and that SP was introduced without adequate patient consultation and information. One of the 
tensions alluded to by several stakeholders was that some doctors may be threatened by SP, and 
several examples were provided of conflicts between nurses and pharmacists in practice. 
In 2009, Winstanley suggested problems with the ongoing implementation and sustainability 
of pharmacist prescribing due to a lack of credible evaluation of the new service, either from a pilot 
phase or after implementation.[180] 
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In 2010, the National Health Workforce Planning and Research Collaboration (NHWPRC) 
undertook a thorough review of the literature, as already discussed previously.[37] The report 
concluded that whilst there is a sizable body of literature addressing non-medical prescribing, there 
is a lack of rigorous evaluation data published. 
However, in 2010, Latter et al produced the largest and most comprehensive review of nurse 
and pharmacist independent prescribing through the University of Southampton.[86] The study used 
three phases. 
Phase 1 included a national questionnaire survey of nurse (N=976/1462, 58% response rate) 
and pharmacist independent prescribers (N=208/358, 58.1% response rate), a telephone survey of 
non-medical prescribing Trust leads (N=86/168, 52% response rate) and focus group discussions, 
involving 23 people split into two focus groups of 9 and 12, with Higher Education Institutions non-
medical prescribing program leads and Designated Medical Practitioners. 
Phase 2 used case studies of practice, including analysis of the appropriateness of nurse and 
pharmacist prescribing using the MAI, case record analysis of nurse and pharmacist independent 
prescriber consultations against national prescribing standards (n=451), patient surveys (N=273, 
141 from patients of nurse prescribers, 132 from patients of pharmacist prescribers) of experiences, 
outcomes and preferences and interviews with health care professionals (N=10). 
Phase 3 was a multi stakeholder workshop where all stakeholders were invited to consider and 
prioritise the initial study findings. 
Key points of the findings of the report were summarised, namely: 
• between 2% and 3% of the current nursing and pharmacy workforce were qualified to 
prescribe medicines 
• prescribing was predominantly in primary care 
• study results indicated that prescribing was overall safe and appropriate 
• current educational programmes were largely satisfactory and provide fit for purpose 
clinicians 
• acceptability to patients is high 
• most patients did not express a strong preference to their medical or non-medical prescriber 
• nurse and pharmacist prescribing in England is becoming a well integrated and established 
means of managing a patient’s condition and providing access to medications 
In 2011, Bhanbhro et al undertook an integrative review of the literature, using CINAHL, 
MEDLINE, BNI, AMED, ISI Web of Knowledge and Index to Theses.[8] The review found 19 
papers, from 17 empirical studies, mainly from UK. Only 2 two papers investigated clinical 
outcome, seven reported only qualitative data and four studies had fewer than 10 participants. The 
literature review concluded that there were substantial gaps in the knowledge base to help evidence 
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based policy changes, and that the acceptability of non-medical prescribing is based only on the 
perceived value to the health care system.  
In Australia there are published opinions suggesting that evidence already exists of resistance 
to change,[9, 94]  There have been calls for evidence as to the effectiveness and safety of non-
medical prescribing before implementation of this new initiative can be considered.[181] 
Most recently, Gielen et al conducted a literature review of relevant studies, between January 
2006 and January 2012, to assess the effects of nurse prescribing compared to physician prescribing 
on the quantity and types of medication prescribed, and on patient outcomes. The authors searched 
11 databases for quantitative studies which had a comparative design to physician prescribing. 
Models of care included were patient group directions, supplementary and independent prescribing. 
Thirty five studies met the inclusion criteria, only 13 of which reported on clinical outcomes. Most 
of the 13 reported no differences between nurse and physician prescribing.  One study in patients 
with hypertension and diabetes showed a larger drop in diastolic blood pressure in patients 
receiving prescriptions from nurses, whilst another study in diabetic patients showed better 
cholesterol control in patients treated by a medical specialist. The review concluded that due to 
methodological weaknesses in the studies that any conclusions are to remain tentative, the main one 
being that 24 of the 35 studies were not randomised controlled trials, and that more randomised 
controlled trials were needed to be able to draw firm conclusions about the effects of nurse 
prescribing.[182] 
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2 Chapter 2: Evaluation Framework for Non-Medical Prescribing	
2.1 Chapter Introduction 
Without robust and credible evidence for the benefits in health outcomes of non-medical 
prescribing, widespread implementation will be challenging.  
Our aim is to develop a consistent evaluation framework that could be applied to non-medical 
prescribing research. 
An informal collaboration was initiated in 2008 by a group of pharmacists from Australia and New 
Zealand to assist in information sharing, pilot design, methodologies and evaluation for pharmacist 
prescribing. 
Different pilots were using different models, methodologies and evaluation, it was agreed that the 
development of a consistent evaluation framework to be applied to future research on non-medical 
prescribing was required. 
The framework would help to align the outcomes of different research pilots and enable the 
comparison of endpoints to determine the effectiveness of a non-medical prescribing intervention. 
This article presents the results of a workshop held at The University of Queensland in January 
2009. Participants were asked to consider how to evaluate the effectiveness of different models of 
pharmacist prescribing. 
What is known about the topic? Little is known about the effectiveness and safety of non-medical 
prescribing services due to a lack of robust evidence. 
What does this paper add? This paper adds a methodology for clinicians and healthcare managers 
to be able to evaluate any new service of non-medical prescribing, either in the pilot phase or once 
introduced as a new model of care. 
What are the implications for practitioners? The implication for practitioners is the ability to prove 
to healthcare providers that non-medical prescribing services are at least as effective as usual care, 
so informing whether a change should be introduced in the way healthcare is delivered to patients. 
2.2 Published Paper: An Evaluation Framework for Non-Medical Prescribing 
Hale A, Stowasser D, Coombes I, Stokes J, Nissen L. An Evaluation Framework for Non-Medical 
Prescribing Research. Australian Health Review, 2012, 36, 224–228 
This paper is reproduced in full in Appendix A 
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2.2.1 Introduction 
Healthcare workforce shortage is a well-documented global phenomenon. A 2006 report by the 
World Health Organisation (WHO) estimated that a 70% increase in the health workforce is 
required worldwide, including doctors, nurses and midwives, in order to meet current demand. 
Australia is no exception to this phenomenon of health workforce shortage, with several reports 
over recent years highlighting the shortages, the reasons behind them and possible solutions.[15-17] 
In 2003, Brooks et al. expressed concerns regarding doctor shortages, especially in rural areas, and 
suggested various methods that they felt merited further investigation, including: greater flexibility 
for entry of highly trained overseas doctors, increasing medical school student intake and workplace 
practice alternatives (e.g. example ‘task substitution).[18, 183] 
The supply of medicines and pharmaceutical-related services in Australia is guided by the National 
Medicines Policy and the Policy for the Quality Use of Medicines.[183] Both documents prioritise 
the need for timely access to safe, effective and efficient use of medicines. 
Recent reviews suggest that health services in Australia may not be currently meeting these 
requirements.[184] The Quality in Australian Health Care Study  identified the harm associated 
with medicine use in Australia over 13 years ago.[185] Major programs of work have subsequently 
been undertaken to improve medication safety, with one such example being the development and 
implementation of the National Inpatient Medication Chart. This program of work has improved the 
safety of prescribing in the hospital setting.[186] However, as two editorials in particular have 
highlighted, safety issues still remain, with Wilson and Van Der Weyden saying in 2005 that 10 
years on from the original study, hospitals were no safer, noting the inadequacies of the 
organisational and political responses, and saying that Australia needs a patient safety initiative that 
captures the imagination of politicians, professionals and the public.[187] In 2008, Hughes also 
highlighted the ongoing problem of medication error in hospital, asking what could be done.[188] 
Subsequent work has also shown high rates of preventable medication misadventure in the 
Australian community setting, with a review of 1000 patients showing 2222 medication-related 
problems, with 90% of patients experiencing at least one.[189] One in three people were found to 
require additional monitoring, one in four required additional medication, one in four were using the 
wrong or inappropriate medication and one in five were using insufficient medication. 
Also in the community setting, in 2006, a study of 8215 patient encounters with general 
practitioners (GPs) reported 10.4% of patients had experienced an adverse drug event in the 
previous 6 months. GPs classified 23.2% of the adverse drug reactions as preventable, and the study 
concluded that adverse drug events were one of the most significant causes of morbidity 
in the Australian community.[190] 
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The issue of access to health services, in particular medicines, has seen several changes to the 
Pharmaceutical Benefits Scheme and health service provision, for example the Rural and Remote 
Section 100 program. In spite of these initiatives, the quality of medicine services 
remains an issue for many Australians, with access to medications still a problem, especially in the 
rural setting. In 2004, Kowanko et al sent out 225 surveys to workers and managers from ~30 health 
and human service organisations across metropolitan, rural and remote areas of South Australia.[42] 
The purposively selected sample had to have some involvement with Aboriginal people suffering 
from mental health disorders, and management of their medications. Several issues influenced 
quality use of medicines in the patient population, including limited access to specialist services. 
The authors also concluded that the range of workers providing medication services was very wide, 
and many workers lacked adequate training or resources. 
Another study by Gordon et al from Townsville Hospital also highlighted the issue of access to 
services.[43] In the study, involving a computer-assisted telephone interview of 410 cancer patients, 
the authors found that over 46% of patients lived more than 100 km away from the hospital and 3% 
lived more than 600 km away. Average out-of-pocket expenses involved in attending hospital for 
treatment ranged between $563 and $6231, with a mean value of $4311. The National Health and 
Hospitals Reform Commission and the establishment of the National Health Workforce Taskforce 
have both recognised the need to reform the way healthcare services in Australia are delivered.[191] 
2.2.2 International developments 
Following recommendations made in the Crown Reports to the government of the United Kingdom 
(UK) in 1999, changes were made in legislation, resulting in the extension of prescribing privileges 
to non-medical professionals, including pharmacists.[2, 3] The UK Canada, USA and New Zealand 
have all extended prescribing of ‘prescription only medicines’ to healthcare professionals other than 
doctors.[192-197] In a literature review published by Cooper et al in 2008, pharmacists and nurses 
were found to be best represented in published trials of non-medical prescribing.[7] The authors 
searched the literature between 1997 and 2007, and found 35 published trials of nurse and 
pharmacist prescribing, 20 alluding to pharmacies and 15 to nursing. Studies were mainly 
qualitative in nature, and assessed the views of different members of the healthcare team with 
regards to the possible advantages of non-medical prescribing, without backing these theories up 
with prescribing audits and data. Few studies assessed clinical indicators as an evaluation of the 
quality of prescribing by non-medical prescribers. A lack of robust evidence of increased safety 
from the introduction of non-medical prescribing services into other countries has led to calls for 
evidence to prove the effectiveness of non-medical prescribing services and resistance to such 
change in Australia.[9, 181] 
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In recognition of a lack of evidence and the need for a nationally consistent framework to evaluate 
non-medical prescribing, a collaboration of pharmacists from Australia and New Zealand was 
established in 2008. This collaboration was born from the common goal of establishing an evidence 
base for the effectiveness of pharmacist prescribing being undertaken in a series of pilots in 
Australia. The objectives of the collaboration were to: 
* Share information, methodologies, barriers and enablers of pilots of pharmacist prescribing; 
* Establish an evidence base as to the effectiveness of pharmacist prescribing; 
* Establish a framework for uniformly measuring effectiveness, so as to enable the alignment of 
research outcomes and comparison of data and evidence; and 
* Develop a framework that could be used to measure the ongoing effectiveness of pharmacist 
prescribing services following the pilot phase. 
It is hoped that if evidence can be provided in a robust, credible and consistent manner, it may 
address some of this resistance to change. 
Evidence as to the effectiveness of non-medical prescribing may also avoid some of the suggested 
problems with the ongoing implementation and sustainability of pharmacist prescribing in the UK 
due to a lack of credible evaluation of the new service, either from a pilot phase or after 
implementation.[180] With significant changes to health service delivery pending, there is an urgent 
need to define a uniform framework for the evaluation of non-medical, including pharmacist, 
prescribing. The broad practice of hospital pharmacy lends itself well to developing models of 
pharmacist prescribing for the Australian setting, as pharmacists have medicinal knowledge and the 
skills inherent to prescribing, along with access to patient clinical records and experience in 
practising as part of a multidisciplinary team. 
As highlighted by The Pharmacy Guild in ‘The Roadmap – The Strategic Direction for Community 
Pharmacy’, community pharmacists remain the most accessible of all health professionals, available 
for consultations at short notice and without appointment across a variety of locations all across 
Australia.[198] Without robust evidence for this new scope of practice, further development of this 
role is unlikely. This paper presents some of the outcomes of this informal collaboration. 
2.2.3 Background 
In 2000, the National Health Performance Committee developed the National Health Performance 
Framework for the Australian Health Minister’s Conference. The framework was reviewed in 
2007–08, and a revised framework was agreed and noted by the Health Ministers in 2009.[11] This 
performance framework has been endorsed by each jurisdiction and was used as the basis for a 
pharmacist prescribing performance framework. 
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2.2.4 Objective 
To develop an evaluation framework that can be utilised to assess the performance of non-medical 
prescribing services uniformly, in several different models. 
2.2.5 Method 
Groups of researchers undertaking pilots of pharmacist prescribing across Australia were identified. 
An open invitation was sent across Australia and New Zealand, to which 30 attendees responded 
from NSW, Victoria, South Australia, Queensland and New Zealand. A day-and-a-half workshop 
was held at University of Queensland, which involved presentations from the different sites on their 
planned pilots. From the presentations, it was clear that each site was assessing different models of 
pharmacist prescribing and subsequently using different evaluation methods. Following the 
presentations, attendees were split into five groups. Each group was given a different model of 
pharmacist prescribing and asked to consider how to evaluate these models: 
* Pharmacist prescriber (global), 
* Community generalist, 
* Community specialist, 
* Hospital generalist, 
* Hospital specialist. 
The models of care were chosen to reflect that the two most likely practice settings of pharmacists 
are either in a hospital or in the community. Within those settings, pharmacists may provide a 
generalist role (e.g. ward pharmacist on a general medical ward or a community pharmacist) or a 
specialist role (e.g. renal specialist pharmacist, pharmacist in a surgical preadmission clinic). 
The groups were asked to consider the measures necessary to prove the effectiveness of each model. 
Data were collated by the project team and measures and indicators have since been aligned with 
the six dimensions of the National Health Performance Framework, namely: 
* Accessibility 
* Continuity 
* Effectiveness 
* Efficiency and sustainability 
* Responsiveness 
* Safety 
Following development of the non-medical prescribing evaluation framework, the document was 
circulated to the collaboration for endorsement. 
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2.2.6 Results 
The proposed non-medical prescribing evaluation framework is described below. 
Australian Institute of Health and Welfare domains of health system performance 
(1) Accessibility. People can obtain healthcare at the right place and time irrespective of income, 
physical location and cultural background. 
(2) Continuity. The ability to provide uninterrupted, coordinated care or service across programs, 
practitioners, organisations and levels over time. 
(3) Effectiveness. The care, intervention or action provided is relevant to the client’s needs and is 
based on established standards. The care, intervention or action achieves the 
desired outcome. 
(4) Efficiency and sustainability. Achieving the desired results with cost-effective use of resources, 
and the capacity of the system to sustain the workforce and infrastructure, and to 
innovate and respond to emerging needs. 
(5) Responsiveness. Service is client-orientated. Clients are treated with dignity and confidentiality, 
and encouraged to participate in choices related to their care. 
(6) Safety. The avoidance of reduction to acceptable levels of actual or potential harm from 
healthcare management or the environment in which healthcare is delivered. 
Table 1 shows examples of proposed different models of care and a small selection of some 
measures that might be evaluated to show that the model is as good as traditional models of care. 
2.2.7 Discussion 
The workshop identified several key points. There are several pilots being planned and undertaken 
in Australia and New Zealand. Each of these pilots is investigating a different model of pharmacist 
prescribing, each within a different setting. In order to address criticisms regarding the lack of 
evidence as to the benefit of pharmacist prescribing, a uniform framework to assess the benefits and 
performance of the pharmacist prescribing service is essential. 
With a uniform framework, the profession will be able to take a common approach to lobby for the 
introduction of pharmacist prescribing services in the future, something that is essential for 
successful progression of the agenda nationally. International pharmacy experience and Australian 
experience in other professions, for example optometrists, has demonstrated the need for such a 
unified approach. In order for the profession to be ready for changes arising out of the establishment 
of the National Health Workforce Taskforce and the recommendations of the Health and Hospitals 
Reform Commission, strong leadership and clear direction is required from all areas of the 
profession. Where non-medical prescribing has been introduced in other countries without a 
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uniform framework for evaluation, issues have arisen retrospectively that could have been 
addressed earlier, and therefore pre-empted the need to continually justify services.[180] 
However, it is important that the framework adopted to measure the performance of non-medical 
prescribing in the pilot phase must also be appropriate to evaluate ongoing services. Although the 
settings, models and services may differ, unless safe access to medicines is assured within an 
effective, efficient and sustainable service, the objectives of the National Medicines Policy will not 
be met. 
The framework outlines general principles that should be evaluated within several dimensions. 
There is some overlap between the dimensions and not all measures for all dimensions will be 
collectable or appropriate in each setting. Therefore, pilots should select appropriate measures to 
reflect each dimension adequately. The framework is intended to provide objective evaluation but 
be customisable to different settings and models. For example, the ‘sustainability’ of a pharmacist 
prescribing service in a pre-admission clinic may require cost justification based on efficiency, 
whereas ‘sustainability’ for other models may require an ongoing source of suitably trained 
pharmacists, such as in the setting of specialist HIV pharmacy services. Within different models, 
the relative importance of one dimension over another may differ. For example, ‘continuity’ is the 
major driving force behind the introduction of discharge medication services, whereas safe ‘access’ 
to medicines services in rural and remote areas is a major driver for health service reform. It is 
important to note that irrespective of the model or setting, patient safety is the underlying principle. 
The collaboration strongly recommends the development of prescribing competencies that can be 
applied across the board irrespective of the professions involved. Given that training and 
competencies for pharmacist prescribing are determined by the performance requirements of the 
service, the authors propose that a competency and training framework for non-medical prescribing 
be developed. 
Patient safety associated with medicine use remains the ultimate goal. 
2.2.8 Conclusions 
The National Health Performance Framework has provided the basis for a non-medical prescribing 
evaluation framework that can be applied to pilots and for the evaluation of future services and 
research. A collaboration of pharmacists from Australian and New Zealand recommend a consistent 
approach to measuring non-medical prescribing uniformly in order to establish an evidence base, 
professional consensus and the basis of requirements for national competency and the accreditation 
of prescribers. 
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Table 1 ‐ Pharmacist Prescribing Evaluation Framework 
 
 Indicator Measure Model / examples 
1. Accessibility – obtaining healthcare at the right time and place 
 • Time to access to 
prescriber 
• Ability to enrol new 
patients 
Time to appointment 
Doctor time freed up by 
pharmacist taking patient load 
Community outpatient clinic 
eg HIV 
2. Continuity - ability to provide uninterrupted, coordinated care / intervention / action across 
programs, practitioners, organisations and levels 
 • Prescribing on discharge 
 
Accuracy of discharge 
medication list 
Provision of information to 
allow continuity of care across 
healthcare settings 
Prescribing on discharge from 
hospital 
3. Effectiveness – care/intervention/action is relevant to the client's needs and based on established 
standards, and achieves desired outcome 
 • Appropriateness of 
prescribing according to 
guideline 
• Clinical Outcome 
Appropriate of VTE 
prophylaxis against agreed 
guidelines 
Blood pressure control 
Surgical pre-admission clinic 
 
Outpatient hypertension clinic 
4. Efficiency and Sustainability – achieving desired results with cost effective use of resources, 
capacity of system to sustain workforce and infrastructure, to innovate and respond to emerging 
needs 
 • Technical efficiency 
 
• Sustainable workforce 
Accuracy of medication history 
and completeness of medication 
prescribing information 
Time with no pharmacist 
prescriber service 
Emergency Department 
Pharmacist 
 
All models 
5. Responsiveness – service is client orientated. Clients are treated with dignity, confidentiality, and 
encouraged to participate in choices about their care 
 • Patient satisfaction Patient satisfaction surveys All models 
6. Safety – the avoidance or reduction to acceptable levels of actual or potential harm form health 
care management or the environment in which health care is delivered 
 • Prescribing errors and 
safety 
Prescription audit of quality 
(errors) of individual 
medication order (inpatient or 
outpatient) 
All models 
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3 Chapter 3 - Assessment of the Safety, Accuracy and Effectiveness of 
National Inpatient Medication Charts 
3.1 Chapter Introduction 
 
An elective surgery PAC was chosen for the doctor - pharmacist prescribing study for several 
reasons, all of which were considered prior to the study as critical success factors for the 
collaborative prescribing model of care.  
The PAC at PAH has a well-established pharmacy service, initiated in 1998, with evidence to show 
the effectiveness of the pharmacy service in providing improved quality of information as patients 
crossed healthcare settings.[199] 
Due to the scope of practice of the PAC pharmacist, and involvement in the clinical decision 
making process with regards to medication management, the role is that of an advanced level 
pharmacy practitioner. It is envisaged that prescribing will be a role for advanced practice 
pharmacists in future, with post graduate qualifications a requirement prior to commencing 
prescribing training.  
The PAC is a collaborative working environment, with good access for the pharmacist to surgical 
RMOs and senior anaesthetists, to enable discussion and referral of medication management 
decisions in a timely and efficient manner.  
The issues with regards to medication management and prescribing of inpatient medication charts 
were known, as a result of an audit prior to the main study commencing, evaluating the quality of 
the existing model of care.[200] This allowed the research question to be formulated, as it was clear 
where improvements needed to be made in terms of medication management in PAC, and 
specifically with regards to the prescribing of the NIMC.  
The scope of the prescribing in PAC allowed evaluation of a number of facets of prescribing; 
stopping medications permanently, withholding medications temporarily prior to surgery, 
therapeutic substitution of withheld medication where necessary, and initiation of new medications 
for the patient’s admission. 
Chapter 2 called for a standardised methodology for evaluation of pilots of non-medical prescribing, 
via utilisation of the National Health Performance Framework.[11] This chapter of the thesis reports 
the results for the main outcome of the study, the safety and accuracy of national inpatient 
medication charts produced in both arms. The NHPF indicators assessed in this chapter are the 
continuity, effectiveness, efficiency and safety of the prescribing in the collaborative model of care, 
compared to usual care. 
In the 2009 review of the framework, ‘effective’, ‘appropriate’ and ‘capable’ were combined in to 
the one indicator, ‘effectiveness’. This chapter also reports briefly on the appropriateness of 
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prescribing of venous thromboembolism (VTE) prophylaxis, giving more evidence as to the 
effectiveness of the model of care within that defined scope of practice. 
3.2 Published Paper - Perioperative medication management: expanding the 
role of the preadmission clinic pharmacist in a single centre, randomised 
controlled trial of collaborative prescribing 
 
Hale A, Coombes ID, Stokes J, McDougall D, Whitfield K, Maycock E, Nissen L. BMJ Open 
2013;3:e003027.doi:10.1136/bmjopen-2013-003027 
This paper is reproduced in full in Appendix B 
Abstract 
3.2.1.1 Objective 
Current evidence to support non-medical prescribing is predominantly qualitative, with little 
evaluation of accuracy, safety and appropriateness. Our aim was to evaluate a new model of service 
for the Australia healthcare system, of inpatient medication prescribing by a pharmacist in an 
elective surgery preadmission clinic (PAC) against usual care, using an endorsed performance 
framework. 
3.2.1.2 Design 
Single centre, randomised controlled, two-arm trial. 
3.2.1.3 Setting 
Elective surgery PAC in a Brisbane-based tertiary hospital. 
3.2.1.4 Participants 
400 adults scheduled for elective surgery were randomised to intervention or control. 
3.2.1.5 Intervention 
A pharmacist generated the inpatient medication chart to reflect the patient’s regular medication, 
made a plan for medication perioperatively and prescribed venous thromboembolism (VTE) 
prophylaxis. In the control arm, the medication chart was generated by the Resident Medical 
Officers 
3.2.1.6 Outcome Measure 
Primary outcome was frequency of omissions and prescribing errors when compared against the 
medication history. The clinical significance of omissions was also analysed. 
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Secondary outcome was appropriateness of VTE prophylaxis prescribing. 
3.2.1.7 Results 
 
There were significantly less unintended omissions of medications: 11 of 887 (1.2%) intervention 
orders compared with 383 of 1217 (31.5%) control ( p<0.001). There were significantly less 
prescribing errors involving selection of drug, dose or frequency: 2 in 857 (0.2%) intervention 
orders compared with 51 in 807 (6.3%) control (p<0.001). 
Orders with at least one component of the prescription missing, incorrect or unclear occurred in 208 
of 904 (23%) intervention orders and 445 of 1034 (43%) controls ( p<0.001). VTE prophylaxis on 
admission to the ward was appropriate in 93% of intervention patients and 90% controls ( p=0.29). 
3.2.1.8 Conclusion 
 
Medication charts in the intervention arm contained fewer clinically significant omissions, and 
prescribing errors, when compared with controls. There was no difference in appropriateness of 
VTE prophylaxis on admission between the two groups. 
3.2.1.9 Trial Registration 
 
Registered with ANZCTR—ACTR Number ACTRN12609000426280 
 
3.2.1.10 Article Summary 
3.2.1.10.1  Article focus 
 
▪ A doctor–pharmacist collaborative prescribing model provides as least as high a quality of care as 
usual care, with regard to safety, access, appropriateness, effectiveness, efficiency and 
consumer participation. 
▪ Workforce shortages are prompting a review of the way the current workforce is utilised, and 
whether different roles could be taken on by healthcare professionals to alleviate some of the 
pressures within the system. 
▪ Research on non-medical prescribing so far is predominantly qualitative in nature. Our study has 
analysed quantitative data on the safety, accuracy and appropriateness of prescribing to try and 
assess whether this model is at least as good as usual care 
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3.2.1.10.2  Key messages 
 
▪ Pharmacists’ skills in medication management are currently underutilised, and with appropriate 
training and education they could be contributing to medication management much more effectively 
by taking on a prescribing role. 
▪ The prescribing is collaborative and driven by guidelines and under the supervision of a 
medical team. Diagnosis is not within the scope of practice of the prescribing pharmacist. 
▪ This model of care has been proved to be highly effective in this study, with an increased 
accuracy, safety and appropriateness of prescribing within the intervention arm. 
3.2.1.10.3  Strengths and limitations of this study 
 
▪ The results with regard to the accuracy and safety of medication charts produced in the study are 
emphatic and statistically significant. 
▪ The intervention is reproducible in other settings with a pharmacist of appropriate experience, 
training and education. 
▪ The study assessed one pharmacist prescriber versus a cohort of medical prescribers. While this 
has been accounted for in the analysis, it also reflects what usual practice would be in a model care 
such as this. The authors recognise and acknowledge it as a limitation. 
3.2.2 Introduction 
 
Prescribing involves four stages: information gathering, clinical decision-making, communication 
of decision and monitoring.[201] Taking a medication history, continuing, ceasing and withholding 
of medications and initiating new medications are critical components of prescribing associated 
with an admission for surgery. Medication errors are common, occur most often at the time of 
prescribing, and frequently on the day of hospital admission, resulting in discrepancies between 
regular medications and admission orders.[202-204] A small, but significant, proportion of errors 
result in adverse drug events (ADEs).[205] Errors have been defined as when there is “a failure to 
communicate essential information; the use of drugs or doses is inappropriate for the individual 
patient; and transcription error.”[102] To be able to communicate a clinical decision safely and 
effectively in the form of a written prescription, it is necessary to select the correct drug, together 
with the route, form, dose, frequency and duration.[206] Multiple interventions have been suggested 
in an attempt to improve prescribing, with suggestions that increased training of the individual, a 
controlled environment and a change in organisational culture are necessary.[207] Within hospital, 
the medication chart provides instructions for safe medication supply and administration, and 
ensures the patient access to medications as an inpatient. It is an integral part of communication 
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between doctors, pharmacists and nurses about prescribing decisions and is used as the primary 
source of information regarding medications on discharge. The pharmacy service in the Princess 
Alexandra Hospital (PAH) preadmission clinic (PAC) began in 1998 to provide timely, accurate 
and comprehensive information about medication as patients crossed between healthcare settings. It 
ensured accurate transfer of information at admission, during the inpatient stay and at discharge, the 
benefits of which were a reduction in both readmissions and contact with community healthcare 
providers postdischarge.[208] The importance of accurate transfer of information across the whole 
surgical care pathway from preadmission to discharge, including information about medications, 
has been highlighted in a recent study that reported how communication failures led to patient 
morbidity and mortality. Standardisation and systemisation of communication processes, along with 
other interventions targeted at the entire surgical pathway, were recommended with a view to 
improving information transfer and quality of care.[209] 
Pharmacists in PACs have been shown to improve the accuracy of medication histories and 
medication orders, when compared with standard care, and the efficacy of prescribing 
perioperatively in line with recognised guidelines.[210, 211] Only with an accurate history of 
medication usage can decisions be made safely regarding the perioperative management of 
medications. Medication histories are elicited from a variety of sources of information: patient’s 
own medications, the patient or carer, general practitioner summaries, community pharmacies, 
previous hospital admissions and nursing home records. A number of sources may be consulted to 
build an accurate record of medication that the patient is taking, both regularly and occasionally. 
The range of prescribers has been expanded in a number of countries, with changes in legislation to 
allow for extension of prescribing privileges to non-medical professionals, including pharmacists. 
The objective of this was to make greater use of the skills and specialisation of pharmacists so that a 
more flexible system for the prescribing, supply and administration of medicines could be 
developed, while maintaining safe and appropriate access to medicines.[3, 193] In response to the 
documented workforce shortages in Australia, Brooks et al described possible solutions, including 
‘task substitution’, and a focus has been placed recently on non-medical prescribers within the 
healthcare system.[15, 17, 18, 37, 40] Pharmacists, with training in pharmacology and therapeutics, 
are potentially well placed to undertake prescribing roles. An Australian study identified the main 
driver behind pharmacist prescribing as the desire to work collaboratively with medical and nursing 
staff to: 
• Provide consumers with improved, responsible and safe access to prescription medicines; 
• Optimise use of pharmacists’ and doctors’ skills and time; 
• Reduce inefficient use of health resources.[1] 
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Evidence to support non-medical prescribing so far has been mainly qualitative, with minimal 
evaluation of access, safety and appropriateness. One recent review concluded that acceptability of 
non-medical prescribing services is based on the perceived value to the health service.[8] This lack 
of evidence has led to calls to prove the safety and effectiveness of non-medical prescribing 
services in Australia.[181] The aim of the data analysis discussed in this paper was to compare a 
doctor—pharmacist collaborative prescribing model with usual care, with regard to safety, access, 
appropriateness and effectiveness; the null hypothesis being that no difference exists between the 
two models of care.[11] 
3.2.3 Methods 
 
The study was conducted between June and September 2009 in the surgical PAC at PAH, a 750-bed 
tertiary teaching hospital in Queensland. The definition of error used in the study was: “a failure to 
communicate essential information; the use of drugs or doses is inappropriate for the individual 
patient; and transcription error.”[203] All patients who attended PAC and could provide written 
informed consent were considered for participation. Patients were excluded if they were under 18 
years of age, unable to communicate due to language difficulties or undergoing day surgery  
(figure 4). 
 
Figure 4 ‐ Randomisation Flow Chart 
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Patients were approached on arrival at the clinic and written consent was obtained. After consent, 
patients were randomised using a computer generated randomisation list, in blocks of 10 (Microsoft 
Excel). Sealed envelopes (not prepared by the recruiting researcher) contained a zero or one as per 
the computer list; the next envelope was opened after consent to determine whether a patient 
entered the control or intervention arm, respectively. If a patient had been randomised and their 
surgery cancelled during PAC, the patient was removed from the study and not replaced. A 
previous pilot study in the PAC showed an error rate of 12% of orders.[200] Using an expected 
error rate of 8% in the intervention arm, a sample size of 932 orders per group was calculated to be 
required for a power of 80%. Assuming an average of five orders per patient, approximately 200 
patients per arm would be required. Only one pharmacist in the PAC, with 3 years’ experience as a 
hospital pharmacist and having a postgraduate diploma in clinical pharmacy, was trained to be a 
prescriber. The pharmacist attended a prescribing course which was accredited by the General 
Pharmaceutical Council, UK as an Independent Pharmacist Prescribing Course.[212] Training 
included a minimum of 12 days of ‘period of learning in practice’ under a ‘designated medical 
practitioner’ (DMP), who was the consultant anaesthetist for PAC. The training included case 
studies and sessions on venous thromboembolism (VTE) prophylaxis with a consultant vascular 
physician and the clinical nurse consultant (CNC) for VTE prophylaxis at PAH. The DMP endorsed 
the pharmacist’s competency to prescribe before the study could start. 
For the pilot, an amendment was facilitated to the Queensland Health (Drugs and Poisons) 
Regulation 1996 to allow ‘Pharmacists registered in Queensland who are employed or contracted to 
Queensland Health and working in the Pharmacist Prescribing Pilot’ to prescribe 
controlled drugs, restricted drugs and schedule 2 and 3 poisons. 
3.2.3.1 Intervention Cohort 
 
Patients were seen by a nurse, prescribing pharmacist, Resident Medical Officer (RMO) and 
anaesthetist. Patients had to be seen by the pharmacist before they were seen by the RMO to allow 
usual RMO duties and a countersignature of the pharmacist prescriptions, a site requirement. The 
pharmacist undertook all pharmacist duties as per usual care, as well as prescribing medications on 
the medication chart. The scope of prescribing was continuing or withholding regular medications 
and prescribing VTE prophylaxis according to local and national guidelines, following a risk and 
contraindication assessment. [213] 
Directors of surgery were consulted prior to the start of the trial for permission to include patients in 
prescribing of VTE prophylaxis, according to their specific unit guidelines, which had been defined 
in advance in collaboration with the CNC for VTE prophylaxis at PAH. Urology and renal 
transplant patients were excluded (N=43 control, N=34 intervention) from VTE prophylaxis 
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prescribing as the director of urology was unavailable to confirm the scope of the project, and the 
director for transplant requested exclusion on the grounds that VTE prophylaxis in these patients 
was driven more by consultant discretion as opposed to being driven by guidelines. 
3.2.3.2 Control Cohort 
 
Patients were seen by all four healthcare professionals in clinic, in no particular order, as per usual 
care. Either pharmacist in the clinic saw control patients for documentation of medication history. 
The prescribing of the medication chart was the responsibility of the RMO. In both arms, review 
and monitoring were undertaken, both by RMOs in clinic at countersignature and by RMOs and 
clinical pharmacists at the ward level, once the patient was admitted. Changes made by RMOs to 
intervention patient medication charts in clinic were recorded. 
3.2.4 Outcome Measures 
 
The primary endpoint for the study was the accuracy of medication charts, with regard to 
concordance of the medication chart with the medication history, the plan for medications 
perioperatively and the quality of the individual orders related to legality and safety for 
administration purposes. The secondary endpoint was the appropriateness of prescribing for both 
chemical and mechanical VTE prophylaxis according to local and national guidelines.26 
Analysis of scanned copies of medication charts, for the primary outcomes of omissions and errors, 
was conducted in tandem by two assessors, one a member of the research team and the other an 
external assessor, both trained in the use of validated audit tools1 and blinded to randomisation. 
Any ambiguities were clarified by consensus. 
Appropriateness of VTE prophylaxis prescribed in both arms in clinic was analysed using scanned 
copies of medication charts, in tandem by two assessors, one a member of the research team and the 
other a CNC for VTE prophylaxis at PAH. Prescribing was also assessed on admission to the ward 
to ensure that VTE prophylaxis was appropriate. 
An expert panel, comprising a surgeon, a clinical pharmacologist, an anaesthetist, a RMO, a 
pharmacist and a nurse, was convened to assess the clinical significance of omissions in a randomly 
selected 5% sample of the total cohort of patients from both arms (N=10 control, N=9 intervention). 
Panel members were blinded to randomisation. 
Tables 2 and 3 describe the collection methods and definitions of these endpoints. 
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Table 2 ‐ Analysis to assess the accuracy and safety of medication charts generated in the study 
 
Measure Definition Method Assessing 
Omissions Medication in patient’s 
medication history not 
prescribed on 
medication chart, with 
no reason documented 
in patient chart  
Every medication in 
patient’s medication 
history audited against 
medication chart - 
omissions from 
medication chart noted 
Whether or not 
medication is 
prescribed 
Prescribing Errors Anomaly in drug 
name, strength, dose, 
frequency or route, 
with no documentation 
in patient chart 
Every medication in 
patient’s medication 
history audited against 
medication chart – 
anomalies noted 
Whether or not 
prescription is accurate 
in terms of drug name, 
strength, dose, 
frequency and route 
Communication Errors Unclear prescription in 
terms of name, route, 
dose, frequency, slow 
release medication 
notification or 
intermittent order 
prescribing 
Every prescription 
written audited using 
validated audit tool – 
unclear prescribing 
noted, as agreed by 
both auditors 
Whether or not 
prescription is safe for 
administration 
purposes 
 
Table  3  ‐  Analysis  to  assess  accuracy  of  VTE  risk  and  contraindication  assessments  and 
appropriateness of VTE prescribing 
 
Measure Definition Method Assessing 
VTE Risk Assessment Patient categorised in 
to low or high risk for 
VTE, as per guidelines 
Every patient medical 
record audited for a 
documented VTE risk 
assessment  
Risk assessment 
documented Y/N 
Risk assessment 
correct Y/N 
VTE Contraindication 
Assessment 
Patient highlighted as 
inappropriate for 
mechanical or 
chemical prophylaxis, 
as per guidelines 
Every patient medical 
record audited for a 
documented 
contraindication 
assessment 
Contraindication 
assessment 
documented Y/N 
Contraindication 
assessment correct 
Y/N 
VTE prescribing Whether patient 
prescribed mechanical 
and/or chemical VTE 
prophylaxis, as per 
guidelines 
Prescribing of 
mechanical and 
chemical VTE 
prophylaxis audited 
against agreed local 
and national guidelines 
VTE prescribing 
appropriate according 
to guidelines and 
individual patient 
factors Y/N 
 
Categorical data were compared using χ² tests for independence. When any one cell had a count of 
less than 10, Fisher’s exact test was substituted. Logistic regression was used to analyse the overall 
omissions between the two groups. The number of regular and ‘PRN’ medications that the patient 
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was currently taking was included as an explanatory variable in the model as it was deemed more 
likely that an individual medication would be omitted in a patient taking a large number of 
medications. Logistic regression was also used to analyse the overall communications prescribing 
errors between the two groups. The assumption of independence between observations is clearly 
violated as multiple observations exist for most patients. As such, robust SEs clustered by patient 
were calculated. No other covariates were adjusted for. All reported p values are two-sided using a 
level of significance of 0.05. All statistical analysis and sample size calculations were conducted 
using Stata V.11.2 (StataCorp, College Station, Texas, USA). 
3.2.5 Results 
 
The demographics of the patients randomised into the trial were similar, except for the higher 
number of medications taken by patients in the control arm (table 4) 
Table 4 ‐ Characteristics of study population 
 
 Control  Intervention  
Total Patients 190 194 
Age ‡ 57.6 [18-89] 55.8 [18-86] 
Male (%)  58% 59% 
*Regular Medications† 4[0-16] 3[0-18] 
#When Required ‘PRN’ Medications† 2[0-7] 1[0-4] 
Complementary and Alternative Medicines (CAM) † (0)[0-9]  (0)[0-6] 
Over The Counter (OTC) Medications†  (0)[0-2] (0)[0-2] 
Total Medications 1364 983 
Total medications (regular and prn only) 1217 887 
Medication Charts Prescribed 161 (85%) 194 (100%) 
‡ mean [range] 
† median [range] 
*Regular medications are defined as medications prescribed with the intent to be taken on a regular 
basis  
#Pro Re Nata (PRN) medications are defined as medications prescribed with the intent to be taken only 
when required 
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3.2.5.1 Omissions 
 
Total unintentional medication omissions from medication charts were higher for control patients 
(31.5%) compared with interventions (1.2%) The OR for an order in the control group to be 
omitted, compared with that for the intervention group, was 41.0 (95% CI 20.6 to 81.8; p<0.001 
logistic regression) after adjusting for the number of medications the patient was currently taking 
(figure 5 and table 5). There were 59 prescribers in the control arm, 54 of whom reviewed patients 
who were currently taking regular or PRN medications at home, and as such had the opportunity to 
omit a patient’s medication. Of these 54 prescribers, the median percentage of medications that 
were omitted per prescriber in the control arm was 21 (range 0–100). 
 
Figure 5 ‐ Percentage of Medication Omitted 
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Table 5 ‐ Medication omissions from medication chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*CAM and OTC medications were not classed as omissions in either arm if not prescribed on the inpatient 
medication chart 
3.2.5.2 Clinical significance of omissions 
 
Omissions from a randomly selected 5% of the total cohort were evaluated for clinical significance. 
Of the 89 regular medications in the patients’ medication histories in the control arm, 25 (28%) 
were omitted from the medication charts, compared with 1 of 55 (2%) in the control arm. When 
asked to assess the severity of omission, the average across the panel showed that 52% of omissions 
Type of Medication and Perioperative Plan Control (N)[%]  
Intervention(N)[
%]  
Regular   
Continue 179 (805)[22.2] 3 (620)[0.5] 
Withhold prior to surgery 46(75)[7.4] 0(48) 
Withhold on morning of surgery 21(54)[38.9] 0(39) 
Adjust dose 1(5)[20.0] 0(5) 
Review 1(7)[14.2] 0(6) 
Cease 0(1) 0(2) 
PRN   
Continue 128(248)[51.6] 6(142)[4.2] 
Withhold prior to surgery 7(12)[58.3] 2(13)[15.4] 
Adjust dose 0(2)[20.0] 0(1) 
Review 0(8)[14.3] 0(11) 
Total Omissions 
383(1217)[31.5] 
 
11(887)[1.2] 
 
*Complementary and Alternative Medicines 
(CAMs) 
126 87 
*Over The Counter Medications (OTC) 21 9 
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in the control arm had the potential for patient harm or ward inconvenience (figure 6). Only one 
reviewer thought the omission in the intervention arm was significant. 
 
 
Figure 6 ‐ Assessment of clinical significance of omissions 
3.2.5.3 Prescribing errors related to drug, dose and frequency selection 
 
Overall, 53 errors were identified where the drug strength, dose or frequency prescribed did not 
match the medication history or perioperative plan (figure 7). This equates to 6.3% of control 
orders compared with 0.2% of intervention orders (p<0.001, Fisher’s exact test). 
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Figure 7 ‐ Number of prescribing errors 
3.2.5.4 Communication errors 
 
Communication errors, where prescriptions were rated as ambiguous or unclear, were significantly 
higher in the control arm compared with the intervention arm. The OR for an order in the control 
arm to have a communication error compared with an order in the intervention arm was 2.52 (95% 
CI 1.96 to 3.27; logistic regression p<0.001). As there were multiple orders per patient, robust SEs, 
clustered by patient, were utilised (table 6). Individually, communication errors were significantly 
higher in the control arm for all types  of error except the route of administration (p=0.57 χ2 test). 
From the control arm prescribers, 44 of them prescribed medication on the medication charts, with a 
median number of orders of 21 (range 1–85). The median percentage of orders in the control arm 
that contained at least one communication error per prescriber was 38 (range 0–100). 
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Table 6 ‐ Prescribing errors with an ambiguity in at least one component of the prescription 
 
 Control 
Number of errors  
(% of total orders) 
Intervention 
Number of errors  
(% of total orders) 
P value 
Total Orders 1034 904  
Orders with at Least One 
Communication Error 
445(43) 208(23) <0.001 Π † 
Prescribing 
Communication Errors 
667 229 <0.001† 
 
Prescribing Communication Errors 
Drug name 23 (2.1) 0 <0.001‡ 
 
Route 79 (7.6) 76 (8.4) 0.57† 
 
Dose 48 (4.6) 5 (0.6) <0.001‡ 
 
Frequency 190 (18.4) 96 (10.6) <0.001‡ 
 
Administration times 
incorrect or missing 
117 (14.9) 
(781 orders) 
4 (0.5%) 
(762 orders) 
<0.001‡ 
 
prn max dose missing 178 (74.5) 
(241 orders) 
47 (32.6) 
(142 orders) 
<0.001‡ 
 
Slow Release not 
specified 
15 (30.0) 
(50 orders) 
1 (1.5) 
(66 orders) 
<0.001‡ 
 
Intermittent order not 
specified 
17 (57.5) 
(30 orders) 
0 
(38 orders) 
<0.001‡ 
 
Π Logistic regression 
† Chi-Square 
‡ Fisher’s Exact 
3.2.5.5 VTE prophylaxis 
 
Patients in the intervention arm were significantly more likely than controls to have appropriate 
VTE prophylaxis prescribed on the medication chart in PAC and to have documented VTE 
assessment (figure 8). On admission to the ward, approximately 90% of both intervention and 
control patients were prescribed appropriate VTE prophylaxis. 
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Figure 8 ‐ Venous thromboembolism assessments and prescribing 
3.2.6 Discussion 
 
This study has built on the findings from previous research of pharmacists prescribing in PAC 
settings, which have found improved accuracy of information gathered, and improved prescribing 
according to guidelines.[208, 214] Similar studies of pharmacist interventions in different settings 
have shown improvements in clinical endpoints such as blood pressure control, increased 
appropriateness of prescribing and reductions in ADEs, such as warfarin-associated bleeds.[155, 
215] 
The traditional scope of practice for the PAC pharmacist consists of taking a medication history, 
using guidelines, clinical judgement and referral to the surgical team to suggest a plan for 
medications perioperatively, and providing this information to the RMOs to generate the medication 
charts. This scope has been extended in our study by providing an appropriately trained pharmacist 
to generate the medication chart and prescribe VTE prophylaxis, which has led to a significant 
reduction in omissions and prescribing errors, ensuring that patients get the correct medication 
while in hospital. The evaluation of VTE prophylaxis prescribing was essential to assess the safety 
and appropriateness of initiation of a new medication, within guidelines, by the prescribing 
pharmacist. The results from this study have shown the prescribing to be as appropriate as usual 
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care at the time the patient is admitted to the ward. Issues still remain with the prescribing, 
especially with the use of inappropriate abbreviations.[216] For example, a large proportion of 
communication errors in the intervention arm were due to the use of s/c to indicate subcutaneous, 
which has informed the researchers on future educational requirements of prescribers, especially 
with regard to safe prescribing. Electronic prescribing may be one solution to such errors involving 
legibility and inappropriate abbreviations, but studies have shown that the systems introduce errors 
of their own.[217] These errors need to be fully assessed and appreciated if the quality of 
prescribing is to be improved by the introduction of computerised prescribing into the healthcare 
system. 
The results presented in this paper are part of a larger study. Further work is required to assess the 
appropriateness of prescribing of medication charts and consumer participation of this new model 
of care.[11] There are a number of limitations. Even though the trial was randomised, the total 
number of medications that the patients were taking was higher in the control arm (1364) compared 
with the intervention arm (983). The explanation for this is unknown but may in part be due to large 
randomisation block sizes, possibly meaning that a number of consecutive patients were 
randomised to the control arm during clinic sessions, where patients were more likely to have a 
higher burden of medication, for example, during a vascular surgery clinic. There was more 
opportunity for omissions from the control arm as a result of more medications needing to be 
continued, and this was allowed for in the analysis. RMOs in clinic during the study were aware of 
the intervention pharmacist’s role, which may have led to an increased number and quality of 
medication charts prescribed in the control arm. Even with this potential effect, the study still 
showed a significant improvement in the safety and accuracy of medication charts. Review of 
medication orders is not a role that an RMO routinely undertakes. All RMOs were educated with 
regard to the requirement of a countersignature of pharmacist orders, and to amend anything as 
required prior to sign off. In the trial, 10 charts were amended— 5 changes were minor, 3 were 
addition of analgesics out of the pharmacist’s prescribing scope and 2 changes actually resulted in 
inappropriate VTE prophylaxis. Despite the legislative changes, countersignature of pharmacist 
orders was a local requirement owing to the concern that junior doctors may become deskilled as a 
result of being removed from the prescribing process. However, the authors suggest that having an 
appropriately trained prescribing pharmacist in clinic, for the RMOs to use as guidance and to 
provide feedback on any prescribing errors, may increase the effectiveness of the learning 
environment. Having only one pharmacist prescribing in the intervention arm and multiple RMOs 
prescribing in the control arm is a potential source of bias that is unavoidable where individual 
knowledge, skills and capabilities determine the quality of prescribing. It has been suggested that 
medical undergraduate training may not prepare graduates to prescribe, which if addressed may 
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reduce this individual variance.[218] The model of care tested in our study was successful as we 
were able to reduce the variance within a group by training one individual pharmacist to manage 
medications perioperatively, within a set scope of practice, and to include prescribing. It could be 
argued that the same results may have been obtained by providing the RMOs with extra prescribing 
training, and that the improved performance may not necessarily be solely due to the introduction of 
a new professional discipline. 
The authors acknowledge that the improved results may well be multifactorial, but would also 
suggest that the underlying competencies of an experienced, ‘advanced level’ pharmacist, plus the 
prescribing training provided, have ensured appropriate competencies to prescribe in the model of 
care in which the prescribing took place.[219] 
The order of consultation in the intervention arm was set by trial design. The order in the control 
arm was not set, which is a true reflection of usual care, where the patient could see the RMO prior 
to the pharmacist. This may have impacted on the quality of control medication charts prescribed by 
the RMO, without information available from the pharmacist history. While this could be classed as 
a limitation, this does reflect usual care in PAC and highlights the collaborative nature of the 
existing model of care. The prescribing pharmacist was able to see control patients for usual care 
duties of a medication history, which may be perceived as introducing bias. However, as both 
pharmacists have received the same undergraduate and general-level pharmacist training, the 
quality of medication history gathered for the RMO to use to prescribe the medication chart would 
be the same. Another limitation is the potential sustainability of the model of care, and capacity to 
train pharmacists as prescribers. This was only one pharmacist in one hospital who had received 
special training to be able to prescribe. Evaluation of the requirements of non-medical prescribing 
courses is underway, but substantial further thought needs to be applied to ensure reproducibility of 
these results in a larger sample and consistent production of safe and effective prescribers.[220] 
Further work is required to address the actual and perceived medicolegal implications for both 
doctors and pharmacists in such collaborations. 
3.2.7 Conclusion 
 
Medication charts in the intervention arm were significantly safer and more accurate with regard to 
the patients’ regular medications than medication charts in the control arm. There was no difference 
in appropriateness of VTE prophylaxis prescribing between arms on admission to the ward. 
Our study has shown that the pharmacist in a PAC was able to effectively gather all the information 
required to collaboratively formulate a clinical decision in clinic within an agreed scope of practice, 
and communicate the decisions safely and accurately onto the medication chart. 
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A collaborative doctor–pharmacist prescribing model in a PAC was as safe and accurate as usual 
care in ensuring that patients were prescribed the medication required on admission for elective 
surgery. 
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3.3 Next Steps 
 
Large differences in the number of medication omissions in the results reported in Chapter 3 
prompted the question about appropriateness of prescribing in both arms, and namely the 
appropriateness of medications prescribed (commissions) and the appropriateness and significance 
of medications omitted from the NIMC, both in terms of likelihood to cause ward inconvenience 
and patient harm. 
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4 Chapter 4 – Appropriateness of Prescribing and Significance of 
Omissions.                                                                 
4.1 Chapter Introduction 
The results in Chapter 3 showed a large difference between the control and intervention arms in the 
percentage of patients’ regular medications omitted from the NIMC. This raised the question of the 
importance of these omissions, and whether they were likely to be clinically significant, and hold 
any potential for patient harm from missing doses, or ward inconvenience in having to find a 
medical officer to prescribe them on to the NIMC on admission to the ward. It was crucial to assess 
the possible impact of omissions, and the appropriateness of the medications that had been 
prescribed on to the NIMC for the patient’s admission. This was to ensure the prescribing on the 
NIMC was not only safe and accurate, as shown in Chapter 3, but also appropriate. 
A sub study methodology was designed, utilising an expert panel of clinicians relevant to a patient’s 
surgical pre admission and admission, and a validated tool for assessing appropriateness of 
prescribing, the Medication Appropriateness Index (MAI). The purpose of the panel was to assess a 
‘snap shot’ of the prescribing in the study from both arms, as to whether medications that had been 
prescribed were appropriate and whether omissions of any patients’ regular medications from the 
NIMC were potentially significant, in terms of ward inconvenience or patient harm.  
In the 2009 review of the National Health Performance Framework the effective, appropriate and 
capable dimensions were combined into one dimension effectiveness. Effectiveness is defined as 
the ‘intervention achieves the desired outcomes’, which in this case is an appropriately prescribed 
and complete medication chart. The medication chart provides information for administration of 
medications on the ward, and is also the number one source of information on discharge. A 
complete and accurate medication chart is important for inpatient access to medications, and 
continuity of care across healthcare settings. 
4.2 Published Paper - A Pilot Study to Assess the Appropriateness of 
Prescribing From a Collaborative Pharmacist Prescribing Study in a 
Surgical Pre Admission Clinic 
 
Hale A, Martin J, Coombes I, McDougall D, Coombes J, Nissen L. Pilot Study to Assess the 
Appropriateness of Prescribing From a Collaborative Pharmacist Prescribing Study in a Surgical 
Pre Admission Clinic. J Pharma Care Health Sys 1:110. doi:10.4172/jpchs.1000110 
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4.2.1 Abstract 
4.2.1.1 Background 
Current evidence to support non-medical prescribing is predominantly qualitative, with little 
evaluation of quality, safety or appropriateness of prescribing. 
4.2.1.2 Objective 
This study aims to evaluate the appropriateness of prescribing, and significance of omissions, from 
a doctor-pharmacist collaborative prescribing model. 
4.2.1.3 Setting 
An elective surgery pre admission clinic (PAC) in a Brisbane based tertiary hospital 
4.2.1.4 Method 
A modified version of the Medication Appropriate Index (MAI) was developed, piloted and 
subsequently used by an expert panel, comprised of a surgeon, anaesthetist, clinical pharmacologist, 
pharmacist, resident medical officer (RMO) and clinical nurse.  
4.2.1.5 Main outcome measures 
A modified version of the Medication Appropriate Index (MAI) was developed, piloted and 
subsequently used by an expert panel, comprised of a surgeon, anaesthetist, clinical pharmacologist, 
pharmacist, resident medical officer (RMO) and clinical nurse.  
4.2.1.6 Results 
When reviewer assessments were combined, 32 out of 294 (10.9%) medications assessed for 
appropriateness in the control arm were classed as inappropriate, compared to 13 of 266 (4.9%) in 
the intervention arm.  
Out of 89 regular medications in the control arm, 25 (28%) were omitted from the medication 
charts, compared to 1 out of 55 (2%) in the intervention arm (p<0.001, fishers exact) 
On average, 52% of omissions in the control arm were judged to have potential for patient harm or 
ward inconvenience. 
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4.2.1.7 Conclusion 
For the appropriateness of prescribing, overall results were similar between arms, as judged by 
individual panel members. Medication charts in the control arm contained significantly more 
omissions than in the intervention arm, a number of which were rated by the panel members as 
having the potential for patient harm or ward inconvenience. 
• Pharmacist prescribing is a model of care that has the potential to increase access, for the 
general public, to safe and appropriate medication usage, and better utilise the skills of the 
current healthcare workforce 
• Research on pharmacist prescribing has been predominantly qualitative, with little 
assessment of quality, safety or appropriateness of prescribing.  
• Our study analysed the safety, accuracy and appropriateness of prescribing within this 
model of care, to provide the more robust quantitative data required to aid in the 
implementation of pharmacist prescribing in Australia 
• Pharmacist prescribing will make for a more efficient system; freeing up doctor time, whilst 
ensuring the knowledge and skills of pharmacists, in quality use of medicines, are utilised to 
their full potential. 
4.2.2 Introduction 
 
Inappropriate prescribing is the failure to provide the quality of care related to medication use that 
should be achieved in practice, and encompasses overprescribing, misprescribing, and 
underprescribing.[221] Inappropriate medicine use has been defined as that which poses greater risk 
of harms than benefits, especially when safer alternatives exist.[222] Elderly patients, in particular, 
are susceptible to the consequences of inappropriate prescribing, increasing the risk of adverse drug 
events and related morbidity and hospitalisations.[223, 224]  Patients recently discharged from 
hospital are also at increased risk of medication misadventure, as medication is often reviewed and 
changed during an admission, and poorly communicated with community practitioners.[225] The 
importance of accurate transfer of information across the whole surgical care pathway from 
preadmission to discharge, including information about medications, was highlighted in a study that 
reported communication failures led to patient morbidity and mortality.[209] The Australian 
Commission on Quality and Safety in Health Care has highlighted medication reconciliation, and 
the accurate transfer of information about medication as a national priority.[226]  
Within hospital, the medication chart provides a record of patient’s medication, instructions for safe 
medication supply and administration, and ensures patient access to medications as an inpatient. It 
is a communication tool between doctors, pharmacists and nurses about prescribing decisions, and 
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is used as the primary source of information regarding medications, both during the inpatient stay 
and on discharge. An appropriate and accurate medication chart is essential, and unless prescribing 
errors are found and corrected early, they can lead to errors in supply and administration.[227] 
Pre admission clinic (PAC) at Princess Alexandra Hospital (PAH) is a multidisciplinary clinic, 
comprising of nurse, Resident Medical Officer (RMO), pharmacy and anaesthetic review. The 
pharmacy service in PAC was initiated in 1998, with the aim of improvement in the accuracy of 
information exchange as patients cross healthcare setting.[208] The benefits of pharmacy 
involvement in PAC on medication management and information transfer prior to admission and on 
discharge, and the associated risks of omissions of medications at these times, were highlighted as 
part of a randomised controlled trial.[199] Pharmacy in PAC is now a well-recognised role in 
Australia, with the Society of Hospital Pharmacists of Australia (SHPA) publishing a fact sheet on 
how pharmacists in PAC can contribute to better patient outcomes and quality of care.[228] 
Several countries have extended the prescribing of prescription only medicines to health care 
professionals other than doctors, with the aim of increasing patients’ access and choice, and make 
best use of health professionals’ skills, whilst ensuring patient safety.[229] Health Workforce 
Australia has highlighted possible models of prescribing for non-medical health professionals 
within the Australian healthcare system.[37, 230] However, there is a lack of evidence to support 
this model of care. Current literature is predominantly qualitative, with little in the way of 
evaluation of quality, safety or appropriateness of prescribing. A recent review suggested that 
acceptance of the model of care was mainly based on the perceived value to the healthcare 
system.[8] 
4.2.3 Aim of the study 
 
To use a validated national health performance framework to compare a collaborative pharmacist 
prescribing model with usual care, with regards to effectiveness (incorporating appropriateness), 
safety, responsiveness, continuity, accessibility and efficiency.[11] The hypothesis was that no 
difference exists between the models of care. Results so far have shown pharmacist prescribing is as 
good as usual care in safety and accuracy of medication charts, and appropriateness of venous 
thromboembolism (VTE) prophylaxis.[231] 
The significant difference in omissions of medications prompted further investigation in to the 
appropriateness of prescribing, and the significance of medications that had not been prescribed on 
to the national inpatient medication chart (NIMC). The aim of the data discussed in this paper is to 
assess a ‘snapshot’ of the appropriateness of prescribing, and the potential health impact or ward 
inconvenience of omissions from the NIMC. 
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4.2.4 Ethical approval 
 
Ethics approval was obtained from the PAH Human Research Ethics Committee 
4.2.5 Methods 
 
The main study was conducted  between June to September 2009 in the surgical, multidisciplinary 
PAC at PAH, a 750 bed tertiary teaching hospital in Queensland. 
All patients who attended PAC and could provide written, informed consent were considered for 
participation. Patients were excluded if they were under 18 years of age, unable to communicate 
due to language difficulties or undergoing day surgery 
A previous audit in PAH PAC showed an error rate of 12% of orders.[200] Using an expected error 
rate of 8% in the intervention arm a sample size of 932 orders per group was calculated to be 
required for a power of 80%.  Assuming an average of 5 orders per patient, it was estimated that 
200 patients per arm would be required for the main study. 
4.2.5.1 Intervention Cohort 
Patients were seen by a nurse, prescribing pharmacist, Resident Medical Officer (RMO) and 
anaesthetist. Patients were seen by the pharmacist before they were seen by the RMO to allow usual 
RMO duties and a countersignature of the pharmacist prescriptions, a site requirement. The 
pharmacist undertook all pharmacist duties as per usual care, as well as prescribing medications on 
the NIMC. 
4.2.5.2 Control Cohort 
 
Patients were seen by all four health care professionals in clinic, as per usual care. The prescribing 
of the NIMC was the responsibility of the RMO. 
4.2.5.3 Sample of Patients for Panel Assessment of Appropriateness 
 
Intervention and control patients from the main study were stratified in to 5 groups, from the first 
patient recruited to the last patient, in blocks of 40. Microsoft Excel random number generator was 
used to pick 2 numbers from each stratified group, giving a total of 10 patients (5%) from both 
arms. The rationale for the stratification was to enable a selection of patients from across the study 
timeline, and a selection of prescribers in the control arm, as the study spanned across two rotations 
of junior doctors. Patients identified in the medication history in PAC as not taking any medication 
were excluded, and another number was generated until a patient who was taking medication prior 
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to admission was selected. One patient was subsequently removed from the control group, due to 
being lost to follow up from the main study 
4.2.5.4 Panel Selection 
 
The panel consisted of a number of different health professionals, recognising either their 
involvement in the care of surgical patients, prescribing expertise or both; a consultant anaesthetist, 
a consultant hepatobiliary surgeon, a consultant clinical pharmacologist, a senior pharmacist with 
previous PAC experience, a senior PAC nurse, and a RMO with previous surgical and PAC 
experience. 
All panel members were independent to the research team. 
4.2.5.5 Medication Appropriateness Index 
 
Previous studies assessing appropriateness of prescribing, including non-medical prescribing, have 
identified the Medication Appropriateness Index (MAI) as the most suitable tool with which to 
assess appropriateness in an acute setting, with good inter and intra rater variability.[139] The tool 
consists of a 10-item rating system; indication, effectiveness, dose, correct directions, practical 
directions, drug-drug interactions, drug-disease interactions, duplication, duration and cost. 
Amendments were made to the MAI for our study; items regarding duration of therapy and cost 
effectiveness were not considered applicable, due to the scope of the pharmacist’s prescribing being 
medications that the patient was already taking. Additional questions were added, as the MAI does 
not assess underprescribing. Our finalised tool contained two questions to assess whether there had 
been an omission, and the significance in terms of potential ward inconvenience and patient harm. 
With regards to appropriateness of prescribing, the final tool contained 8 items. The original three-
point Likert scale was dichotomised to either appropriate or inappropriate, as the original midpoint 
(marginally appropriate) was considered too subjective, as per previous studies.[139]  
Five patients were piloted by one member of the research team and one panel member prior to the 
panel assessment to assess whether the modified MAI could be applied to the patients appropriately, 
and to gain a rough estimate of an average time per patient. Time was an important factor, as this 
determined the number of patients that could be reasonably assessed, taking in to consideration 
panel members’ availability. A member of the research team met with all panel members prior to 
the panel sittings to discuss the modified MAI. Agreement was reached that it would be an 
appropriate tool to assess appropriateness and significance of omissions. 
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4.2.5.6 Assessment of Prescribing and Omissions 
 
Panel members were provided with copies of patient’s PAC notes, including the medication history 
taken by the PAC pharmacist, and the NIMC. The panel was blinded as to whether the patients were 
control or intervention. Resources provided included the Australian Medicines Handbook (AMH), 
locally produced PAC medication guidelines containing recommendations for management of 
medications peri operatively, and individual consultant preferences obtained by clinic for 
management of certain groups of medications peri operatively, for example anticoagulants. The 
panel was convened for 2 sittings, and each individual panel member rated every medication 
prescribed on to the NIMC using the criteria set out by the amended MAI. An unintentional 
omission was defined as any medication from the medication history not prescribed on the 
medication chart, with no supporting documentation as to why. Omissions were noted and panel 
members rated each one as whether it had the potential for patient harm, ward inconvenience, or 
both. Due to clinical duties only three panel members, the surgeon, clinical pharmacologist and 
pharmacist were able to make both sittings, and review all 19 patients. The other three panel 
members were only able to make one of the 2 sittings and reviewed as many patients possible in 
that time. 
4.2.5.7 Data Analysis 
 
A medication was scored zero, and classed appropriate, if none of the 8 items on the MAI was rated 
as inappropriate. A medication was given a score of 1, and classed inappropriate, if one or more of 
the 8 items received a rating of inappropriate.  
Each panel member’s ratings were evaluated individually, and ratings from all 6 panel members 
were combined, by adding the number of inappropriate reviews together. This gave the total number 
of medications that were rated as inappropriately prescribed, from the total number of reviews of 
medications that were undertaken by the panel.  
All statistical analysis was conducted using  Stata 11.2  (StataCorp, College Station, Tx).  
Categorical data was analysed by chi-square tests. When the value in any one cell was below ten a 
Fisher’s exact test was used as chi-square tests can become unreliable 
A p-value of < 0.05 was considered statistically significant for the total number of omissions and 
individual reviewer assessment of appropriateness of prescribing. 
4.2.6 Results 
 
The sample included 19 patients, resulting in 294 medication assessments for appropriateness for 
the control arm, and 266 for the intervention arm, from the entire panel. 
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The demographics of patients selected for the appropriateness panel assessment were similar to 
those of patients from the main study. (see Table 4) 
4.2.6.1 Appropriateness of Prescribing 
 
Based on individual reviewer’s assessments only one reviewer, the pharmacist, showed statistical 
significance, 6/61 medications assessed  inappropriate in the control arm, compared to 0/54 in the 
intervention (p=0.029). 
Reviewer assessments were combined by adding the results together, in an attempt to describe the 
overall appropriateness. Out of 294 medication assessments across the panel for appropriateness, 32 
(10.9%) of the medications prescribed in the control arm were classed inappropriate, when 
compared to 13 out of 266 (4.9%) in the intervention arm.  
From the entire panel, an average of 5.7% of reviews across both arms were judged as 
inappropriate, with a range of 0 – 18.8%. Nine of the 19 patients were judged as having no 
inappropriate prescribing, 4 from the control arm and 5 from the intervention arm. 
There was a 78% agreement between panel members on inappropriateness of prescribing. 
Table7 shows total medications reviewed by each panel member, and a breakdown of reasons why 
each reviewer thought an individual medication was prescribed inappropriately. 
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Table 7  ‐ Number of  Inappropriate Ratings and Reasons  for Being Classed as  Inappropriate by 
Reviewer (some data missing) 
 
 
C = Control 
I = Intervention 
 
Reviewer Anaesthetist Pharmacologist Nurse Pharmacist RMO Surgeon 
Medications 
Reviewed 
77 110 73 115 68 117 
Inappropriate 
Medications (%) 
4 (5) 10 (9) 6 (8) 6 (5) 6 (9) 13 (11) 
       
Reason C I C I C I C I C I C I 
Medication 
Indicated 
0 0 2 3 0 0 1 0 1 2 1 2 
Medication 
Effective 
0 0 1 3 0 0 1 0 0 1 1 1 
Dose Correct 1 0 0 0 4 0 1 0 0 0 0 1 
Directions 
Correct 
2 0 0 0 3 0 0 0 2 0 2 2 
Directions 
Practical 
0 0 0 0 0 0 0 0  0 0 1 2 
Drug–Drug 
Interaction 
0 0 3 0 4 0 3 0 0 0 1 0 
Drug–Disease 
Interaction 
0 1 0 0 0 0 0 0 1 0 2 6 
Duplication 0 0 4 0 2 0 1 0 0 0 2 0 
Total 3 1 10 6 13 0 7 0 4 3 10 14 
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4.2.6.2 Omissions 
 
There were significantly more omissions in the control arm, of which four panel members’ 
individual assessments showed significant numbers had the potential for either patient harm or ward 
inconvenience. Total unintentional medication omissions from the NIMC in the main study was 
significantly higher for control patients (31.5%) compared to intervention (1.2%) (p<0.001, chi-
square). Omissions from the 5% sample of patients were reflective of these results. Out of 89 
regular medications in the patients’ medication histories in the control arm, 25 (28%) were omitted 
from the NIMC, compared to 1 out of 55 (2%) in the control arm (p<0.001, exact). In the control 
group, all patients had at least one omission. The median number of omissions was 2, with a range 
between 1-7. When asked to assess the severity of omission, all the reviewers thought a percentage 
of the omissions had the potential for patient harm, ward inconvenience, or both. The lowest 
individual reviewer assessment was 40% and the highest 78%, with the average across the panel 
showing 52% of omissions in the control arm were assessed as having the potential for patient harm 
or ward inconvenience (figure 1). Only one reviewer thought the omission in the intervention arm 
was significant. 
Difference of opinion regarding significance of an omission is inevitable, some of the examples of 
omissions that were rated as ‘potential for harm’ by all reviewers were; omission of aspirin from the 
medication chart in two patients, one of whom had a previous cerebrovascular accident (CVA) in 
1995, and one of whom  had a history of ischaemic heart disease (IHD); omission of esomeprazole 
40mg from the medication chart of a patient who suffered from chronic gastro-oesophogeal reflux 
disease (GORD), and omission of perindopril 2.5mg daily in a patient diagnosed with hypertension.  
4.2.7 Discussion 
 
Our study showed that the appropriateness of prescribing from a collaborative doctor – pharmacist 
approach to prescribing was similar to usual care prescribing, and produced medication charts that 
contained significantly fewer omissions of relevant medications.  
Previous interventions to improve the appropriateness of prescribing have included an increase in 
clinical pharmacy involvement during the inpatient stay, which improved the prescribing of 
medicines.[232, 233] Since the introduction of non-medical prescribing in UK, studies of 
appropriateness where nurses and pharmacists have taken on the prescribing role have shown that 
nurse and pharmacists were making clinically appropriate prescribing decisions.[139, 234] 
There are various methods and tools in the literature to assess the appropriateness of prescribing, 
each with their own limitations.[235, 236] The method chosen for our study was one of individual 
clinician, judgement based assessment. It has been suggested the results from this method may not 
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always be valid, reproducible or generalisable. However, the same authors suggested that these 
limitations were remediable by using detailed specifications, validated instruments to obtain data 
and by training data collectors.[221] The use of the MAI satisfied all of these remedial criteria, 
although amongst the 6 panel members differences of opinion as to the appropriateness of 
prescribing, or the significance of an omission is inevitable. Another approach could have been to 
ask the panel to use the MAI to rate each medication as a panel, rather than individually. The 
authors felt the issue of perceived seniority within the panel may have introduced bias in to the final 
decision, hence it was felt more reliable to ask each panel member to rate autonomously. 
From table 7, it can be seen that no one item from the assessment tool stood out as being the main 
reason why the prescribing was assessed as inappropriate across both arms. No indication, 
ineffective medications and duplication of medications can contribute to inappropriate 
polypharmacy, and increase the chance of medication misadventure.[223] Inappropriate doses and 
directions for medication increase the chance of incorrect administration of medication as an 
inpatient.[227] Omissions of medications from the inpatient medication chart, if not rectified during 
the inpatient stay, are likely to be omitted on any discharge information and summary as patients 
cross settings. This will expose the patient to an increased chance of poor outcomes, including 
unplanned 30 day readmission.[208] 
The study is limited by the small numbers of patients assessed by the panel for appropriateness of 
prescribing, and the inability of all of the panel to review all the patients, due to time constraints. 
One of the recognised limitations of the MAI is that it is time consuming, however it was 
considered the best tool for the clinical setting in which the study was conducted. Panel members’ 
availability and the amount of time deemed reasonable for members to commit to the panel amongst 
other clinical commitments, limited the number of patients that it was possible to assess, which 
affected the statistical power of the study, and the ability to assess rater variability.  
The summing of the individual reviewer assessments to describe overall appropriateness would be 
flawed in the event of a panel not agreeing on what makes prescribing inappropriate. However, the 
use of an objective, validated tool with good inter rater variability was used to counteract that 
concern. Difference of opinion is inevitable, but our panel reached 78% agreement, with regards to 
inappropriate prescribing. 
It can be challenging to link inappropriate prescribing to important outcome measures, such as 
mortality, morbidity and adverse drug events. However, from what is known on the subject of 
polypharmacy, and omissions of medication, there is little doubt that a review of medications on 
admission, a complete and accurate medication chart during the inpatient stay, and accurate transfer 
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of information on discharge are all essential components of effective medication management and 
quality use of medicines.[208, 223, 225, 226] 
Results from this small snapshot of prescribing are encouraging, and merit repeating the panel 
assessment on a larger scale. Larger numbers and more robust statistical analysis are necessary to 
enable any sound conclusions to be drawn, and for the results to be extrapolated and generalised 
outside of our small study. 
4.2.8 Conclusion 
 
For the appropriateness of prescribing, observed results were similar between arms, as judged by 
individual panel members. Medication charts in the control arm contained significantly more 
omissions than in the intervention arm, a number of which were rated by the panel members as 
having the potential for patient harm or ward inconvenience. 
A larger sample size is required to make statistical significance or non-inferior conclusions between 
the two arms. 
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4.3 Next Steps 
 
Evaluation of the prescribing of patients’ regular medications in the study was crucial to show that, 
within the collaborative model, the pharmacist could make appropriate clinical decisions with 
regards to what medications were to be withheld and continued prior to surgery, and that this could 
be communicated accurately and safely on to the inpatient medication chart. Results in Chapters 3 
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and 4 have proved that this to be the case, with the end result being a more accurate and safer 
medication chart to provide the patient with access to appropriate medication, as an inpatient. 
It was equally important to show that, within the collaborative model of care and with the use of 
agreed guidelines, that the pharmacist was capable of initiating a new medication in PAC 
appropriately and safely. From the pre study audit that was undertaken, it was clear that there were 
3 main classes of medication initiated in PAC by the RMOs in preparation for the patient’s 
admission to the ward; perioperative analgesia, perioperative nausea and vomiting treatment and 
venous thromboembolism (VTE) prophylaxis.[200] 
Prior to the study commencing, when agreeing the prescribing pharmacist’s scope of practice during 
the study, it was agreed by hospital executive that the pharmacist in clinic could initiate VTE 
prophylaxis, due to the fact that Princess Alexandra Hospital had agreed guidelines for each 
surgical unit, which clearly highlighted which patients were to be treated as low and high risk, and 
the appropriate treatment options once a patient had been risk assessed. 
Chapter 5 reports the results of VTE risk assessments and VTE prophylaxis prescribing in both 
arms in PAC. 
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5 Chapter 5 – Appropriateness of Venous Thromboembolism (VTE) 
Prophylaxis Prescribing.  
5.1 Chapter Introduction 
 
Recording of a VTE risk assessment and prescribing of appropriate VTE prophylaxis are essential 
parts of a patient’s admission to hospital, especially considering surgery is often a risk factor for 
VTE. The secondary outcome for our study was a pre-determined analysis of the appropriateness of 
VTE prophylaxis prescribing on both arms, with the hypothesis being that the pharmacist would be 
as appropriate in their prescribing as the control arm. 
The NHPF domains assessed during this part of the evaluation are;  
• effectiveness, in ensuring that the care provided is relevant to the patient’s needs and based 
on established standards, or in this case agreed guidelines as to what is considered best 
practice 
• safety, in ensuring there is a reduction in potential harm by appropriate use of medications to 
avoid VTE 
Evaluation of VTE prescribing was crucial to show that an appropriately trained pharmacist was 
appropriate in the initiation of a new medication for the patient’s admission. This appropriateness 
can be translated to initiation of medications across many different models of care, and different 
settings, where guidelines provide recommendations for treatment options. This chapter of the study 
shows that appropriate training, to enable interpretation of individual patient parameters, in addition 
to the use of guidelines, and referral to medical officers where appropriate, can improve prescribing 
of important new medications required for a patient admission, to improve patient outcomes. 
5.2 Published Letter to the Editor: Pharmacist Prescribing of Venous 
Thromboembolism Prophylaxis in a Surgical Pre Admission Clinic 
 
Hale A, Gibbs H, Coombes I, Collins R, Maycock E, Nissen L. 
Pharmacist prescribing of venous thromboembolism prophylaxis in a surgical pre admission clinic. 
Anaesthesia and Intensive Care 2014;42:419-420 
The letter is reproduced in full in Appendix G. 
5.2.1 Abstract Summary 
Our study evaluated a potential new model of care for the Australian healthcare system, 
collaborative doctor-pharmacist prescribing of venous thromboembolism (VTE) prophylaxis in a 
pre admission clinic (PAC). The model of care seeks to better utilise the skills within the current 
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multidisciplinary team, and free up doctor time to allow for more efficient processes, whilst 
ensuring safe and appropriate access to medications. 
Four hundred adults scheduled for elective surgery were randomised to either intervention; a 
pharmacist generated the inpatient medication chart and prescribed VTE prophylaxis following a 
risk and contraindication assessment, or control; prescribing of the medication chart and VTE 
prophylaxis was the responsibility of Resident Medical Officers (RMO). Secondary outcome was 
appropriateness of VTE prophylaxis prescribing. 
The primary outcome was the safety and accuracy of medication charts prescribed in clinic. 
Secondary outcome was the appropriateness of VTE prophylaxis prescribing in clinic, which is 
crucial to ensure a patient’s probability of VTE is minimised whilst in hospital. 
The rate of documented VTE risk assessment and documented contraindication assessments were 
also evaluated, due to the evidence that suggests that appropriateness of VTE prophylaxis is more 
likely in the presence of a documented risk assessment. Healthcare services in other countries are 
subject to targets of VTE risk assessment being set, and linked to financial incentives. Financial 
penalties are also imposed in the event of any 30 day post-operative readmission to hospital for 
VTE, on the grounds they are considered preventable errors.  
Our study highlights some concerns if similar initiatives are to be considered within the Australian 
healthcare system, and suggests a new model of care to increase both documented risk and 
appropriateness of prophylaxis. 
VTE risk assessment was documented in significantly more patients in the intervention arm, 
153/160 (96%), compared to 1/147 (1%) in the control arm (p=<0.0001), and when undertaken was 
correct 94% of the time.  
VTE prophylaxis was appropriately prescribed in clinic in 150/160 (94%) intervention patients, and 
94/147 (64%) control (p<0.0001) 
The documentation of risk assessment, and prescribing of VTE prophylaxis by the pharmacist in 
clinic, was significantly more appropriate. 
Trial Registration: Registered with ANZCTR—ACTR Number ACTRN12609000426280 
5.2.2 Introduction 
Venous thromboembolism (VTE) is the term used to describe the disease process which presents as 
either deep vein thrombosis (DVT) or pulmonary embolism (PE).VTE is a major cause of death and 
disability worldwide, and places a large financial burden on health care systems.[237] 
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In 2003, VTE was a more common cause of death than the most common types of cancer, and 7% 
of all deaths in hospital were due to VTE.[238] In 2008 there were almost 15000 cases of VTE in 
Australia, at a financial cost of $1.72 billion, or 0.15% of the GDP. A recent systematic review of 
the literature has shown that initial episodes of DVT or PE are associated with significant healthcare 
costs, estimated at $3,000-9,500 in the United States (US), and € 2,000-4,000 in Europe.[239] 
Multiple risk factors have been identified for development of VTE, including hospitalisation for 
acute medical illness or surgery.[240] Appropriate use of prophylaxis, using anticoagulants and/or 
mechanical devices has been shown to reduce the development of VTE. Studies have achieved a 
80% reduction in VTE, and reduction in some of the long term morbidity associated with VTE, 
which can include chronic venous insufficiency, oedema and recurrent venous ulceration.[241, 242] 
Despite the availability of clear, evidence based guidelines which outline the appropriate use of 
prophylaxis, these recommendations are underutilised.[243]  
Documentation of VTE risk assessment is a critical part of any patient admission, driven by 
evidence that a risk assessment is a trigger for the VTE prevention pathway, and thinking about the 
risks of VTE and bleeding in each patient will improve outcomes by ensuring appropriate 
prophylaxis.[244] Such is the perceived importance of a documented risk assessment, that in United 
Kingdom (UK), a financial incentive is offered through the Commissioning for Quality and 
Innovation (CQUIN) for organisations that document a risk assessment for at least 90% of patients 
admitted to hospital.[245] 
Several barriers have been identified for undertaking VTE risk assessment, including lack of 
awareness by healthcare professionals about incidence of VTE, lack of education about the risk 
assessment, disagreement with best practice clinical guidelines and inadequate system support for 
conducting VTE assessments, such as no clear delegation for the responsibility of completing the 
risk assessment.[246] 
Pharmacist prescribing has been successfully implemented in a number of countries, the objectives 
being to make better use of the skills of the current multidisciplinary team, and that a more flexible 
system for the prescribing, supply and administration of medicines could be developed, while 
maintaining safe and appropriate access to medicines.[3] Evidence so far suggests pharmacists are 
making clinically appropriate prescribing decisions, acceptability to patients is high and the role is 
generally viewed positively by other healthcare professionals.[247] 
The overall aim of our main study was to compare a doctor – pharmacist collaborative prescribing 
model with usual care, with regards to safety, access, effectiveness (incorporating appropriateness), 
efficiency and responsiveness.[248] Results so far have showed improvements in accuracy and 
safety of medication charts prescribed by the pharmacist.[231] 
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We have previously reported the appropriateness of VTE prophylaxis in a cohort of patients on 
admission to hospital.[231] Given the importance, from the literature, and potential efficiency 
benefits of undertaking risk assessments and prescribing VTE prophylaxis in clinic, we undertook 
an analysis of the rate of risk assessments and appropriate of prescribing in a larger cohort of 
patients at the end of clinic. The aim of the data in this paper is to assess how this new model of 
care may assist in the rate of documentation of VTE risk and contraindication assessments, and 
appropriateness of VTE prophylaxis prescribed in pre admission clinic. 
5.2.3 Method 
This main study was conducted between June to September 2009 in the surgical PAC of a 750 bed 
tertiary teaching hospital in Queensland. Ethics approval was obtained from the PAH Human 
Research Ethics Committee, research protocol approval number 2009/050. 
All patients who attended PAC and could provide written, informed consent were considered for 
participation. Patients were excluded if they were under 18 years of age, unable to communicate 
due to language difficulties or undergoing day surgery. After consent, patients were randomised 
using a computer generated randomisation list, in blocks of 10 (Microsoft Excel). Sealed envelopes 
(not prepared by the recruiting researcher) contained a zero or one as per the computer list; the next 
envelope was opened after consent to determine whether a patient entered the control or 
intervention arm, respectively. Patients were randomised to have their medications prescribed on 
the National Inpatient Medication Chart (NIMC) in PAC by either a clinical pharmacist, and 
countersigned by a Resident Medical Officer (RMO), or to usual care, where the medications were 
prescribed by the RMO. If a patient had been randomised and their surgery cancelled during PAC, 
the patient was removed from the study and not replaced.  
The primary outcome for the main study was the combined accuracy and safety of medication 
charts produced by the prescribing pharmacist in clinic, compared to usual care. Statistical power 
was calculated from a previous pilot study in PAC.[200] After loss of patients due to cancellation of 
surgery in clinic, the final cohort for the main study was 384 patients; 190 control and 194 
intervention. This paper was a predetermined sub-study of the main study, and the effect of a 
prescribing pharmacist on documented risk assessments, and appropriateness of VTE prophylaxis 
prescribed in clinic was evaluated. Appropriate VTE prophylaxis was defined as the guideline 
recommended prophylaxis for the surgical unit under which the patient was to be admitted. Each 
surgical unit has a VTE prophylaxis guideline which is available on the hospital intranet, and which 
is given to RMOs during their unit orientation. These guidelines differ due to local input and 
opinion from individual surgical units, but are based on international guidelines.[213] The locally 
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produced guidelines define criteria that determine the need for anticoagulant and/or mechanical 
methods of VTE prophylaxis in high risk patients, and also contraindications to their use. 
Training for the prescribing pharmacist included a minimum of 12 days of ‘period of learning in 
practice’ under a ‘designated medical practitioner’ (DMP), who was the consultant anaesthetist for 
PAC. The training included case studies and sessions on VTE prophylaxis with a consultant 
vascular physician and the clinical nurse consultant (CNC) for VTE prophylaxis at PAH. The DMP 
endorsed the pharmacist’s competency to prescribe before the study could commence. 
5.2.3.1 Intervention Cohort 
 
Patients were seen by a nurse, prescribing pharmacist, Resident Medical Officer (RMO) and 
anaesthetist. Patients had to be seen by the pharmacist before they were seen by the RMO to allow 
usual RMO duties and a countersignature of the pharmacist prescriptions, a site requirement. 
The pharmacist undertook all pharmacist duties as per usual care, as well as prescribing medications 
on the medication chart. The scope of prescribing was to continue or withhold regular medications, 
according to the plan for medications perioperatively, and to prescribe VTE prophylaxis according 
to local and national guidelines, following a risk and contraindication assessment. 
5.2.3.2 Control Cohort 
 
Patients were seen by all four health care professionals in clinic, in no particular order, as per usual 
care. The prescribing of the medication chart, and VTE prophylaxis, was the responsibility of the 
RMO.  
Patient charts were assessed for a documented VTE risk assessment, documented mechanical and 
anticoagulant contraindication assessments, and appropriateness of VTE prescribing in clinic by the 
CNC for VTE prophylaxis and the project manager for the research team.  
5.2.3.3 Data Analysis 
 
All statistical analysis was conducted using  Stata 11.2  (StataCorp, College Station, Tx).  
Categorical data was analysed by chi-square tests. When the value in any one cell was below ten a 
Fisher’s exact test was used as chi-square tests can become unreliable. All reported p values are 
two-sided using a level of significance of 0.05. 
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5.2.4 Results 
 
Table 8 - Summary of Results of VTE Assessments and Appropriateness of Prescribing 
 
 Intervention n(%)
n=160 
Control n(%) 
n=147 
p 
 
VTE Risk Assessment Documented 153 (96) 1 (1) <0.0001, exact
Anticoagulant Contraindication Documented 109 (68) 0 <0.0001, 2 
Mechanical Contraindication Documented 133 (83) 0 <0.0001, 2 
Appropriate VTE Prophylaxis 150 (94) 94 (64) <0.0001, 2
 
 
Directors of surgery were consulted prior to commencement of the trial for permission to include 
patients in prescribing of VTE prophylaxis, according to their specific unit guidelines. Urology and 
renal transplant patients were excluded (N=34 intervention, N=43 control) from VTE prophylaxis 
prescribing as the director of urology was unavailable to confirm the scope of the project, and the 
director for transplant requested exclusion on the grounds that VTE prophylaxis in these patients 
being more consultant discretion as opposed to guideline driven. 
 
Figure 9 ‐ Randomisation Flow Chart 
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5.2.4.1 VTE Risk Assessment 
 
In the intervention arm, out of 160 patient charts assessed a VTE risk assessment was documented 
153 times (96%).  In the control arm, out of 147 patient charts assessed, a risk assessment was 
documented on one occasion (p=<0.0001, exact) 
In the intervention arm, the risk assessment was assessed as being correct on 144 occasions, or 94% 
of the time. All 9 risk assessments that were evaluated as incorrect were documented as high risk by 
the pharmacist, when they should have been low risk, according to guidelines. 
5.2.4.2 Contraindication Assessments 
 
In the intervention arm contraindication assessments to anticoagulant and mechanical prophylaxis 
were documented 109 (68%) times and 133 (83%) times, respectively. All contraindication 
assessments were assessed as being correct. 
In the control arm, no contraindication assessments, to either mechanical or anticoagulant 
prophylaxis, were documented. 
5.2.4.3 VTE Prophylaxis Prescribed in Clinic – Mechanical 
 
In the intervention arm, out of 160 patients assessed for mechanical prophylaxis, 125 (78%) were 
prescribed compression stockings, which was assessed as being 100% appropriate. Patients not 
prescribed stockings were assessed as being contraindicated for various reasons. 
In the control arm, 38 out of 147 (26%) patients had stockings prescribed. Out of the 109 patients 
not prescribed stockings, 40 (37%) were assessed as requiring them, according to risk stratification. 
5.2.4.4 VTE Prophylaxis Prescribed in Clinic – Anticoagulant 
 
Table 9 ‐ Summary of Appropriateness of Anticoagulant Prescribing 
 
 Intervention n (%) 
n=160 
Control n (%) 
n=147 
Anticoagulant prescribed 77 (48) 40 (27) 
Anticoagulant prescribed inappropriately 6 (8) 
3 by RMO 
6 (15) 
Reason for Anticoagulant Not Prescribed 
Low risk 46 (55) 51 (48) 
Contraindication 33 (40) 35 (33) 
Omitted 4 (5) 21 (20) 
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In the intervention arm, 77 out of 160 (48%) patients had anticoagulants prescribed. Out of the 77 
patients, 71 had prophylaxis prescribed by the pharmacist, and six by an RMO. Five of these were 
following referral from the pharmacist, requesting a final decision on whether heparin was required 
for that particular patient, due to individual patient factors outside of guidelines which were 
perceived by the pharmacist to require medical input.  
There were 6 patients prescribed heparin who should not have been, either due to being low risk or 
having contraindications.  
Out of 83 patients not prescribed anticoagulants, 46 were assessed as low risk, 33 were assessed as 
having contraindications, and 4 had heparin omitted from their medication chart when it should 
have been prescribed. 
Out of the 10 patients with inappropriate prophylaxis, 3 had heparin prescribed by the RMO, when 
it was originally appropriately not prescribed by the pharmacist. 
In the control arm, 40 out of 147 (27%) patients had anticoagulants prescribed, 6 of whom should 
not have had heparin, either due to being low risk or having contraindications. Out of the 107 
patients not prescribed heparin, 51 were assessed as low risk, 35 were assessed as having 
contraindications and 21 had heparin omitted from their medication chart when it should have been 
prescribed. 
The intervention arm had an overall appropriateness for VTE prophylaxis prescribing in clinic of 
150/160 (94%), compared to the control arm appropriateness of 94/147 (64%) (p<0.0001) 
5.2.5 Discussion 
 
In line with previous research on pharmacist prescribing, our study has shown a pharmacist in a 
collaborative prescribing model has made a high percentage of appropriate clinical decisions, in this 
case with regards to the prescribing of VTE prophylaxis.[145] VTE risk assessment documentation 
is documented more than usual care, and above the target set by CQUIN in UK, at which financial 
incentives are paid to organisations.[245] Appropriateness of VTE prophylaxis prescribed in clinic 
was more appropriate than usual care, the benefits of which are a reduction in probability of VTE 
whilst an inpatient[237]. 
In 2003, the National Health and Medical Research Council’s (NHMRC) National Institute of 
Clinical Studies (NICS) developed a national program to improve the prevention of VTE in 
hospitalised patients in Australia.[249] A system based approach to patient VTE risk assessment 
and management was one approach highlighted that would account for significant improvements in 
compliance with best practice guidelines. In 2009, the Australian Institute of Health and Welfare 
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(AIHW) produced recommendations for a set of 55 national indicators of safety and quality in 
healthcare, one of which was the proportion of admitted patients who have a documented VTE risk 
assessment.[250] In 2010 in the United Kingdom (UK), the National Institute for Clinical 
Excellence (NICE) released a guideline, the key priorities of which were to assess patients for risk 
of VTE on admission to hospital, assess patients for bleeding risk and evaluate the risks and 
benefits of prescribing VTE prophylaxis.[251] In 2012, the Health Quality and Complaints 
Commission (HQCC) in Australia produced standards with a view to minimise VTE rates in 
hospitalised patients.[252] The first reporting requirement was the proportion of admitted patients 
with a documented VTE risk, with all Queensland hospitals required to report data to HQCC 
through and Annual Quality and Activity Return (AQAR), with the information used to drive 
healthcare quality improvement. Also in 2012, the Australian Commission on Safety and Quality in 
Health Care produced the Medication Safety Action Guide, which set several proposed outcomes 
for health care, focusing on a small number of key safety and quality challenges which, if improved, 
would have a significant impact on the health and wellbeing of individuals, or on the healthcare 
system as a whole.[226] One of the outcomes was adults receive less venous thromboembolisms 
associated with hospitalisation, and the document highlighted possible actions by healthcare 
providers required to ensure all adult inpatients are assessed for risk of VTE on admission, and 
receive appropriate prophylaxis. 
In the US, institutions are financially penalised in an attempt to ensure appropriate VTE prophylaxis 
is considered and prescribed. The Centers for Medicare and Medicaid Services (CMS) refuses to 
reimburse for hospital treatment of a primary diagnosis for VTE following recent (30 day) total hip 
or knee arthroplasty, on the grounds they are considered the result of preventable medical 
errors.[253] If similar financial penalties were to be introduced in Australia, new methods to 
maximise appropriate VTE prophylaxis would become even more crucial. 
In line with results from studies in the UK, prior to guidelines and mandatory reporting of 
documented VTE risk assessments, the documented risk assessments in the current model of care in 
PAC are far from reaching the recommended level of 95% stipulated by NICE, or the 90% required 
by CQUIN in UK for financial incentives to be paid[245, 251]. Subsequent guidelines released in 
Australia by AIHW and HQCC have not gone so far to recommend a target percentage that should 
have a documented risk assessment, and as of yet there are no financial incentives linked to 
performance in Australia. Should this model ever be adopted, that there was only one documented 
risk assessment in the control arm, out of 147 patients, is an area for grave concern.[250, 252]  
The lack of documented risk assessment is reflected in the appropriateness of VTE prescribing, and 
a previous study has shown that a documented risk assessment is more likely to lead to appropriate 
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choice of prophylaxis by acting as a trigger for the VTE prevention pathway.[244] With the systems 
that are in place in hospital, such as VTE advocates on the ward, nurse assessment of VTE risk on 
admission, and ward pharmacy review on admission and during the inpatient stay, the 
appropriateness of VTE prophylaxis in the control arm should increase. However, the efficiencies 
of a pharmacist documenting risk and prescribing prophylaxis in clinic are apparent. The initiative 
will save clinician time, both in PAC and the ward, and ensure more patients receive appropriate 
prophylaxis on admission to the ward in a timely manner. 
The medication safety document produced by the Australian Commission on Safety and Quality in 
Health Care recommended possible actions by healthcare providers to ensure appropriate 
prophylaxis.[226] These included routinely assessing all adults admitted to hospital for VTE risk, 
assessing bleeding risk and ordering appropriate prophylaxis where indicated, development of VTE 
prevention policies and clinical pathways, and to train staff in VTE risk assessment, risk of 
bleeding, contraindications to prophylaxis and appropriate prophylaxis prescribing.  
Guidelines for VTE prophylaxis were previously facilitated between the individual surgical units in 
the hospital and the CNC for VTE prophylaxis. The authors believe the model of care evaluated in 
this paper, in having an appropriately trained pharmacist delegated to focus on VTE risk assessment 
and prophylaxis prescribing, as part of a defined scope of practice, has facilitated the other 
recommendations, and counteracted all of the barriers mentioned previously.[246] 
Whilst guidelines provide support for clinicians in their clinical decision making and prescribing, 
they are not objective tools, with many patients requiring individualised consideration due to unique 
patient factors.[254] Guidelines do not cover every patient, or clinical scenario, and this was 
highlighted in the study with the referrals made from the pharmacist to the RMO in clinic, 
requesting a final decision on whether chemical prophylaxis was appropriate to be prescribed. This 
ability to refer is a crucial part of a collaborative model of care, requiring recognition of limitations 
in scope of practice on behalf of the pharmacist, and access to medical officers to be able to discuss 
individual cases when necessary. 
A common reason for inappropriate prophylaxis in both arms was overprescribing of heparin in 
patients who were assessed as not requiring chemical prophylaxis. This is a concern when 
prescribing anticoagulants perioperatively, and may be a symptom of the increased awareness and 
push within organisations for VTE prophylaxis to be prescribed.[255, 256]  
Limitations of the study include this being one pharmacist in one hospital, and further work must be 
undertaken to ensure the underlying skills and knowledge of an advanced level pharmacist, along 
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with appropriate postgraduate prescribing training, can reliably produce competent and fit for 
purpose prescribers, irrespective of model of care or scope of practice. 
The fact that the study is reliant on a surrogate endpoint of appropriateness of prescribing, as 
opposed to actual clinical outcomes of events is also a limitation. However, numbers required to 
show a difference in either VTE or bleeds would be unrealistic for the scope of our study. Reviews 
have shown probabilities of poor outcomes, with regards to VTE, to be higher in surgical patients 
who do not receive appropriate prophylaxis.[257]  
VTE is a costly outcome, both in terms of a financial burden to the healthcare system, and quality of 
life for the patient.[238, 239] The saving of doctor time will be offset by an increased time 
requirement for the pharmacist to complete the assessment and prescribe prophylaxis. Further work 
is required to assess the cost effectiveness of this new model of care, and to assess whether any 
increased cost of the new model of care would be justified in terms of healthcare costs saved and 
health benefits gained. 
Whilst a figure of 94% appropriateness is an improvement, the end goal, irrespective of model of 
care, should be appropriate VTE prophylaxis in all patient 
5.2.6 Conclusion 
 
Documentation of VTE risk assessment and VTE prophylaxis prescribing was more appropriate in 
this new model of care. A multidisciplinary approach and investigation of new roles for existing 
healthcare professionals may be approaches to consider, in an attempt to primarily ensure patients 
receive appropriate VTE prophylaxis. 
5.2.7 Competing Interests 
 
No external funding and no competing interests declared 
5.3 Next Steps 
 
Chapters 3, 4 and 5 have established that a pharmacist, with appropriate training and education, can 
make clinically appropriate decisions in the PAC setting, and communicate these accurately and 
safely on to the NIMC. The hypothesis that the pharmacist is as good as usual care when it comes to 
producing a safe and accurate medication chart, and prescribe appropriate VTE prophylaxis, has 
been proved. 
Now it is crucial to assess whether the patients in the study were satisfied with the service they 
received in clinic and with the model of care, and whether there are any major concerns which 
might be a barrier to implementation of pharmacist prescribing in Australia. 
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6 Chapter 6 – Submitted Paper. Patient Satisfaction from Two 
Studies of Collaborative Doctor – Pharmacist Prescribing in 
Australia                                                                                          
Under Review at Time of Thesis Submission in Health Expectations. 
6.1 Chapter Introduction 
 
The NHPF stipulates as part of any evaluation of a health service, responsiveness should be 
assessed, namely whether the service is client orientated, and whether clients are treated with 
dignity, confidentiality and encouraged to participate in choices related to their healthcare. 
The importance of patient views is acknowledged in developing services, and the healthcare sector 
has used a variety of methods to assess patient feedback, which can be divided in to individual or 
group based approaches.[258] Examples of individual approaches include questionnaires to assess a 
patient’s needs before a consultation, shared decision making, one-to-one interviews and surveys to 
be filled out by patients after a consultation. Examples of group based approaches include focus 
groups, consensus mapping, consensus panels and public meetings. Methods need to be examined 
in terms of validity, effectiveness and implementation. In our studies, it was predominantly the ease 
of implementation that defined the methodology selected. Whereas focus groups may allow for 
more scope to express different preferences, by using more open ended approaches, it was 
considered not feasible to convene groups as part of our study, due to the inconvenience that would 
have been caused to patients by having to return to hospital again. Questionnaires allowed patient 
views to be elicited in a timely and efficient manner, while the consultation experience was still 
recent. Previous international literature utilising the same methodology also allows us to compare 
results within similar cohorts of patients. 
Patients in the PAC study were requested to complete a satisfaction survey at the end of their clinic 
appointment, the results of which are reported in Chapter 6.  
The data analysis in this chapter also includes the patient satisfaction results from another pilot of 
pharmacist prescribing, in a different model of care. The pilot took place in an outpatient sexual 
health clinic, and aimed to assess the safety and effectiveness of a pharmacist managing the ongoing 
treatment and medication of medically stable patients with a diagnosis of HIV (Human 
Immunodeficiency Virus), under an agreed care plan made between pharmacist, patient, and the 
patient’s usual medical specialist. 
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6.2 Patient Satisfaction from Two Studies of Collaborative Doctor - Pharmacist 
Prescribing in Australia 
6.2.1 Abstract 
6.2.1.1 Background  
Pharmacist prescribing has been introduced in several countries, and is a possible future role for 
pharmacy in Australia.  
6.2.1.2 Objective  
 
To assess whether patient satisfaction and patient experiences in two settings of collaborative doctor 
pharmacist prescribing may be barriers to implementation of pharmacist prescribing in Australia. 
6.2.1.3 Design  
 
Surveys containing closed questions, and Likert scale response options, were completed in both 
settings to investigate patient satisfaction after each consultation. A further survey investigating 
attitudes towards pharmacist prescribing, after multiple consultations, was completed in the sexual 
health clinic study only. 
6.2.1.4 Setting and Participants 
 
A surgical pre admission clinic (PAC) in a tertiary hospital, and an outpatient sexual health clinic 
attached to a university hospital. Two hundred patients scheduled for elective surgery, and 17 
patients diagnosed with HIV, respectively, recruited in to the pharmacist prescribing arm of two 
collaborative doctor pharmacist prescribing studies. 
6.2.1.5 Results 
 
Consultation satisfaction response rates in PAC and the sexual health clinic were 182/200 (91%) 
and 29/34 (85%), respectively. In the sexual health clinic, the attitudes towards pharmacist 
prescribing survey response rate was14/17 (82%)  
Consultation satisfaction was high in both studies, most patients (98% and 97% respectively) 
agreed they were satisfied with the consultation. 
In the sexual health clinic, all patients (14/14) agreed that they trusted the pharmacist’s ability to 
prescribe, the care was as good as usual care, and they would recommend seeing a pharmacist 
prescriber to friends.  
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6.2.1.6 Discussion and Conclusion 
 
Most of the patients from both studies had a high satisfaction with pharmacist prescriber 
consultations, and a positive outlook on the collaborative model of care in the sexual health clinic. 
6.2.2 Introduction 
 
Non-medical prescribing is one proposed strategy to assist in meeting growing demand in Australia 
for healthcare, and improving access to medicines. The Health Workforce Australia (HWA) Health 
Professionals Prescribing Pathway (HPPP) Project is developing a national pathway to prescribing 
by health professionals other than doctors.[259] The first stage is complete, with the 
recommendations for implementation approved at a national policy level in November 2013. Key 
issues such as regulatory practice, education, training and accreditation requirements will now be 
addressed with key stakeholders. There is little evidence in Australia of patient perspectives and 
opinions on non-medical prescribing, will also be important to inform the implementation of this 
new model of healthcare. 
Previous exploration of Australian patient views about pharmacist prescribing were based on 
surveys about a hypothetical role, utilising a theoretical framework to examine opinions on the 
expanded role, and any factors that contributed positively to their perception of trust in 
pharmacists.[260] Hoti et al showed that most clients indicated trust in pharmacists assuming an 
extended role, where doctors made the primary diagnosis, and the recommendation was made that 
any introduction be made in a way that facilitates the already established relationships between 
doctors and patients. Before now, no study in Australia has examined patient perspectives after 
experiencing the pharmacist prescribing model of care. 
The National Health Performance Framework (NHPF) provides indicators; effectiveness, safety, 
responsiveness, continuity of care, accessibility and efficiency, and sustainability, that were used as 
a guide for evaluation of the two pilots of collaborative doctor-pharmacist prescribing discussed in 
this paper.[11] The study in preadmission clinic (PAC) has shown benefits in safety, effectiveness 
and appropriateness.[231] Both studies examined patient satisfaction, with the experience as a 
measure of responsiveness. The need to involve patients in decision making, especially in 
prescribing, has also become an integral part of healthcare. 
Non-medical prescribing has been introduced in a number of countries and evidence so far suggests 
acceptability to patients is high.[247]  In Australia a focus has been placed recently on non-medical 
prescribers within the healthcare system, and in light of some resistance it is important to have 
evidence that this potential new model of care meets satisfies any concerns.[17, 37, 40, 181, 261]  
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This data discussed in this paper describes what elements of prescriber behaviour during a 
consultation lead to patient satisfaction in the two models of care. Attitudes towards pharmacist 
prescribing are investigated, to assess whether this may be a barrier to expansion of the pharmacist 
role in Australia, and implementation of collaborative doctor-pharmacist prescribing. 
6.2.3 Method 
6.2.3.1 Pharmacist Training 
 
Both pharmacists attended a prescribing course, accredited by the General Pharmaceutical Council, 
UK as an Independent Pharmacist Prescribing Course.[262] 
6.2.3.2 Pre Admission Clinic 
 
Four hundred patients scheduled for elective surgery were recruited into the study, and randomised 
to intervention or control (N=200 intervention, N=200 control). Intervention patients were seen by a 
nurse, prescribing pharmacist, resident medical officer (RMO) and anaesthetist. The pharmacist was 
responsible for taking a medication history, plus the prescribing of the inpatient medication chart. 
This was to ensure continuation of the patient’s regular medications on admission, and that the 
medication chart reflected the plan for medication perioperatively, including initiation of venous 
thromboembolism (VTE) prophylaxis. The pharmacist was unknown to the intervention patients, 
unless there was a small chance they had previously been thorough clinic and met the pharmacist at 
a prior appointment. This is possible, but unlikely to have happened often enough to influence the 
data. Control patients were seen by the same four health professionals in clinic, but the prescribing 
of the inpatient medication chart was the responsibility of the RMO. Intervention patients were 
asked to complete a satisfaction questionnaire after their appointment with the prescribing 
pharmacist, in order to be able to assess the prescribing pharmacist’s consultation behaviours, and 
how these impacted on patient satisfaction and views of pharmacist prescribing. 
6.2.3.3 Sexual Health Clinic 
 
Thirty three patients with a diagnosis of Human Immunodeficiency Virus (HIV), and judged to be 
medically stable by the sexual health staff specialist in the clinic, were recruited in to the study and 
randomised to intervention or control (N=17 intervention, N=16 control). Patients were excluded if 
they had any contact with the pharmacist prior to the study. The patient’s first appointment was 
with both the medical specialist, and the prescribing pharmacist, for the development of an agreed 
care plan. Second and third appointments in the study were undertaken by the prescribing 
pharmacist alone. The pharmacist’s scope of practice included ongoing management and 
prescribing of regular HIV medicines, with referral to the medical specialist still possible at the 
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pharmacist’s discretion, and in particular for anything outside of the care plan. Intervention patients 
were asked to complete a consultation satisfaction questionnaire at the end of each appointment 
with the pharmacist, in order to assess consultation behaviours of the pharmacist, and how these 
impacted on patient satisfaction. At the end of their last appointment intervention patients were also 
asked to complete an attitudes towards pharmacist prescribing questionnaire, to assess their 
attitudes towards the new collaborative pharmacist prescribing model of care they had experienced 
during the study.  
6.2.3.4 Questionnaire Development 
 
Patient satisfaction is an important outcome of care, and satisfied patients are more likely to 
cooperate with treatment (ref Kincey J, GP). For this reason patient satisfaction was evaluated as a 
consultation goal in both studies. Patient satisfaction questionnaires were developed for both pilots, 
with relevant statements chosen from a scale developed initially for general practitioners (ref Baker 
R- GP in general practice) Relevant statements on attitudes towards pharmacist prescribing were 
chosen from a scale developed previously in the UK.[263]  
Statements were developed to assess important elements of the scope of practice of the pharmacist 
in both settings that would contribute towards consultation goals, for example an assessment of the 
explanation of the plan for the patient’s medication before their operation in PAC, 
One questionnaire was developed for the PAC trial which focused on satisfaction and preparedness 
for surgery, elicited from experiences related to the delivery of the consultation. There were 12 
questions in total, with information collected on a 5 point Likert scale, from strongly agree to 
strongly disagree. 
Pre admission clinic services prepare patients for their admission for elective surgery, aiminbg to 
ensure patients are admitted in the best possible state of health. Questionnaires were designed to 
assess whether the pharmacist has assisted in the patient feeling ‘prepared for surgery’. One 
questionnaire was developed for the PAC trial which focused on the goals of satisfaction and 
preparedness, elicited from experiences related to the delivery of the consultation. There were 12 
questions in total, with information collected on a 5 point Likert scale, from strongly agree to 
strongly disagree. 
Consultation goals in the sexual health clinic were satisfaction, and the extent to which patient felt 
involved in decisions about their healthcare, as evidence suggests that a patient centred approach 
contributes to the goals of treatment for patients with chronic disease; to reduce hospital admission 
and improve quality of life. (ref Q Health strategy for chronic disease). Two questionnaires were 
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developed for the sexual health clinic, one focusing on consultation satisfaction, quality and patient 
involvement in treatments as the goals of consultation, and the other on attitudes towards the 
pharmacist prescriber model of care. There were 15 questions in the appointment questionnaire, and 
10 in the attitudes towards pharmacist prescribing questionnaire. Both questionnaires collected 
information on a 5 point Likert scale, from strongly agree to strongly disagree. 
Ethics approval for the PAC and the sexual health questionnaires was sought from the Princess 
Alexandra Hospital and the Gold Coast Health Service District Human Research Ethics 
Committees, respectively. Changes were requested to the PAC questionnaires, and for questions 2, 
2, 4, 6 and 9 to be changed to make the questionnaire a mixture of positive and negative responses. 
For example, question 2 was changed from “The pharmacist listened to what I had to say” to “The 
pharmacist did not listen to me”. No changes were requested to the sexual health clinic 
questionnaires. 
Following ethics approval, all questionnaires were piloted on 5 non study patients in each clinic 
prior to the studies commencing, with respondents asked about ease of completion, understanding 
and length. On the basis of the pilot, no changes were made to any of the questionnaires. 
6.2.3.5 Statistical Analysis 
 
For reporting purposes, the 5 point Likert scale in all questionnaires was collapsed in to a 3 point 
scale; agree (strongly agree/agree), disagree (strongly disagree/disagree) and neutral. Cronbach’s 
alpha coefficient was used to evaluate the internal consistency reliability for the different themes in 
surveys. For these calculations, the 5 point Likert scales were used.  
The consultation behaviours associated with achievement of consultation goals in both settings were 
examined using the Spearman’s rank correlation test. 
6.2.4 Results 
6.2.4.1 Pre Admission Clinic 
 
The patient response rate was 91% (182/200). Respondents had a median age of 56 (range 18-86) 
and 60% were male. At the time of the PAC appointment, 83% (148/178) were taking regular 
medications. (Table 10) 
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Consultation Goals – Satisfaction and Preparedness for Surgery 
Responses showed a very high level of satisfaction with the consultation, 98% of patients agreed that 
they were satisfied with the consultation provided by the pharmacist. Importantly, 92% of patients 
agreed the information the pharmacist had given them helped prepare them for surgery.  
Consultation Experience 
High percentages of patients agreed that the pharmacist explained their role in clinic (98%), that the 
pharmacist listened to them (92%), that they had a plan for medications, both before and after their 
operation, clearly explained to them (85% and 81% respectively). 
With regards to responsiveness to patients, high percentages agreed that the pharmacist checked 
their understanding of the plan for medication (98%), and that the pharmacist answered questions in 
a way that was easily understood (97%) and understood their concerns about medications (96%).  
High percentages of patients agreed that any information they were given was easy to understand, 
and 88% of patient agreed they trusted the pharmacist’s ability to provide them with a plan. 
Spearman correlation results highlighted elements of the consultation which are most strongly 
associated with feelings of patient satisfaction and preparedness for surgery. Both goals shared the 
highest ranked elements, namely the pharmacist explaining their role clearly, checking the patient 
understanding, understanding patient concerns and answering any questions the patient had 
effectively. This would suggest effective listening and communication, information provision and 
empathy are all important in ensuring patient satisfaction and preparedness. (Table 11) 
The independence of the pharmacist caused most ambivalence, and uncertain responses (14%), 
amongst respondents was whether patients would like the plan given to them by the pharmacist to 
be checked by the doctor 
The independence of the pharmacist caused most ambivalence, and uncertainty (14%), amongst 
respondents, as indicated by responses to the question whether patients would like t plan given to 
them by the pharmacist checked by the doctor? 
6.2.4.2 Sexual Health Clinic 
 
Consultation Satisfaction 
The patient response for appointment feedback was 85%, with one patient only completing one 
questionnaire after the first pharmacist appointment, and two patients not completing either. Median 
age was 49 (range 33-65) and 87% were male. (Table 12) 
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Consultation Goals – Consultation Satisfaction, Quality and Patient Empowerment 
There was a high satisfaction with the consultation, patients agreed they were satisfied for 97% of 
appointments, and only after 3% of consultations did they agree that some things could have been 
better. All of the patients agreed the pharmacist allowed them the opportunity to be involved in 
decisions about their care. 
Professional Care  
All of the patients agreed that the prescriber told them everything about their treatment during the 
appointment, checked that they understood their medications, and how to take them, and that any 
information given to them by the pharmacist was relevant and easy to understand. After their 
appointment, 72% of patients agreed that they understood their illness more, and 79% agreed that 
they understood their medications, and how to take them more. Overall, all of the patients agreed 
that they would follow the pharmacist’s advice because he/she was absolutely right. 
Empathy 
All of the patients agreed the pharmacist understood their health problem, listened to them, took 
time to answer any questions and appeared genuinely caring and concerned for their well-being. 
In line with results from PAC, the Spearman’s correlation showed that elements of the consultation 
behaviour that were most strongly associated with patient satisfaction were those concerning 
effective listening and answering of questions, information provision, and checking of patient 
understanding. The highest correlation with satisfaction was patients feeling they were involved in 
decisions concerning their treatment. (Table 13) 
Attitudes Towards Pharmacist Prescribing 
The response rate for the attitudes towards pharmacist prescribing questionnaire was 82% (14/17). 
Respondents’ median age was 49 (range 33-65), and 87% were male. (Table 14) 
The Consultation 
Consistent with the consultation satisfaction questionnaire, all of the patients were satisfied with the 
consultations provided by the pharmacist. All patients agreed that they had enough time to discuss 
medication related issues. 
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Provision of Information and Understanding of Treatment Plan 
All patients who had changes to their treatment plan or medication agreed that changes had been 
explained to their satisfaction. 
Trust in Pharmacist 
All of the patients trusted the pharmacist’s ability to prescribe, and thought that care provided was 
as good as usual care. This was all reflected in the overall willingness to engage with a pharmacist 
prescriber; 93% agreed they would consider seeing a pharmacist prescriber for ongoing 
management of their condition and medication, and all patients would recommend seeing a 
pharmacist prescriber to other people. 
One question that caused most ambivalence amongst respondents was as to whether they were more 
interested in the quality of care than the profession of the person who provides it; 63% agreed, 21% 
disagreed and 14% were unsure.  
End of consult goals were consistent with overall study satisfaction. 
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Table 10 ‐ Patient Satisfaction Pre Admission Clinic 
 Strongly 
Agree  
5 
Agree 
4 
Uncertain 
3 
Disagree 
2 
Strongly 
Disagree 
1 
Median 
Score 
(range) 
Consultation Experience       
The pharmacist explained to me 
clearly what his/her role was in Pre-
Admission Clinic  
98 
(54%) 
 
80 
(44) 
3 
(1) 
 
1 
(1) 
0 
 
 
Median  
1 
(2-5) 
The pharmacist did not listen to me 5 
(3%) 
 
5 
(3) 
5 
(3) 
 
47 
(27) 
115 
(65) 
 
Median 1 
(1-5) 
The pharmacist did not explain 
clearly what to do with my 
medications before my operation 
10 
(6%) 
 
15 
(8) 
1 
(1) 
 
40 
(23) 
110 
(62) 
 
Median 1 
(1-5) 
The pharmacist did not explain 
clearly what to do with my 
medications after my operation  
7 
(4%) 
 
16 
(9) 
11 
(6) 
 
44 
(25) 
101 
(56) 
 
Median 1 
(1-5) 
The pharmacist checked that I 
understood what to do with my 
medications  
99 
(55%) 
 
78 
(43) 
1 
(1) 
 
2 
(1) 
1 
(1) 
 
Median 5 
(1-5) 
Any information the pharmacist 
gave me was irrelevant and difficult 
to understand  
5 
(3%) 
 
7 
(4) 
3 
(2) 
 
54 
(30) 
109 
(61) 
 
Median 1 
(1-5) 
The pharmacist answered any 
questions I asked in a way I easily 
understood  
95 
(53%) 
 
80 
(44) 
3 
(2) 
1 
(1) 
1 
(1) 
 
Median 5 
(1-5) 
I felt the pharmacist understood any 
concerns I had about my 
medications  
81 
(45%) 
 
91 
(51) 
4 
(2) 
 
2 
(1) 
1 
(1) 
 
Median 4 
(1-5) 
I did not trust the pharmacist’s 
ability to provide me with a plan for 
the management of my medication 
6 
(3%) 
 
11 
(6) 
5 
(3) 
 
49 
(28) 
106 
(60) 
 
Median 1 
(1-5) 
To make sure the pharmacist is 
giving me the right plan I would 
like it to be checked by a doctor in 
the clinic  
22 
(12%) 
 
44 
(25) 
24 
(14) 
 
48 
(27) 
39 
(22) 
 
Median 3 
(1-5) 
Cronbach’s Alpha: 0.612      
Consultation Goals      
I am satisfied by the consultation 
provided by the pharmacist  
104 
(57%) 
74 
(41) 
4 
(2) 
 
0 0 
 
 
Median 1 
(3-5) 
The information the pharmacist 
gave me has helped me prepare for 
my surgery  
72 
(40%) 
 
95 
(52) 
13 
(7) 
 
2 
(1) 
0 
 
 
Median 2 
(2-5) 
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Table 11 ‐ Spearman’s Rank Correlation with Consultation Goals‐Pre Admission Clinic 
 
 I am satisfied by the 
consultation provided by the 
pharmacist 
The information the 
pharmacist gave me has 
helped me prepare for my 
surgery 
The pharmacist explained to 
me clearly what his/her role 
was in Pre-Admission Clinic 
0.712** 0.574** 
The pharmacist did not listen 
to me 
-0.381** -0.277** 
The pharmacist did not 
explain clearly what to do 
with my medications before 
my operation 
-0.334** -0.213** 
The pharmacist did not 
explain clearly what to do 
with my medications after 
my operation 
-0.400** -0.284** 
The pharmacist checked that 
I understood what to do with 
my medications 
0.632** 0.583** 
Any information the 
pharmacist gave me was 
irrelevant and difficult to 
understand 
-0.360** -0.314** 
The pharmacist answered any 
questions I asked in a way I 
easily understood 
0.637** 0.554** 
I felt the pharmacist 
understood any concerns I 
had about my medications 
0.615** 0.618** 
I did not trust the 
pharmacist’s ability to 
provide me with a plan for 
the management of my 
medication 
-0.428** -0.319** 
To make sure the pharmacist 
is giving me the right plan I 
would like it to be checked 
by a doctor in the clinic 
-0.185* -0.085 
The information the 
pharmacist gave me has 
helped me prepare for my 
surgery 
0.581** - 
** Correlation is significant at the 0.01 level (2-tailed) 
*Correlation is significant at the 0.05 level (2-tailed) 
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Table 12 ‐ Consultation Satisfaction Sexual Health Clinic (n = 29 consultations) 
 
 
 
Strongly 
Agree  
5 
Agree 
4 
Uncertain 
3 
Disagree 
2 
Strongly 
Disagree 
1 
Median 
Score 
(range) 
Professional Care       
The prescriber told me everything 
about my treatment. 
27 
(93%) 
2 
(7) 
0 
 
0 
 
0 
 
5 
(4-5) 
I understand my illness more after 
seeing the prescriber than I did 
beforehand. 
9 
(31%) 
 
12 
(41) 
7 
(24) 
 
1 
(3) 
 
() 
 
4 
(2-5) 
 
I understand my medications and 
how to take them more after seeing 
the prescriber than beforehand. 
13 
(45%) 
 
10 
(34) 
5 
(17) 
 
0 
 
1 
(3) 
 
4 
(1-5) 
The prescriber checked that I 
understood my medications and that 
I would take them correctly. 
25 
(86%) 
 
4 
(14) 
0 
 
 
0 
 
0 
 
 
5 
(4-5) 
Any information the prescriber 
gave me was relevant and easy to 
understand. 
23 
(79%) 
 
6 
(21) 
0 
 
0 
 
0 
 
 
5 
(4-5) 
I will follow this prescriber’s advice 
because I think he/she is absolutely 
right. 
19 
(66%) 
 
10 
(34) 
0 
 
 
0 
 
0 
 
5 
(4-5) 
The prescriber was interested in me 
as a person, not just my illness. 
20 
(69%) 
8 
(28) 
1 
(3) 
0 
 
0 
 
4 
(3-5) 
I felt the prescriber appeared to 
understand my concerns about 
medication. 
18 
(62%) 
9 
(31) 
2 
(7) 
0 0 5 
(3-5) 
Cronbach’s Alpha: 0.70      
Empathy       
The prescriber understood my 
health problem. 
26 
(90%) 
3 
(10) 
0 
 
0 
 
0 
 
5 
(4-5) 
The prescriber listened to what I 
had to say. 
25 
(86%) 
4 
(14) 
0 
 
0 
 
0 
 
5 
(4-5) 
The prescriber took time to discuss 
any questions or worries I had. 
22 
(76%) 
7 
(24) 
0 0 0 5 
(4-5) 
The prescriber appeared genuinely 
caring and concerned for my well-
being. 
26 
(90%) 
3 
(10) 
0 0 0 5 
(4-5) 
Cronbach’s Alpha: 0.85      
Consultation Goals       
I am totally satisfied with my visit 
to the prescriber 
 
24 
(83%) 
4 
(14) 
1 
(3) 
 
0 0 
 
 
5 
(3-5) 
Some things about my consultation 
with the prescriber could have been 
better. 
1 
(3%) 
 
2 
(7) 
2 
(7) 
 
5 
(17) 
19 
(66) 
1 
(1-5) 
The prescriber allowed me an 
opportunity to be involved in 
making decisions about my care. 
24 
(83%) 
 
5 
(17) 
0 
 
 
0 
 
0 
 
 
5 
(4-5) 
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Table 13 ‐ Spearman’s Rank Correlation with Consultation Goals‐Sexual Health Clinic 
 
 I am totally 
satisfied with my 
visit to the 
prescriber 
Some things about 
my consultation 
with the prescriber 
could have been 
better 
The prescriber 
allowed me an 
opportunity to be 
involved in 
making decisions 
about my care 
I am totally satisfied with my 
visit to the prescriber 
- -.639** .764** 
Some things about my 
consultation with the 
prescriber could have been 
better 
- - -.413* 
The prescriber told me 
everything about my 
treatment. 
0.632** -0.443* 0.596** 
I understand my illness more 
after seeing the prescriber than 
I did beforehand 
-0.088 0.056 0.185 
I understand my medications 
and how to take them more 
after seeing the prescriber than 
beforehand 
-0.078 -0.067 0.158 
The prescriber checked that I 
understood my medications 
and that I would take them 
correctly 
0.583** -0.474** 0.612** 
Any information the 
prescriber gave me was 
relevant and easy to 
understand 
0.674** -0.614** 0.668** 
I will follow this prescriber’s 
advice because I think he/she 
is absolutely right 
0.627** -0.570** 0.629** 
The prescriber was interested 
in me as a person, not just my 
illness 
0.458* -0.226 0.453* 
I felt the prescriber appeared 
to understand my concerns 
about medication. 
0.343 -0.487** 0.338 
The prescriber understood my 
health problem 
0.474** -0.481** 0.444* 
The prescriber listened to what 
I had to say 
0.883** -0.523** 0.876** 
The prescriber took time to 
discuss any questions or 
worries I had 
0.601** -0.388* 0.596** 
The prescriber appeared 
genuinely caring and 
concerned for my well-being 
0.763** -0.481** 0.744** 
** Correlation is significant at the 0.01 level (2-tailed) 
*Correlation is significant at the 0.05 level (2-tailed) 
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Table 14 ‐ Patient responses relating to experience of pharmacist prescribing in the sexual health 
clinic (n = 14) 
 
 
 
 
Strongly 
Agree  
5 
Agree 
4 
Uncertain 
3 
Disagree 
2 
Strongly 
Disagree 
1 
Median 
Score 
(range) 
I trusted the pharmacist's ability to 
prescribe. 
12 
(86%) 
2 
(14) 
0 
 
 
0 0 
 
 
5 
(4-5) 
I was satisfied by the 
consultation(s) provided by the 
pharmacist prescriber. 
11 
(79%) 
 
3 
(21) 
0 
 
 
0 
 
0 
 
5 
(4-5) 
I think the care provided by the 
prescribing pharmacist was as good 
as my usual care. 
10 
(71%) 
4 
(29) 
0 
 
 
0 
 
0 
 
5 
(4-5) 
I think the pharmacist prescriber 
improved the health care I received. 
5 
(36%) 
 
6 
(43) 
3 
(21) 
 
0 
 
0 
 
 
4 
(3-5) 
Changes to my treatment plan were 
explained to my satisfaction. 
9 
(64%) 
 
2 
(14) 
3 
(21) 
 
0 
 
0 
 
 
5 
(3-5) 
Changes to my medication were 
explained to my satisfaction 
8 
(57%) 
 
2 
(14) 
4 
(29) 
 
0 
 
0 
 
 
5 
(3-5) 
I had enough time with the 
pharmacist prescriber for discussing 
medication related issues. 
13 
(93%) 
 
1 
(7) 
0 
 
 
0 
 
0 
 
 
5 
(4-5) 
I am more interested in the quality 
of care than the profession of the 
person who provides it. 
8 
(57%) 
 
1 
(7) 
2 
(14) 
0 
 
3 
(21) 
 
5 
(1-5) 
I would recommend seeing a 
pharmacist prescriber to other 
people. 
11 
(79%) 
 
3 
(21) 
0 
 
 
0 
 
0 
 
5 
(4-5) 
I would consider seeing a 
pharmacist prescriber for ongoing 
management, under an agreed care 
plan, of my condition and 
medication.  
9 
(64%) 
 
4 
(29) 
1 
(7) 
 
0 
 
0 
 
 
5 
(3-5) 
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6.2.5 Discussion 
 
In line with previous research on patient perspectives of non-medical prescribing, patients in PAC 
and the sexual health clinic were highly satisfied with the consultations, and patients in the sexual 
health clinic positive about their experiences in the model of care.[168, 247, 263]   
A recent review suggested consultations with patients need to be treated as partnerships, and 
patients must be given the confidence, skills and knowledge to be partners.[264]  A questionnaire 
for assessing satisfaction with General Practitioner (GP) consults was developed in 1990, with the 
appreciation that patient satisfaction is an important outcome of care, and in light of previous 
research which showed satisfied patients are more likely to cooperate with treatment.[265, 266] 
United Kingdom (UK) guidelines have since highlighted key consultation characteristics that 
support adherence to medication, including rapport, being given relevant information about 
medicines, being understood by the prescriber and being involved in decisions about their 
medicines, and a previous literature review reported that most of the studies reviewed demonstrated 
correlation between effective physician-patient communication and improved patient health 
outcomes.[267, 268] Giving patients the opportunity to feed back on the health care they receive is 
an important part of any healthcare program, and if used effectively, can drive improvements in 
healthcare delivery.[269, 270] 
The two models of care in our studies differ significantly, with PAC being an acute, single meeting 
between patient and prescriber, and the sexual health clinic being a chronic model of care, with 
repeat appointments. Desired outcomes for the models of care are different, with the main goal in 
PAC ensuring the patient’s medication is optimised prior to surgery, and that the patient 
understands and follows a clear plan for their medications perioperatively. Not following the plan 
for medications, especially with regards to anticoagulants, for example, increase the likelihood of 
surgery cancellation, and patient morbidity and mortality.[271, 272] The positive responses in PAC 
with regards to the pharmacist explaining their role, listening, providing effective information, 
effectively answering any questions and understanding of concerns are suggestive of the pharmacist 
managing to build a good rapport within a relatively short space of time. Most patients agreed the 
pharmacist explained instructions clearly, and also checked their level of understanding. From 
previous research, these are all key components in forming an effective partnership with a patient, 
and maximising the chance of cooperation and adherence with treatment plans.[264-267] 
From the Spearman’s correlation, it was also shown that these elements of the questionnaire were 
the most strongly correlated to both the overall feeling of consultation satisfaction, and the feeling 
of being prepared for surgery.  
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In models of care such as the sexual health clinic a patient centred approach, which empowers 
individuals to manage their health and health care, contributes to the goals of treatment; to reduce 
hospital admissions and improve quality of life for people with chronic disease.[273] 
Patients in the sexual health clinic were highly satisfied with the consultation, with the consistently 
high positive feedback across all questions again suggestive that an effective partnership was built 
between prescriber and patient. Patients felt like they were understood, given effective information 
and involved in treatment decisions, all keys to patient empowerment and indicators for adherence 
and positive health outcomes.[267, 268]  
There were some reservations in PAC with regards to the trust in the pharmacist to take on the 
extended role over the usual model of care, which again was in line with UK research in 2006 
which explored patient perspectives, as part of a study of pharmacist prescribers in both primary 
and secondary care.[274] The results showed positive consultation experiences, and positive 
attitudes towards pharmacist prescribing. However, 65% of patients reported they would rather see 
a doctor. There question in PAC which divided opinion, and had the highest percentage of ‘unsure’ 
respondents; whether the patients would like a doctor to double check the plan for medications. This 
would suggest that patients are not altogether comfortable to relinquish contact with a medical 
officer within clinic, when it comes to the medication related aspect of their appointment, which is 
also in line with the Australian survey of pharmacy clients’ attitudes to pharmacist prescribing.[260]  
The advantage of the collaborative prescribing model of care proposed within this study is that 
having to choose between health care professionals is not a requirement, and it facilitates the 
already established relations between doctors and patients by ensuring lines of referral between 
pharmacist and doctor are readily available.  
A recent study from a UK study ascertained views from patients on the impact of prescribing by 
nurse and pharmacist prescribers, including satisfaction with the consultation and the impact on 
choice, access, quality of care, knowledge, adherence and control of their condition.[275] The 
results showed a high satisfaction with their last consultation, and a good relationship with, and 
high confidence in, their non-medical prescriber. When comparing non-medical prescribing and 
doctor prescribing, most patients reported no difference in their experience of care provided. The 
difference between the results in this study with regards to willingness to engage with non-medical 
prescribers in previous UK studies may be explained by a maturation of attitudes within the general 
public, as non-medical prescribing becomes an accepted model of care with time. 
Consistent with other research, patients in the sexual health clinic were also highly satisfied with the 
concept of pharmacist prescribing, having experienced it over multiple appointments.[168] The 
trust that patients had in the pharmacist’s abilities to prescribe was high, patients were willing to 
engage with the pharmacist prescriber on an ongoing basis, and all patients thought that care was as 
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good as usual care, with some believing the standard of care was better. Almost two thirds of 
patients were more interested in the quality of care provided, than the profession of the person who 
provided it. From the results, the authors would suggest an effective patient centred model of care 
was achieved, maximising the chances of positive health outcomes.[273] The difference between 
the two models in terms of willingness to engage with a pharmacist over medical staff may well be 
a reflection of the chronic nature of the sexual health clinic model, in that the pharmacist was able 
to build a relationship with the patients through several appointments, when compared to the acute 
model of a single appointment in PAC. The collaborative model of care that seems so important to 
patients in the early stages of pharmacist prescribing implementation may have been more obvious 
to patients in the sexual health clinic than those in the PAC.[260, 274] 
The results from our studies bode well for any future introduction of pharmacist prescribing in to 
the Australian health care system, and suggest initially that models of care which are more 
obviously collaborative would be most acceptable to patients.  
Limitations include small numbers of patients in the sexual health clinic, with 14 respondents to the 
overall satisfaction questionnaire, however the authors suggest the emphatic nature of the results 
overcome this. In PAC, it was difficult to ascertain views on the pharmacist prescribing model of 
care in the same way as in the sexual health clinic, due to the acute nature and also because, from 
the patient’s perspective, the appointment differed in no way from usual care. Generalisability of 
the results from this study to pharmacist prescribing in general may be limited. This is partly due to 
the questionnaires containing normative questions, which tend to define how things should be 
according to the researchers. Questions of this nature may not always provide a totally unbiased 
picture of patient views.[182] 
Recognising these limitations of the study is important, however the trustworthiness of findings is 
supported by the use of an evaluation framework which means evidence can be added to that from 
other studies, to strengthen the overall evidence base. The findings of our study are consistent with 
previous studies undertaken in Australia and UK.[260, 274] There is also a strong consistency in the 
results between our two studies, and strong internal consistency in the results of the sexual health 
clinic study, This study is also in keeping with findings from other studies where patient perception 
of service quality has a positive relationship with satisfaction and behavioural intent.[257] In both 
models, there are consistent responses between ratings of satisfaction and behavioural intent 
(preparedness for surgery in PAC and recommending the pharmacist prescriber to other in the 
sexual health clinic). 
Our studies trialled a single pharmacist prescriber in a designated scope of practice. Communication 
and consultation skills are a key component of the UK pharmacist prescribing course, as directed by 
the General Pharmaceutical Council guide on learning outcomes and indicative content.[262] 
 
 
116
Prescribing competencies have recently been produced in Australia, to guide and direct learning 
outcomes for prescribers, and to be used in the development, or revision, of prescribing 
curricula.[276] The results of our study show that effective listening and communication, empathy, 
effective information provision and empowerment of the patient in their treatment would seem to be 
the most important behaviours which are responsible for patient satisfaction, and the associated 
benefits. The challenge lies in ensuring training and education requirements for any future 
collaborative prescribing course are appropriate, and courses consistently and reliably produce 
competent and fit for purpose prescribers, who can replicate these results and outcomes on an 
ongoing basis. 
6.2.6 Conclusion 
 
Most patients were highly satisfied with the consultations with pharmacists in both studies, with 
positive attitudes on the model of care from patients in the sexual health clinic. The results suggest 
that patient satisfaction and willingness to engage will not be barriers to the implementation of 
collaborative doctor pharmacist prescribing models in Australia. 
6.3 Next Steps 
 
Previous chapters have described an analysis, via use of the NHPF, of how the collaborative 
prescribing model of care was at least as good as usual care with regards to effectiveness, safety, 
responsiveness, continuity of care and access to medications.  
As the review by Bhanbhro has highlighted,  in 2011, there have been few assessments of the cost 
effectiveness of this new model of care.[8] The last domain of the NHPF which required evaluation 
was ‘efficiency and sustainability’. Efficiency is defined as ‘achieving the desired results with the 
most cost effective use of resources.’ 
Sustainability is defined the ‘capacity of the system to sustain workforce and infrastructure, to 
innovate and respond to emerging needs’. Efficiency and sustainability were not rigorously assessed 
as part of this thesis, but is discussed in Chapter 7 under ‘Future Research’ 
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7 Chapter 7 – Overall Discussion and Conclusion 
7.1 Chapter Introduction 
 
This final chapter discusses the overall findings of the previous chapters, and describes how the 
body of work in this thesis has added to pre-existing knowledge. It also describes the limitations of 
the work, and recommends future directions for research in the area. 
The thesis set out to investigate the outcomes of a collaborative doctor-pharmacist prescribing 
model in an elective surgical PAC, using the validated national health performance framework 
utilised by Australian Institute of Health and Welfare, to assess how health services are performing 
at a national level.[248] The framework can also be used as a guide when developing performance 
indicators for a particular program, and was used as such in the design of our pilot. The framework 
consists of six domains; effectiveness, safety, responsiveness, continuity of care, accessibility and 
efficiency and sustainability (Figure 3) 
Chapter 1 of this thesis provides an insight in to the current evidence base on non-medical 
prescribing, and in particular pharmacist prescribing. The recurrent themes throughout the literature, 
and indeed the literature reviews, are a lack of robust evidence and substantial gaps in the 
knowledge base.[7, 8] Our study has addressed some of these gaps by providing robust evidence, 
from a randomised controlled trial, on the safety, effectiveness, appropriateness and responsiveness 
of a collaborative doctor – pharmacist prescribing model of care. 
Data collection and evaluation was designed to show our pilot was as good as usual care, as per the 
hypothesis, across as many domains as possible within this scope of practice. The advantage of 
using an objective framework in the evaluation of non-medical prescribing, both pre- and post-
implementation, is that different models of care can utilise the framework in the same manner, and 
tailor evaluation to relevant domains of the framework, as described in Chapter 2. The aim is to 
provide an understanding of the scope of this proposed new model of care and how it might best 
align, and work with current healthcare services to provide improved access to safe and appropriate 
medication usage, and more efficient usage of the time and skills of the current multidisciplinary 
team. 
7.2 Discussion 
7.2.1 Safety and Accuracy of Medication Charts 
 
Under usual care, the scope of practice of the PAC pharmacist is the eliciting of a complete and 
accurate medication history, and assistance in the formulation of a plan for medications peri 
operatively, namely which medications to continue, withhold and stop prior to surgery. Although 
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predominantly driven by guidelines, there is the need for individual clinical assessment and decision 
making outside of guidelines. Surgical RMOs are readily available for consult in clinic for 
confirmation of any plan, with this availability being one reason why PAC lends itself well to a 
collaborative prescribing model of care.  
Under usual care, the pharmacist provides the information from the medication history to the 
relevant RMO for confirmation of a plan as necessary, and to prescribe the inpatient medication 
chart, in preparation for the patient’s admission to hospital. The advantage of the pharmacist seeing 
the patient prior to the RMO was shown during a small pre study audit, which showed that out of 19 
patients only four saw the RMO first. Out of those four, only one (25%) had a medication chart 
prescribed, compared to 11 out of 15 (73%) who saw the pharmacist first. The same audit showed a 
number of issues with the prescribing of medication charts in clinic, namely prescribing omissions 
and errors.[200]  
The advanced scope of practice evaluated in our study was the production of the inpatient 
medication chart by the prescribing pharmacist in clinic, with our hypothesis being that the 
pharmacist would be as good as usual care, with regards to medication chart accuracy and safety. 
Results showed significantly less unintended omissions of medications: 11 of 887 (1.2%) 
intervention orders compared with 383 of 1217 (31.5%) control ( p<0.001). There were 
significantly less prescribing errors involving selection of drug, dose or frequency: 2 in 857 (0.2%) 
intervention orders compared with 51 in 807 (6.3%) control (p<0.001). 
Orders with at least one component of the prescription missing, incorrect or unclear occurred in 208 
of 904 (23%) intervention orders and 445 of 1034 (43%) controls ( p<0.001).  
Our results have shown an improvement in the safety and accuracy of medication chart prescribing, 
and is the first study to do so in the PAC setting.[231] The evidence from our study has enabled 
progression of the pharmacist prescribing agenda in Australia, looking to drive legislation and 
policy change from dissemination of the results to relevant stakeholders, to enable pharmacists to 
undertake a prescribing role. The proposed benefits to patients and the healthcare system of such an 
initiative are evident in the results from this study. 
7.2.2 Appropriateness of Prescribing  
 
The large difference in the number of omissions of medication from the NIMC between control arm 
and intervention arm (31% vs 1.2%) prompted further investigation as to the appropriateness of 
commissions and omissions. Whilst this was not a pre-determined sub study, an ‘expert panel’ 
methodology was devised from a similar study in the literature assessing the appropriateness of 
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nurse prescribing [139]. Individual panel members were asked to rate a selection of commissions 
and omissions from a randomly selected 5% sample of the total cohort of patient, using an amended 
and validated version of the Medication Appropriateness Index (MAI).  
Results showed the appropriateness of prescribing in both arms was the same. From the 5% sample 
there were significantly more omissions of medication from the NIMC in the control, and each 
panel member was requested to rate each omission as whether it had potential for patient harm, 
ward inconvenience, both or neither. Out of 89 regular medications in the control arm, 25 (28%) 
were omitted from the medication charts, compared to 1 out of 55 (2%) in the intervention arm 
(p<0.001, fishers exact) 
When reviewer assessments were combined, 32 out of 294 (10.9%) medications assessed for 
appropriateness in the control arm were classed as inappropriate, compared to 13 of 266 (4.9%) in 
the intervention arm.  
On average, 52% of omissions in the control arm were judged to have potential for patient harm or 
ward inconvenience. 
Whilst the sub study lacked statistical power, it provided a useful ‘snap shot’ of the prescribing, to 
show that the appropriateness of prescribing by the pharmacist assessed in the study was the same 
as usual care, and is described in Chapter 4. 
Few studies have assessed the appropriateness of non-medical prescribing, and the results from this 
part of the study are the first time that the appropriateness of a pharmacist’s prescribing has been 
evaluated. Whilst Chapter 3 assessed the medication chart as safe and accurate, according to the 
patient’s medication history, there was no evaluation of whether inclusion of medications on the 
medication chart were appropriate, or how much of an impact any omission from the medication 
chart may have had.  The results from this part of the study show that the clinical decision making 
by the pharmacist with regards to what to continue, withhold and omit from the NIMC, was 
appropriate.[277] 
7.2.3 Appropriateness of Venous Thromboembolism (VTE) Prophylaxis  
 
Whilst prescribing of patients’ regular medications for an inpatient stay is essential, it was also 
important as part of our study to evaluate the initiation of a new medication. Surgery is a known 
risk factor for VTE and a routine part of any admission should be assessment of individual patient 
VTE risk and prescribing of VTE prophylaxis, as per guideline.[213] VTE prophylaxis lends itself 
well to a collaborative prescribing model, due to the availability of national and local guidelines, 
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which clearly defined criteria for assessment of patient risk and contraindications, and definitive 
treatment paths for low and high risk patients.   
It was agreed by hospital executive and the Designated Medical Practitioner that the pharmacist’s 
prescribing scope could include VTE prophylaxis, following a documented risk and 
contraindication assessment. With patients that fall outside of guidelines, there is access for the 
pharmacist to surgical RMOs for confirmation of VTE prophylaxis requirements. This is another 
reason why this is a good example of a scope of practice suitable for a collaborative prescribing 
model. The hypothesis was that the pharmacist would be as appropriate as usual care. Results 
showed that VTE risk assessment was documented in significantly more patients in the intervention 
arm, 153/160 (96%), compared to 1/147 (1%) in the control arm (p=<0.0001), and when undertaken 
was correct 94% of the time.  
VTE prophylaxis was appropriately prescribed in clinic in 150/160 (94%) intervention patients, and 
94/147 (64%) control (p<0.0001) 
The documentation of risk assessment, and prescribing of VTE prophylaxis by the pharmacist in 
clinic, was significantly more appropriate. 
Chapter 5 describes the results of the prescribing of VTE prophylaxis, and is the first time 
pharmacist prescribing of VTE prophylaxis has been evaluated.[278] This outcome has significant 
potential for improving patient outcomes peri operatively, both in terms of patient morbidity and 
mortality, and reducing the high healthcare costs associated with hospital associated 
thromboembolus.[238] 
Importantly, results can also be translated in to other models of care, where initiation and 
management of medications are guideline driven. Our results show that an appropriately trained 
pharmacist can initiate a medication, via guidelines, safely and appropriately. In the context of 
many chronic diseases, for example asthma, which are managed by treatment guidelines, this 
presents an opportunity for future research on the evaluation of chronic disease management by 
pharmacist prescribers within a collaborative model of care. Our study would suggest translation in 
to other models of care and scopes of practice would be feasible. 
7.2.4 Assessment of Unplanned 30 Day Readmissions 
 
Unplanned hospital readmission within 30 days of discharge is an undesirable outcome, and can be 
used as an indicator to gauge quality of hospital care.[279] 
Pharmacists in PAC have been shown to improve the accuracy of medication histories and 
medication orders, when compared with standard care.[210] The pharmacy medication liaison 
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service (MLS) in the preadmission clinic (PAC) at Princess Alexandra Hospital (PAH) was 
introduced and evaluated in 1998, with a view to increasing the accuracy of information exchange 
as patients crossed healthcare settings, via medication reconciliation at pre admission and at 
discharge, and increased communication with community healthcare providers.[208] The study 
followed up post discharge outcomes, with the MLS associated with an almost significant 20% 
reduction in unplanned 30 day readmissions to hospital.[199] The MLS patients also experienced 
significantly fewer unplanned healthcare professional visits per subject in the 30 days post 
discharge. Omission of one medication on discharge was shown to have a 2.3 times increased risk 
of 30 day readmission. 
Similar to the MLS, our study expanded the role of the PAC pharmacist for intervention patients, 
but at the admission stage of the patient journey only. Part of our study assessed 30 day post 
discharge outcomes for patients. Patients were contacted 30 days post discharge by telephone, and 
asked whether they had experienced 30 day unplanned readmissions to hospital, presentations to the 
Emergency Department (ED) and any unscheduled contact with General Practitioners (GP). From 
the control arm, 164/190 (86%) patients were able to be contacted, with 170/194 (88%) from the 
intervention arm. 
Results showed no significant difference in rates of 30 day GP visits, ED visits or unplanned 
readmissions 
Table 15 ‐ Unscheduled 30 Day Post Discharge Readmissions, GP and ED Contact 
 
 Control N=164 (%) Intervention N=170 (%) 
Unscheduled visit to GP 35 (21%) 38 (22%) 
ED visit 16 (10%) 19 (11%) 
Unplanned readmission 10 (6%) 7 (4%) 
 
Despite significant differences in omissions and prescribing errors on the medication charts 
produced at the end of PAC, this may not be an unexpected outcome. Results from Chapter 4, and 
the expert panel assessment of omissions, showed that an average of 52% of omissions were judged 
to have potential for patient harm or ward inconvenience. These were omissions that required 
remedial action whilst the patient was in hospital, otherwise the accuracy of information exchange 
across settings would be compromised, resulting in increased chance for the associated bad 
outcomes for patients, including unplanned 30 day readmission.  
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Patients in both arms have a pharmacist medication history from PAC, and would still be subject to 
all the usual interventions in hospital and on discharge of multidisciplinary pharmaceutical review. 
It may be expected that the safety barriers in place within the current system would fix any 
significant errors and omissions from admission, resulting in an accurate record on discharge in 
both arms (see Figure 10). The advantage in the pharmacist prescribing model of care is the 
assumed efficiency gains in ensuring that the medication history and medication chart, which is 
then used as the primary source of information on discharge, are complete and correct on 
admission. Although this wasn’t assessed as part of our study, there would be less of a requirement 
to correct any of the clinically significant omissions and prescribing errors, freeing up pharmacist 
and doctor time whilst the patient was in hospital and on discharge 
Figure 10 ‐ Current Model of Pharmaceutical Care Impacting on Safety at Discharge 
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7.2.5 Patient Satisfaction  
 
High percentages of patients, from the 182 that responded via a questionnaire at the end of their 
clinic appointment, were satisfied with the consultation provided by the pharmacist in clinic, and 
thought that the information the pharmacist had given them helped prepare them for their surgery. 
Previous literature has suggested that satisfied patients, and patients who feel involved in treatment 
options, are more likely to comply with treatment plans.[266] With regards to medication 
management peri operatively, this is important to avoid surgery cancellations, and to reduce 
chances of patient morbidity and mortality. 
Results suggest that the attitudes and experiences of patients who experienced the pharmacist 
prescribing model of care would not be a barrier to the implementation of pharmacist prescribing in 
Australia. These are encouraging results, especially given that the patients in PAC did not know the 
pharmacist, and there was little time to build a rapport between pharmacist and patient. Many 
proposed scopes of practice and models of care where pharmacist prescribing may benefit patients, 
for example chronic disease management, would present more of an opportunity for the pharmacist 
to build a relationship with the patient through repeat appointments and longer term management.  
7.3 Overall Results 
 
By relating our results to the model of prescribing suggested by Coombes et al (see Figure 2), the 
first three quadrants of the model have been assessed during our study, and found to be as effective 
as usual care. 
7.3.1 Information Gathering 
 
Previous studies have shown that pharmacists in PAC take more accurate medication histories, to be 
able to inform peri operative clinical decisions.[210] As such, our study did not assess the accuracy 
of histories taken in clinic, but the accuracy of transfer of information gathered across the healthcare 
transition from pre admission to admission.  
With regards to VTE risk and contraindication assessments and prescribing, the information 
gathered by the pharmacist to enable VTE prophylaxis to be prescribed, was shown to be 
documented more appropriately. 
7.3.2 Clinical Decision Making 
 
Appropriate clinical decisions, regarding which medications to continue, withhold, stop and initiate 
have been made by the pharmacist and doctors in this collaborative model of care. With regards to 
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VTE prophylaxis prescribing, clinical decisions on mechanical and anticoagulant prophylaxis made 
by the pharmacist in clinic were more appropriate than usual care. 
7.3.3 Communication 
 
The information regarding regular medications, and plan for medication peri operatively, was more 
safely and effectively communicated by the pharmacist in PAC than the RMOs in the control arm. 
This was reflected in more accurate and safer medication charts, for administration of medications 
to inpatients during their hospital admission. 
7.3.4 NHPF Framework 
 
As per the hypothesis, our evaluation has shown a doctor pharmacist collaborative prescribing 
model to be at least as good as usual care in effectiveness, safety, continuity of care and 
accessibility. Whilst responsiveness wasn’t compared against the control arm, patient feedback 
showed the service was client orientated and met patients’ needs.  
7.4 Limitations 
 
The main limitation of the overall study is that the results of the thesis report on the prescribing of 
one pharmacist, in one hospital, working in one specific scope of practice. Whilst this is true, 
prescribing involves a core set of competencies which, following appropriate training and 
education, should be able to be applied to other models, practice settings and scopes of 
practice.[276] 
7.5 Future Research Directions 
7.5.1 Training and Credentialing of the Pharmacist 
 
The Health Practitioners Prescribing Pathway Project, run by Health Workforce Australia is seeking 
to deliver a national approach to prescribing by health professionals, other than doctors.[259] The 
first stage of the project was approved by the Standing Council on 8 November 2013, and HWA 
will now commence work on implementation. 
One of the first challenges for education providers is to define what baseline experience and 
qualifications are required by a pharmacist prior to undertaking a postgraduate prescribing course. 
The Advanced Pharmacy Practice Framework Steering Committee (APPFSC) is undertaking work 
to develop an advanced pharmacy practice recognition model. 
Advanced level practice in pharmacy within a certain speciality entails knowledge, skills and 
attitudes in a particular scope, gained through a combination of work experience and clinical 
 
 
125
postgraduate clinical qualifications. However, there is no mandatory approach as to levels of 
clinical experience, post graduate qualifications and accreditation a pharmacist must undertake 
before they can be recognised as an ‘advanced level practitioner’. This body of work is essential to 
the progression of advanced scopes of practice, such as prescribing, to objectively define who is 
appropriate to be able to undertake a prescribing course. 
The prescribing course should not be responsible for clinical knowledge, but more focused on the 
skills required to be able to prescribe safely, effectively and appropriately within a collaborative 
model of care. The UK and NZ have produced definitive curricula, which may act as a guide for 
Australia for any future prescribing courses.[262] As well as the academic content, both courses 
incorporate a prescribing practicum element in to the training, which is under the guidance of a 
supporting senior medic, or designated medical practitioner (DMP). Only with completion to 
satisfaction of the academic content, the required hours of practicum, and following sign off on 
prescribing competencies by the DMP, can the pharmacist be registered to be a prescriber. 
The challenge is to ensure that education providers tailor courses to satisfy prescribing 
competencies, and reliably produce competent and fit-for-purpose prescribers.[276] The prescribing 
competencies should align and complement other clinical knowledge and competencies gained as 
an advanced level clinician, to allow for safe and appropriate prescribing. 
Future research should also focus on translation of these skills and competencies in to different 
models of care, practice settings and clinical specialities, and continued evaluation of pharmacist 
prescribing post implementation to show the benefits to patients, and the healthcare system alike. 
7.5.2 Cost Effectiveness of Collaborative Prescribing 
 
As highlighted by a previous review, evidence for the cost effectiveness of non-medical prescribing 
is lacking.[8] Future analysis to be undertaken includes the cost effectiveness modelling of this new 
model of care. The improvements shown in the intervention arm, in both the primary and secondary 
endpoints in the study, would suggest there are financial benefits to be gained from implementing 
pharmacist prescribing in the PAC setting. With regards to significantly more accurate and safer 
medication charts, the reduction in medication errors and the associated patient harm would reduce 
costs to the healthcare system. VTE prescribing was also more appropriate in the intervention arm. 
The reduction in cost to the healthcare system and the reduction in patient harm that would prevail 
from the associated reduction in peri operative emboli with appropriate prophylaxis, merits further 
investigation 
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7.5.3 Factors for Success 
 
Barriers and facilitators to running the pilot of pharmacist prescribing have informed the wider 
agenda, and given an idea of what pharmacist prescribing should look like to maximise the chances 
of success in implementation.[280] 
Medical resistance was overcome partly by a clear scope of practice for the prescribing, that was 
acceptable to the relevant senior medics and clear proposed outcomes, focusing on the ability to 
assist doctors make more efficient use of their time.  
A senior, advanced level pharmacist who had undergone accredited education and training to 
prescribe was essential to gain the support from a senior medical officer to act as a DMP.  
Initially, as shown by the patient satisfaction results, it is vital that the scope of practice be 
obviously collaborative with medical staff. It would appear that a maturation of attitudes from the 
general public may be required with regards to the acceptability of pharmacist prescribing, as 
shown in UK with time.  
7.6 Conclusion 
 
The results of our pilot show that pharmacist prescribing within an elective surgery PAC is a 
feasible concept. 
The study has demonstrated increased safety and accuracy of medication chart prescribing and 
increased appropriateness of VTE prophylaxis prescribing. 
It has been demonstrated that a pharmacist who undertakes appropriate training, education and 
assessment has the skills to be able to competently prescribe within a clearly defined scope of 
practice of collaborative prescribing. 
The findings of this project will help in forming the basis of a new model of care for Australian 
pharmacy practice, which will be of benefit to patients, the healthcare system and the profession 
alike. 
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